Chimeric peptides and their usage

By developing chimeric peptides containing the extracellular domain and transmembrane domain of B cell maturation antigens, the challenges of separation and purification in targeted tumor antigen cell therapy have been solved, achieving highly efficient and low-toxicity cell therapy.

CN123076607APending Publication Date: 2026-11-10BOARD OF RGT THE UNIV OF TEXAS SYST
View PDF 12 Cites 0 Cited by

Patent Information

Application Number
CN202580024223.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2024-02-05
Filing Date
2025-01-31
Publication Date
2026-11-10

AI Technical Summary

Technical Problem

Existing therapeutic cell therapies targeting tumor antigens, such as CAR-NK cells and TCR-transduced T cells, suffer from problems such as disease relapse, high manufacturing costs, and toxicity. In particular, it is difficult to isolate, identify, and purify cells during the manufacturing process, and there is a lack of methods to selectively target cells in the event of adverse events.

Method used

We developed chimeric peptides containing the extracellular and transmembrane domains of B cell maturation antigen (BMCA), expressed these peptides in engineered cells, and used antigen-binding proteins to detect, isolate, deplete, and purify the cells, followed by detection using imaging agents.

Benefits of technology

It enables efficient detection, separation, depletion, and purification of cells targeting tumor antigens, reducing the risk of disease recurrence and manufacturing costs, and decreasing the toxicity of cytokine release syndrome and graft-versus-host disease.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN123076607A_ABST
    Figure CN123076607A_ABST
Patent Text Reader

Abstract

Various aspects of this disclosure provide compositions and methods for detecting, separating, depleting, and / or purifying cells, including polypeptides for such methods, including chimeric polypeptides. Various chimeric polypeptides are disclosed, along with their use as selection markers, transduction markers, and / or safety switches. Cells comprising polynucleotides encoding one or more chimeric polypeptides are also disclosed, including therapeutic cells such as T cells, NK cells, NKT cells, and iPSCs.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] Cross-reference to related applications

[0002] This application claims the benefit of U.S. Provisional Application No. 63 / 549,948, filed February 5, 2024, the disclosure of which is incorporated herein by reference in its entirety.

[0003] sequence list

[0004] This application contains a sequence list, which has been submitted in a computer-readable format through the Patent Centre and is incorporated herein by reference in its entirety. This computer-readable file was created on February 1, 2024, and is named “MDACP1372US SequenceListing v3.xml”, with a size of approximately 38,580 bytes. Technical Field

[0005] Various aspects of this disclosure relate to the field of molecular biology. In particular, various aspects of this disclosure relate to chimeric peptides, engineered cells, and methods of using them. Background Technology

[0006] Therapeutic cells targeting tumor antigens, such as CAR-NK cells, CAR T cells, and TCR-transduced T cells, represent a promising approach for treating various malignancies. Despite the success of these therapies to date, several limitations remain, including disease relapse, high manufacturing costs, and toxicity. There is a need for compositions and methods for targeting therapeutic cells, such as for isolation, identification, and purification during the manufacturing process, and for selectively targeting and eliminating these cells in the event of adverse events such as cytokine release syndrome and graft-versus-host disease. Summary of the Invention

[0007] In some aspects, methods and compositions for detecting, isolating, depleting, and / or purifying cells are disclosed herein. Thus, in some aspects, chimeric polypeptides comprising one or more extracellular and transmembrane domains derived from B-cell maturation antigen (BMCA) are disclosed. In some aspects, the chimeric polypeptide comprises at least two extracellular and transmembrane domains derived from B-cell maturation antigen (BMCA). In some aspects, the chimeric polypeptide further comprises one or more additional regions, such as a signal peptide, hinge region, intracellular region, linker region, or any combination thereof. Engineered cells expressing such polypeptides and methods for detecting, isolating, depleting, and / or purifying such cells are also disclosed.

[0008] This disclosure encompasses various aspects including nucleic acids, polynucleotides, polypeptides, proteins, peptides, constructs, vectors, cells, therapeutic cells, immune cells, engineered cells, methods for generating engineered cells, methods for detecting engineered cells, methods for isolating engineered cells, methods for depleting engineered cells, and methods for purifying engineered cells. The nucleic acids of this disclosure may encode one or more polypeptides of this disclosure, including one or more chimeric polypeptides. In some aspects, the nucleic acid molecules of this disclosure encode chimeric polypeptides. In some aspects, the nucleic acid molecules of this disclosure encode two or more chimeric polypeptides. The chimeric polypeptides of this disclosure may comprise at least one, two, three, or more of the following regions or domains: signal peptide, one or more extracellular domains, hinge region, transmembrane domain, intracellular region, one or more linker regions, or any combination thereof. The engineered cells of this disclosure may comprise one, two, three, four, or more polynucleotides and / or polypeptides of this disclosure. The methods disclosed herein may include at least one, two, three, four or more of the following steps: introducing a polynucleotide into a cell, introducing a vector into a cell, introducing a polypeptide into a cell, expressing the polypeptide in the cell, expanding the cell population, contacting the cell with an antigen-binding protein, contacting the cell with an antibody-drug conjugate, and detecting the cell with an imaging agent.

[0009] In some respects, this document discloses a chimeric polypeptide comprising: (a) an extracellular domain comprising one or more repeats of an amino acid sequence having at least, at most, and exactly 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity with SEQ ID NO:33, or an identity between any two values; (b) a hinge region; and (c) a transmembrane domain. In some respects, the extracellular domain comprises at least two repeats of an amino acid sequence having at least, at most, exactly 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity with SEQ ID NO:33, or an identity between any two values.

[0010] In some aspects, the extracellular domain comprises one or more repeats of an amino acid sequence having at least 90% identity with SEQ ID NO:33. In some aspects, the extracellular domain comprises one or more repeats of an amino acid sequence having at least 95% identity with SEQ ID NO:33. In some aspects, the extracellular domain comprises one or more repeats of an amino acid sequence having at least 99% identity with SEQ ID NO:33. In some aspects, the extracellular domain comprises one or more repeats of an amino acid sequence comprising SEQ ID NO:33. In some aspects, the extracellular domain comprises one or more repeats of an amino acid sequence comprising SEQ ID NO:33.

[0011] In some aspects, the extracellular domain comprises at least two repeats of an amino acid sequence having at least 90% identity with SEQ ID NO:33. In some aspects, the extracellular domain comprises at least two repeats of an amino acid sequence having at least 95% identity with SEQ ID NO:33. In some aspects, the extracellular domain comprises at least two repeats of an amino acid sequence having at least 99% identity with SEQ ID NO:33. In some aspects, the extracellular domain comprises at least two repeats of an amino acid sequence comprising SEQ ID NO:33. In some aspects, the extracellular domain comprises at least two repeats of an amino acid sequence consisting of SEQ ID NO:33.

[0012] In some aspects, the extracellular domain comprises one or more repeats of an amino acid sequence having at least, at most, and exactly 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity with SEQ ID NO:1 or SEQ ID NO:2, or an identity between any two values. In some aspects, the extracellular domain comprises one or more repeats of an amino acid sequence comprising SEQ ID NO:1 or SEQ ID NO:2. In some aspects, the extracellular domain comprises one or more repeats of an amino acid sequence consisting of SEQ ID NO:1 or SEQ ID NO:2.

[0013] In some aspects, the extracellular domain comprises at least two repeats of an amino acid sequence having at least, at most, and exactly 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity with SEQ ID NO:1 or SEQ ID NO:2, or an identity between any two values. In some aspects, the extracellular domain comprises at least two repeats of an amino acid sequence comprising SEQ ID NO:1 or SEQ ID NO:2. In some aspects, the extracellular domain comprises at least two repeats of an amino acid sequence consisting of SEQ ID NO:1 or SEQ ID NO:2.

[0014] In some aspects, the hinge region comprises a hinge region derived from programmed cell death 1 ligand 1 (PDL1). In some aspects, the hinge region comprises an amino acid sequence having at least, at most, and exactly 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity with SEQ ID NO:3, or an identity between any two values. In some aspects, the hinge region comprises SEQ ID NO:3. In some aspects, the hinge region consists of SEQ ID NO:3.

[0015] In some aspects, the transmembrane domain comprises a transmembrane domain derived from programmed cell death 1 ligand 1 (PDL1). In some aspects, the transmembrane domain comprises an amino acid sequence having at least, at most, and exactly 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity with SEQ ID NO:4, or an identity between any two values. In some aspects, the transmembrane domain comprises SEQ ID NO:4. In some aspects, the transmembrane domain consists of SEQ ID NO:4.

[0016] In some aspects, the chimeric polypeptide further comprises an intracellular region. In some aspects, the intracellular region has endocytic or internalization activity. In some aspects, the intracellular region comprises a cytoplasmic domain from Trop2. In some aspects, the intracellular region comprises an amino acid sequence having at least, at most, and exactly 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity with SEQ ID NO:5, or an identity between any two values. In some aspects, the intracellular region comprises SEQ ID NO:5. In some aspects, the intracellular region consists of SEQ ID NO:5.

[0017] In some aspects, the chimeric polypeptide further comprises a linker region consisting of one or more (e.g., at least two) repeats of an amino acid sequence having at least 90% identity with SEQ ID NO:33, or repeating therebetween. In some aspects, the linker region comprises one or more CD34 epitopes. In some aspects, each of the one or more CD34 epitopes comprises an amino acid sequence having at least, at most, and exactly 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity with SEQ ID NO:6 or SEQ ID NO:7, or an identity between any two values. In some aspects, each of the one or more CD34 epitopes comprises SEQ ID NO:6 or SEQ ID NO:7. In some aspects, each of the one or more CD34 epitopes consists of SEQ ID NO:6 or SEQ ID NO:7.

[0018] In some aspects, the linker region comprises at least two CD34 epitopes, and the chimeric polypeptide further comprises a linker region following each of the at least two CD34 epitopes. In some aspects, the linker region following each of the at least two CD34 epitopes comprises an amino acid sequence having at least, at most, and exactly 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity with SEQ ID NO:8 or SEQ ID NO:9, or an identity between any two values. In some aspects, the linker region following each of the at least two CD34 epitopes comprises SEQ ID NO:8 or SEQ ID NO:9. In some aspects, the linker region following each of the at least two CD34 epitopes is composed of SEQ ID NO:8 or SEQ ID NO:9.

[0019] In some aspects, the chimeric polypeptide comprises an amino acid sequence having at least, at most, and exactly 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity with SEQ ID NO:10, or an identity between any two values. In some aspects, the chimeric polypeptide comprises SEQ ID NO:10. In some aspects, the chimeric polypeptide consists of SEQ ID NO:10. A nucleic acid molecule comprising a nucleotide sequence encoding the chimeric polypeptide is also disclosed. In some aspects, the nucleic acid molecule comprises a nucleic acid sequence having at least, at most, and exactly 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity with SEQ ID NO:20, or an identity between any two values. In some aspects, the nucleic acid molecule comprises SEQ ID NO:20. A vector comprising the nucleic acid molecule is also disclosed.

[0020] In some aspects, the chimeric polypeptide does not contain a signal transduction domain. In some aspects, the chimeric polypeptide does not contain a signal transduction domain. In some aspects, the chimeric polypeptide does not contain an intracellular region derived from BCMA.

[0021] In some aspects, a method for generating engineered cells is disclosed, which includes introducing chimeric polypeptides, nucleic acid molecules or vectors of the present disclosure into cells.

[0022] In some aspects, an engineered cell is disclosed comprising a nucleic acid molecule encoding a chimeric polypeptide of the present disclosure. In some aspects, the engineered cell is a T cell. In some aspects, the T cell is a CD4 cell. + T cells, CD8 + T cells, iNKT cells, NKT cells, γδ T cells, or regulatory T cells. In some aspects, the engineered cells are natural killer (NK) cells. In some aspects, the engineered cells are induced pluripotent stem cells (iPSCs). In some aspects, the engineered cells are iPSC-derived cells. In some aspects, the engineered cells further comprise a chimeric antigen receptor (CAR). In some aspects, the chimeric polypeptide is operatively linked to the CAR. In some aspects, the engineered cells further comprise a T cell receptor (TCR). In some aspects, the chimeric polypeptide is operatively linked to the TCR. A cell population comprising the engineered cells of this disclosure is also disclosed.

[0023] A further disclosed method for detecting, isolating, depleting, or purifying engineered cells of this disclosure includes contacting the engineered cells with an antigen-binding protein, wherein the antigen-binding protein is capable of binding a polypeptide of the engineered cells. In aspects where the engineered cells express a chimeric polypeptide comprising an extracellular domain from BCMA, the antigen-binding protein is a BCMA-binding protein. In some aspects, the antigen-binding protein is an antigen-specific antibody or an antigen-binding fragment thereof. In some aspects, the antigen-binding protein is conjugated to an imaging agent, and the method further includes detecting the cells with the imaging agent. In some aspects, the antigen-binding protein is conjugated to a T-cell adaptor molecule (e.g., a bispecific antibody) (e.g., teratolimab, elranatamb, alanuctamab, linvoseltamab, ABBV-383, HPN217 (TriTAC), or ISB 2001). In some aspects, contacting the engineered cells with the antigen-binding protein is performed in vitro. In some aspects, contacting the engineered cells with the antigen-binding protein is performed in vitro. In other aspects, contacting the engineered cells with the antigen-binding protein is performed in vivo.

[0024] This document also discloses the following aspects 1-X. Aspect 1 is a chimeric polypeptide comprising: (a) an extracellular domain comprising one or more repeats of an amino acid sequence having at least 90% identity with SEQ ID NO:33; (b) a hinge region; and (c) a transmembrane domain. Aspect 2 is a chimeric polypeptide according to aspect 1, wherein the extracellular domain comprises one or more repeats of an amino acid sequence having at least 95% identity with SEQ ID NO:33. Aspect 3 is a chimeric polypeptide according to aspect 1 or aspect 2, wherein the extracellular domain comprises one or more repeats of an amino acid sequence having at least 99% identity with SEQ ID NO:33. Aspect 4 is a chimeric polypeptide according to any one of aspects 1-3, wherein the extracellular domain comprises one or more repeats of an amino acid sequence comprising SEQ ID NO:33. Aspect 5 is a chimeric polypeptide according to any one of aspects 1-4, wherein the extracellular domain comprises one or more repeats of an amino acid sequence comprising SEQ ID NO:33. Aspect 6 is a chimeric polypeptide according to any one of aspects 1-5, wherein the extracellular domain comprises one or more repeats of an amino acid sequence having at least 95% identity with SEQ ID NO:1 or SEQ ID NO:2. Aspect 7 is a chimeric polypeptide according to any one of aspects 1-6, wherein the extracellular domain comprises one or more repeats of an amino acid sequence containing SEQ ID NO:1 or SEQ ID NO:2. Aspect 8 is a chimeric polypeptide according to any one of aspects 1-7, wherein the extracellular domain comprises one or more repeats of an amino acid sequence consisting of SEQ ID NO:1 or SEQ ID NO:2. Aspect 9 is a chimeric polypeptide according to any one of aspects 1-8, wherein the extracellular domain comprises at least two repeats of an amino acid sequence having at least 95% identity with SEQ ID NO:33. Aspect 10 is a chimeric polypeptide according to any one of aspects 1-9, wherein the extracellular domain comprises at least two repeats of an amino acid sequence having at least 95% identity with SEQ ID NO:33. Aspect 11 is a chimeric polypeptide according to any one of aspects 1-10, wherein the extracellular domain comprises at least two repeats of an amino acid sequence having at least 99% identity with SEQ ID NO:33. Aspect 12 is a chimeric polypeptide according to any one of aspects 1-11, wherein the extracellular domain comprises at least two repeats of an amino acid sequence containing SEQ ID NO:33. Aspect 13 is a chimeric polypeptide according to any one of aspects 1-12, wherein the extracellular domain comprises at least two repeats of an amino acid sequence consisting of SEQ ID NO:33.Aspect 14 is a chimeric polypeptide according to any one of aspects 1-13, wherein the extracellular domain comprises at least two repeats of an amino acid sequence having at least 95% identity with SEQ ID NO:1 or SEQ ID NO:2. Aspect 15 is a chimeric polypeptide according to any one of aspects 1-14, wherein the extracellular domain comprises at least two repeats of an amino acid sequence containing SEQ ID NO:1 or SEQ ID NO:2. Aspect 16 is a chimeric polypeptide according to any one of aspects 1-15, wherein the extracellular domain comprises at least two repeats of an amino acid sequence consisting of SEQ ID NO:1 or SEQ ID NO:2. Aspect 17 is a chimeric polypeptide according to any one of aspects 1-16, wherein the hinge region comprises a hinge region derived from programmed cell death 1 ligand 1 (PDL1). Aspect 18 is a chimeric polypeptide according to any one of aspects 1-17, wherein the hinge region comprises SEQ ID NO:3. Aspect 19 is a chimeric polypeptide according to any one of aspects 1-18, wherein the hinge region is composed of SEQ ID NO:3. Aspect 20 is a chimeric polypeptide according to any one of aspects 1-19, wherein the transmembrane domain comprises a transmembrane domain from programmed cell death 1 ligand 1 (PDL1). Aspect 21 is a chimeric polypeptide according to any one of aspects 1-20, wherein the transmembrane domain comprises an amino acid sequence having at least 95% identity with SEQ ID NO:4. Aspect 22 is a chimeric polypeptide according to any one of aspects 1-21, wherein the transmembrane domain comprises SEQ ID NO:4. Aspect 23 is a chimeric polypeptide according to any one of aspects 1-22, wherein the transmembrane domain is composed of SEQ ID NO:4. Aspect 24 is a chimeric polypeptide according to any one of aspects 1-23, further comprising an intracellular region. Aspect 25 is a chimeric polypeptide according to aspect 24, wherein the intracellular region has endocytic or internalization activity. Aspect 26 is a chimeric polypeptide according to aspect 24 or 25, wherein the intracellular region comprises a cytoplasmic domain from Trop2. Aspect 27 is a chimeric polypeptide according to any one of aspects 24-26, wherein the intracellular region comprises an amino acid sequence having at least 95% identity with SEQ ID NO:5. Aspect 28 is a chimeric polypeptide according to any one of aspects 24-27, wherein the intracellular region comprises SEQ ID NO:5. Aspect 29 is a chimeric polypeptide according to any one of aspects 24-28, wherein the intracellular region comprises SEQ ID NO:5. Aspect 30 is a chimeric polypeptide according to any one of aspects 1-29, further comprising a linker region between one or more repeats of an amino acid sequence having at least 90% identity with SEQ ID NO:33. Aspect 31 is a chimeric polypeptide according to aspect 30, wherein the linker region comprises one or more CD34 epitopes.Aspect 32 is a chimeric polypeptide according to aspect 31, wherein each of the one or more CD34 epitopes comprises an amino acid sequence having at least 95% identity with SEQ ID NO:6 or SEQ ID NO:7. Aspect 33 is a chimeric polypeptide according to aspect 31 or 32, wherein each of the one or more CD34 epitopes comprises SEQ ID NO:6 or SEQ ID NO:7. Aspect 34 is a chimeric polypeptide according to any one of aspects 31-33, wherein each of the one or more CD34 epitopes is composed of SEQ ID NO:6 or SEQ ID NO:7. Aspect 35 is a chimeric polypeptide according to any one of aspects 31-34, wherein the linker region comprises at least two CD34 epitopes. Aspect 36 is a chimeric polypeptide according to aspect 35, further comprising a linker region following each of the at least two CD34 epitopes. Aspect 37 is a chimeric polypeptide according to aspect 36, wherein the linker region comprises an amino acid sequence having at least 95% identity with SEQ ID NO:8 or SEQ ID NO:9. Aspect 38 is a chimeric polypeptide according to aspect 36 or 37, wherein the linker region comprises SEQ ID NO:8 or SEQ ID NO:9. Aspect 39 is a chimeric polypeptide according to any one of aspects 36-38, wherein the linker region comprises SEQ ID NO:8 or SEQ ID NO:9. Aspect 40 is a chimeric polypeptide according to any one of aspects 1-39, wherein the chimeric polypeptide comprises an amino acid sequence having at least 95% identity with SEQ ID NO:10. Aspect 41 is a chimeric polypeptide according to any one of aspects 1-40, wherein the chimeric polypeptide comprises an amino acid sequence having at least 99% identity with SEQ ID NO:10. Aspect 42 is a chimeric polypeptide according to any one of aspects 1-41, wherein the chimeric polypeptide comprises SEQ ID NO:10.

[0025] Aspect 43 is a chimeric polypeptide comprising an amino acid sequence having at least 95% identity with SEQ ID NO:10. Aspect 44 is a chimeric polypeptide comprising SEQ ID NO:10. Aspect 45 is a chimeric polypeptide consisting of SEQ ID NO:10.

[0026] Aspect 46 is a nucleic acid molecule comprising a nucleotide sequence encoding a chimeric polypeptide as described in any one of aspects 1-45. Aspect 47 is a nucleic acid molecule according to aspect 46, wherein the nucleic acid molecule comprises a nucleic acid sequence having at least 95% identity with SEQ ID NO:20. Aspect 48 is a nucleic acid molecule according to aspect 47, wherein the nucleic acid molecule comprises SEQ ID NO:20. Aspect 49 is a vector comprising the nucleic acid molecule as described in any one of aspects 46-48.

[0027] Aspect 50 is a method for generating engineered cells, comprising introducing into cells a chimeric polypeptide as described in any one of aspects 1-45, a nucleic acid molecule as described in any one of aspects 46-48, or a carrier as described in aspect 49. Aspect 51 is an engineered cell comprising a chimeric polypeptide as described in any one of aspects 1-45, a nucleic acid molecule as described in any one of aspects 46-48, or a carrier as described in aspect 49. Aspect 52 is an engineered cell according to aspect 51, wherein the engineered cell is a T cell. Aspect 53 is an engineered cell according to aspect 52, wherein the T cell is a CD4+ cell. + T cells, CD8 +T cells, iNKT cells, NKT cells, γδ T cells, or regulatory T cells. Aspect 54 is an engineered cell according to aspect 51, wherein the engineered cell is a natural killer cell. Aspect 55 is an engineered cell according to aspect 51, wherein the engineered cell is an induced pluripotent stem cell (iPSC). Aspect 56 is an engineered cell according to aspect 51, wherein the engineered cell is an iPSC-derived cell. Aspect 57 is an engineered cell according to any one of aspects 51-56, further comprising a chimeric antigen receptor (CAR). Aspect 58 is an engineered cell according to aspect 57, wherein the chimeric polypeptide is operatively linked to the CAR. Aspect 59 is an engineered cell according to aspects 51-58, further comprising a T cell receptor (TCR). Aspect 60 is an engineered cell according to aspect 59, wherein the chimeric polypeptide is operatively linked to the TCR. Aspect 61 is a population of engineered cells comprising the engineered cells according to any one of aspects 51-60. Aspect 62 is a method for detecting, isolating, depleting, or purifying engineered cells as described in any one of Aspects 51-60, the method comprising contacting the engineered cells with a BCMA-binding protein. Aspect 63 is the method according to Aspect 62, wherein the BCMA-binding protein is an anti-BCMA antibody or an antigen-binding fragment thereof. Aspect 64 is the method according to Aspect 62 or 63, further comprising using the BCMA-binding protein to isolate the cells from a cell population. Aspect 65 is the method according to any one of Aspects 62-64, further comprising detecting the cells with an imaging agent, wherein the BCMA-binding protein is linked to the imaging agent. Aspect 66 is the method according to Aspect 62 or 63, wherein the BCMA-binding protein is linked to a T-cell adaptor molecule. Aspect 67 is the method according to Aspect 66, wherein the T-cell adaptor molecule is teratumab, enatumab, alanuctamab, rivosaminidumab, ABBV-383, HPN217 (TriTAC), or ISB 2001. Aspect 68 is the method according to any one of aspects 62-67, wherein contacting the engineered cells with the BCMA-binding protein is performed in vitro. Aspect 69 is the method according to any one of aspects 62-67, wherein contacting the engineered cells with the BCMA-binding protein is performed in vitro. Aspect 70 is the method according to any one of aspects 62-67, wherein contacting the engineered cells with the BCMA-binding protein is performed in vivo.

[0028] Aspect 71 is a method for detecting, isolating, depleting, or purifying cells comprising: (a) an extracellular domain comprising one or more repeats of an amino acid sequence having at least 90% identity with SEQ ID NO:33; (b) a hinge region; and (c) a transmembrane domain, the method comprising contacting the cells with a BCMA-binding protein. Aspect 72 is the method according to aspect 71, wherein the extracellular domain comprises at least two repeats of an amino acid sequence having at least 90% identity with SEQ ID NO:33.

[0029] Aspect 73 is an expression construct comprising a sequence encoding a BCMA fusion protein, wherein the fusion protein comprises an extracellular domain comprising one or more repeats of an amino acid sequence having at least 90% identity with SEQ ID NO:33, the extracellular domain being fused to an intracellular domain having endocytic or internalizing activity. Aspect 74 is an expression construct according to aspect 73, wherein the extracellular domain comprises at least two repeats of an amino acid sequence having at least 90% identity with SEQ ID NO:33. Aspect 75 is an expression construct according to aspect 73 or 74, wherein the intracellular domain is derived from Trop2. Aspect 76 is an expression construct according to any one of aspects 73-75, wherein the BCMA fusion protein further comprises a PDL1 hinge region, a PDL1 transmembrane domain, or a combination thereof. Aspect 77 is an expression construct according to any one of aspects 73-76, wherein the BCMA fusion protein further comprises a linker region between one or more repeats of an amino acid sequence having at least 90% identity with SEQ ID NO:33, wherein the linker region comprises one or more CD34 epitopes. Aspect 78 is an expression construct according to any one of aspects 73-76, wherein the fusion protein comprises SEQ ID NO:10. Aspect 79 is an expression construct according to any one of aspects 73-78, wherein the sequence encoding the fusion protein comprises SEQ ID NO:20. Aspect 80 is an isolated cell comprising the expression construct according to any one of aspects 73-79. Aspect 81 is a cell according to aspect 80, wherein the cell is an immune cell. Aspect 82 is a cell according to aspect 80 or 81, wherein the cell is an αβ T cell, γδ T cell, NK cell, NKT cell, monocyte, macrophage, B cell, mesenchymal stem cell (MSC) cell, hematopoietic stem cell (HSC), hematopoietic cell, iPSC, or a mixture thereof. Aspect 83 is a cell according to any one of aspects 80-82, wherein the cell expresses one or more heterologous proteins other than the BCMA fusion protein. Aspect 84 is a cell according to aspect 83, wherein the heterologous protein is a therapeutic protein, a cytokine, a fusion of a cytokine and a cytokine receptor, a safety switch, or a mixture thereof. Aspect 85 is a cell according to aspect 84, wherein the therapeutic protein is an engineered antigen receptor or antibody. Aspect 86 is a cell according to aspect 85, wherein the engineered antigen receptor targets a cancer antigen. Aspect 87 is a cell according to aspect 85 or 86, wherein the engineered antigen receptor is a chimeric antigen receptor, a T-cell receptor, or a B-cell receptor. Aspect 88 is an isolated population of cells according to any one of aspects 80-87, the population being contained in a suitable culture medium. Aspect 89 is a population according to aspect 88, which is deposited in a depository.Aspect 90 is the population described in accordance with aspect 88 or 89, wherein the population is cryopreserved.

[0030] Aspect 91 is a method for identifying BCMA-positive cells transduced or transfected with a heterologous BCMA gene or a BCMA fusion protein, said BCMA fusion protein comprising an extracellular domain comprising one or more repeats of an amino acid sequence having at least 90% identity with SEQ ID NO:33, the method comprising the steps of: transducing or transfecting cells with said heterologous BCMA gene or said BCMA fusion protein, said BCMA fusion protein comprising an extracellular domain comprising one or more repeats of an amino acid sequence having at least 90% identity with SEQ ID NO:33; exposing said cells to an effective amount of a BCMA-binding reagent; and directly or indirectly detecting the binding of said reagent to BCMA on the cell surface. Aspect 92 is the method according to aspect 91, wherein said extracellular domain comprises at least two repeats of an amino acid sequence having at least 90% identity with SEQ ID NO:33. Aspect 93 is the method according to aspect 91 or 92, wherein said exposure and detection steps are performed during and / or after cell manufacturing. Aspect 94 is the method according to aspect 91 or 93, further comprising the step of manufacturing the cells. Aspect 95 is the method according to any one of aspects 91-94, further defined as: transfecting or transducing immune cells with the BCMA fusion protein; exposing the immune cells to an effective amount of an antibody or antibody-drug conjugate that binds BCMA; and directly or indirectly detecting the binding of the antibody or antibody-drug conjugate to BCMA on the cell surface. Aspect 96 is the method according to any one of aspects 91-95, wherein the method is performed in vitro. Aspect 97 is the method according to any one of aspects 91-95, wherein at least a portion of the method is performed in vivo. Aspect 98 is the method according to any one of aspects 91-97, wherein the cells express one or more heterologous proteins other than the BCMA fusion protein. Aspect 99 is the method according to aspect 98, wherein the heterologous protein is a therapeutic protein, a cytokine, a fusion of a cytokine and a cytokine receptor, a safety switch, or a mixture thereof. Aspect 100 is the method according to aspect 99, wherein the therapeutic protein is an engineered antigen receptor. Aspect 101 is the method according to any one of aspects 91-100, further comprising the step of transfecting or transforming the immune cells with a heterologous protein other than the heterologous BCMA or the BCMA fusion protein. Aspect 102 is the method according to aspect 101, wherein the BCMA fusion protein and the heterologous protein other than the BCMA fusion protein are expressed from the same vector. Aspect 103 is the method according to aspect 101, wherein the BCMA fusion protein and the heterologous protein other than the BCMA fusion protein are expressed from different vectors.

[0031] Aspect 104 is a method for manufacturing immune cells for adoptive cell therapy, comprising the steps of: (a) transducing or transfecting immune cells with a heterologous BCMA protein or a BCMA fusion protein, wherein the immune cells express BCMA or the BCMA fusion protein, respectively; and (b) transducing or transfecting the immune cells with one or more therapeutic proteins. Aspect 105 is the method according to aspect 104, wherein step (a) is performed before, simultaneously with, or after step (b). Aspect 106 is the method according to aspect 104, wherein the transformation or transfection in step (a) is the same as the transformation or transfection in step (b). Aspect 107 is the method according to any one of aspects 104-106, wherein the BCMA or BCMA fusion protein is on the same carrier as the therapeutic protein. Aspect 108 is the method according to any one of aspects 104-106, wherein the BCMA or BCMA fusion protein is on a different carrier than the therapeutic protein. Aspect 109 is the method according to any one of aspects 104-108, wherein after step (a), the presence of BCMA expressed on the surface of the immune cells from the immune cells of the method is analyzed. Aspect 110 is the method according to aspect 109, wherein the analysis comprises flow cytometry, polymerase chain reaction, or a combination thereof. Aspect 111 is the method according to any one of aspects 104-110, further comprising the step of administering the immune cells generated by the method to an individual in need. Aspect 112 is the method according to aspect 111, wherein the immune cells in the individual are monitored. Aspect 113 is the method according to aspect 111 or 112, wherein the immune cells in the individual are monitored using a BCMA-binding reagent. Aspect 114 is the method according to aspect 113, wherein the reagent is an antibody or an antibody-drug conjugate. Aspect 115 is the method according to any one of aspects 104-114, wherein the individual exhibits one or more harmful effects from the immune cells, and an effective amount of a BCMA-binding reagent is administered to the individual. Aspect 116 is the method according to aspect 115, wherein the individual exhibits toxicity from the immune cells, and an effective amount of a BCMA-binding agent is administered to the individual. Aspect 117 is the method according to aspect 115, wherein the individual exhibits graft-versus-host disease (GVHD) from the immune cells, and an effective amount of a BCMA-binding agent is administered to the individual. Aspect 118 is the method according to any one of aspects 114-117, wherein the individual no longer requires the immune cells, and an effective amount of a BCMA-binding agent is administered to the individual.

[0032] Aspect 119 is a method for reducing or preventing one or more adverse effects from cell therapy in an individual, comprising the step of targeting BCMA expressed on the cell surface of the cell therapy. Aspect 120 is the method according to aspect 119, further defined as administering to the individual an effective amount of one or more agents that bind to BCMA expressed on the cells. Aspect 121 is the method according to aspect 120, wherein the agent is an antibody or an antibody-drug conjugate. Aspect 122 is the method according to aspect 121, wherein the antibody is a monoclonal antibody. Aspect 123 is the method according to any one of aspects 119-122, wherein the adverse effects include GVHD, cytokine release syndrome, or immune effector cell-related neurotoxicity syndrome. Aspect 124 is the method according to any one of aspects 119-123, wherein the BCMA is the intact BCMA protein. Aspect 125 is the method according to any one of aspects 119-123, wherein the BCMA is a fragment of the intact BCMA protein containing at least a portion of an extracellular domain. Aspect 126 is the method according to any one of aspects 119-124, wherein the BCMA is naturally expressed on the immune cells or naturally heterologously expressed on the immune cells. Aspect 127 is the method according to any one of aspects 119-125, wherein the BCMA is a BCMA fusion protein. Aspect 128 is the method according to aspect 127, wherein the fusion protein comprises an extracellular domain comprising one or more repeats of an amino acid sequence having at least 90% identity with SEQ ID NO:33, the extracellular domain being fused to an intracellular domain having endocytic or internalizing activity. Aspect 129 is the method according to aspect 127 or 128, wherein the fusion protein comprises an extracellular domain comprising at least two repeats of an amino acid sequence having at least 90% identity with SEQ ID NO:33, the extracellular domain being fused to an intracellular domain having endocytic or internalizing activity. Aspect 130 is the method according to aspect 128 or 129, wherein the intracellular domain is derived from Trop2. Aspect 131 is the method according to any one of aspects 128-130, wherein the BCMA fusion protein further comprises a PDL1 hinge region, a PDL1 transmembrane domain, or a combination thereof. Aspect 132 is the method according to any one of aspects 128-131, wherein the BCMA fusion protein further comprises a linker region between one or more repeats of an amino acid sequence having at least 90% identity with SEQ ID NO:33, wherein the linker region comprises one or more CD34 epitopes. Aspect 133 is the method according to any one of aspects 119-132, wherein prior to the targeting step, the cells of the individual are monitored in vivo.Aspect 134 is the method according to aspect 133, wherein the cells are monitored using one or more BCMA-targeting agents. Aspect 135 is the method according to aspect 134, wherein the BCMA-targeting agent is used in a sufficiently low amount to not inhibit antibodies on the therapeutic cells. Aspect 136 is the method according to any one of aspects 119-135, wherein the cell therapy is autologous or allogeneic relative to the individual.

[0033] The term "substantially" is defined as generally, but not necessarily entirely, the specified content (and includes the specified content; for example, substantially 90 degrees includes 90 degrees, substantially parallel includes parallel), as understood by one of ordinary skill in the art. In any aspect of the disclosure, the terms "substantially," "approximately," and "about" may be replaced with "within [percentage]" of the specified content, where the percentage is 1%, 1%, 5%, or 10%. These terms may be removed from the relevant disclosed values ​​and may be replaced with precise values.

[0034] A range may be expressed herein as from “about” a particular value, and / or to “about” another particular value. When such a range is expressed, it is specifically considered and regarded as disclosing the range from said particular value and / or to said other particular value, unless the context explicitly indicates otherwise. Similarly, when a value is expressed as an approximation using the preposition “about,” it should be understood that the particular value constitutes another aspect that should be regarded as disclosed, unless the context explicitly indicates otherwise. It should also be understood that the endpoints of each range are meaningful relative to and independent of the other endpoints, unless the context explicitly indicates otherwise. Finally, it should be understood that all individual values ​​and subranges of values ​​contained within an explicitly disclosed range are also specifically considered and should be regarded as disclosed, unless the context explicitly indicates otherwise. The foregoing applies regardless of whether some or all of these aspects are explicitly disclosed in a particular context.

[0035] When used in conjunction with the terms “comprising,” “having,” “including,” or “containing” (or any variation of these words), the use of the word “a” or “an” can mean “one / a type,” but it is also consistent with the meanings of “one or more / a combination of one or more,” “at least one / at least one,” and “one or more / a type or more.”

[0036] The phrase “and / or” means “and” or “or”. For example, A, B and / or C includes: A alone, B alone, C alone, a combination of A and B, a combination of A and C, a combination of B and C, or a combination of A, B and C. In other words, “and / or” functions as an inclusive “or”.

[0037] The words “comprising” (and any form of comprising, such as “comprise” and “comprises”), “having” (and any form of having, such as “have” and “has”), “including” (and any form of including, such as “includes” and “include)”), or “containing” (and any form of containing, such as “contains” and “contain)”) are inclusive or open-ended and do not exclude additional, unlisted elements or methodological steps.

[0038] The composition and its method of use may “comprising” any component or step disclosed throughout the specification, and may be “substantially composed of” or “by” any component or step disclosed throughout the specification. A composition and method “substantially composed of” any disclosed component or step limits the scope of the claims to specific materials or steps that do not materially affect the essential and novel features of the claimed invention.

[0039] Throughout this specification, references to “an aspect,” “aspect,” “specific aspect,” “related aspect,” “a certain aspect,” “additional aspect,” or “further aspect,” or combinations thereof, mean that a particular characteristic, structure, or feature described in connection with said aspect is included in at least one aspect of this disclosure. Therefore, the aforementioned phrases appearing throughout this specification do not necessarily refer to the same aspect. Furthermore, a particular characteristic, structure, or feature may be combined in any suitable manner within one or more aspects.

[0040] Any method in the context of a therapeutic, diagnostic, or physiological purpose or effect may also be described in the language of the “use” claims, such as any compound, composition, or reagent discussed herein for achieving or implementing the described therapeutic, diagnostic, or physiological purpose or effect.

[0041] As used herein, the term "engineered" refers to an artificially generated entity, including cells, nucleic acids, peptides, vectors, etc. In at least some cases, engineered entities are synthetic and include elements that are not naturally present or configured in the manner used in this disclosure. In specific instances, vectors are engineered using recombinant nucleic acid technology, and cells are engineered through transfection or transduction of engineered vectors.

[0042] As used herein, “prevent” and similar terms such as “prevented” and “preventing” refer to methods used to prevent, suppress, or reduce the likelihood of the occurrence or recurrence of a disease or condition (such as cancer). It also refers to delaying the onset or recurrence of a disease or condition, or delaying the occurrence or recurrence of symptoms of a disease or condition. As used herein, “prevention” and similar terms also include reducing the intensity, impact, symptoms, and / or burden of a disease or condition before its onset or recurrence.

[0043] As used herein, the term "subject" generally refers to an individual who has or is suspected of having cancer and is having a biological sample being processed or analyzed, and in specific cases, an individual with or suspected of having cancer. A subject can be any biological or animal subject that is the object of a method or material, including mammals such as humans, laboratory animals (e.g., primates, rats, mice, rabbits), livestock (e.g., cattle, sheep, goats, pigs, turkeys, and chickens), domestic pets (e.g., dogs, cats, and rodents), horses, and genetically modified non-human animals. A subject can be a patient, such as someone with or suspected of having a disease (which may be referred to as a medical condition), such as a benign or malignant tumor or cancer. A subject may be receiving or have received treatment. A subject may be asymptomatic. A subject may be a healthy individual who wishes to prevent cancer. In at least some cases, the term "individual" may be used interchangeably. As used herein, a "subject" or "individual" may or may not be placed in a medical facility and may be treated as an outpatient at a medical facility. An individual may receive one or more medical compositions via the Internet. Individuals can include people or non-human animals of any age, thus including adults and adolescents (i.e., children) and infants, and including individuals in the womb. The term is not intended to imply a need for medical treatment; therefore, individuals may become part of an experiment, voluntarily or involuntarily, whether in clinical trials or experiments supporting basic scientific research.

[0044] As used herein, “treatment” or “treating” includes any beneficial or desired effect on the symptoms or pathology of a disease or pathological condition, and may include even minimal reduction of one or more measurable markers of the disease or condition being treated (e.g., cancer). Treatment may optionally involve alleviating or improving the symptoms of a disease or condition, or delaying the progression of a disease or condition. “Treatment” does not necessarily mean the complete eradication or cure of a disease or condition or its associated symptoms.

[0045] Specifically, any limitations discussed with respect to one aspect of this disclosure may be applied to any other aspect of this disclosure. Furthermore, any composition of this disclosure may be used in any method of this disclosure, and any method of this disclosure may be used to produce or utilize any composition of this disclosure. Any aspect discussed with respect to one aspect of this disclosure also applies to other aspects of this disclosure, and vice versa. For example, any step in a method described herein may be applied to any other method. Furthermore, any method described herein may exclude any step or combination of steps. The aspects illustrated in the examples are also aspects that may be implemented in the context of aspects discussed elsewhere in different examples or elsewhere in this application (such as in the summary, detailed description, claims, and description of drawings).

[0046] Other objects, features, and advantages of the invention will become apparent from the following detailed description. However, it should be understood that while the detailed description and specific examples indicate specific aspects of the invention, they are given by way of example only, and various changes and modifications within the spirit and scope of the invention will become apparent to those skilled in the art from this detailed description. Attached Figure Description

[0047] The following figures form part of this specification and are included to further illustrate certain aspects of this disclosure. A better understanding of these aspects can be achieved by referring to one or more of these figures in conjunction with the detailed description of the specific aspects presented herein.

[0048] Figure 1 A schematic diagram is shown of a construct (“ctdBCMA”) that encodes two extracellular domains of BCMA, according to several aspects.

[0049] Figure 2 The illustration shows, according to some aspects, the co-expression by immune cells of constructs encoding one (left; "ctBCMA") or two (right; "ctdBCMA") BCMA extracellular domains and CD19 CARs.

[0050] Figure 3 The expression of the construct encoding two BCMA extracellular domains (“ctdBCMA”) by immune cells is shown, along with the construct encoding one BCMA extracellular domain (“ctBCMA”) and the control construct.

[0051] Figure 4 The stable expression of the construct encoding two BCMA extracellular domains (“ctdBCMA”) was demonstrated over 6 days in cells expressing the protease.

[0052] Figure 5This study illustrates the co-expression of the construct encoding two BCMA extracellular domains (“ctdBCMA”) and the CD19 CAR by immune cells 24 hours after co-culturing with Daudi tumor cells, in the presence and absence of autologous effector T cells. The percentage change in GFP+ CAR T cells from baseline after 24 hours of co-culture is also shown.

[0053] Figure 6 This diagram illustrates the co-expression of a construct encoding two BCMA extracellular domains (“ctdBCMA”) or one BCMA extracellular domain (“ctBCMA”) and a CD19 CAR by immune cells in the presence of autologous effector T cells 24 hours after co-culturing with Daudi tumor cells. The percentage change in GFP+ CAR T cells from baseline after 24 hours of co-culture is also shown.

[0054] Figure 7 This diagram illustrates GFP expression in immune cells co-transduced with GFP and a construct encoding two BCMA extracellular domains (“ctdBCMA”) 36 hours after co-culturing with Daudi tumor cells, in the presence of autologous effector T cells. Changes in GFP+ CAR T cells (measured by confluence of green regions) from baseline are shown over 36 hours of co-culture.

[0055] Figure 8 The study demonstrates the in vivo expansion of immune cells co-expressing a construct encoding two BCMA extracellular domains (“ctdBCMA”) and a CD19 CAR over 7 days, as monitored by bioluminescence imaging.

[0056] Figure 9 The percentage change in total flux in mice injected with immune cells co-expressing a construct encoding two BCMA extracellular domains (“ctdBCMA”) and CD19CAR after treatment with teratumab in the presence and absence of autologous effector T cells is shown.

[0057] Figure 10This study demonstrates the in vitro elimination of anti-CD19 CAR T cells carrying ctBCMA with teratumab. Primary T cells (designated ITC-101) transduced with anti-CD19CAR, ctBCMA, BCL6, and BCL2L1 were cultured in triplicate wells with or without teratumab or an IgG4 isotype control antibody (at a concentration of 100 ng / mL) and supplemented with 200 IU / mL IL-2 per well. The percentage change in the absolute number of live CAR T cells was determined by flow cytometry on day 4 and compared with day 0. Data are presented as mean ± SD and represent one of three experiments. Significance differences between control and test samples were determined by paired t-tests. p<0.05, p<0.01.

[0058] Figure 11A-11C This demonstrates that teratumab eliminates anti-CD19 CAR T cells carrying ctBCMA in vivo. Figure 11A Experimental design for evaluating the efficacy of teratumab in vivo. Figure 11B The proportion of primary T cells (referred to as ITC-101) transduced with anti-CD19CAR, ctBCMA, BCL6, and BCL2L1 in the bone marrow of representative mice in each group is shown. Figure 11C This is a pooled result from bone marrow samples from all mice in 6 groups. N = 5 mice per group. Statistical significance was determined by one-way ANOVA. P<0.001; P<0.0001.

[0059] Figure 12A-12D This demonstrates that teratumab eliminates anti-CD94 CAR T cells carrying ctdBCMA in vitro and in vivo. Figure 12A Expression of anti-CD94 CAR and ctdBCMA in the CD94 CAR T cell + / - ctdBCMA safety switch. Figure 12B-12C CAR T cells targeting CD94 with a + / - ctdBCMA safety switch were cultured in triplicate wells with or without a specified concentration of teratumab, and the percentage of CAR+ T cells from the triplicate wells was determined by flow cytometry on days 0–3. Figure 12B ) and changes in absolute quantity ( Figure 12C The data represent three independent experiments. Figure 12D Anti-CD94 CAR T cell + / - ctdBCMA safety switch was injected intravenously (IV) into NSG mice carrying KHYG-1 tumors (5 × 10⁶ cells per mouse). 6Two days later, mice received intravenous injection of either IgG4 control Ab or teritumumab (30 μg per mouse). CAR T cells in peripheral blood were assessed before antibody injection (top row) and one week after treatment (bottom row). Data represent 5 mice per group and one of two experiments. Statistical significance was determined by one-way ANOVA. Detailed Implementation

[0060] Various aspects of this disclosure relate to peptides that can be used to detect, isolate, deplete, and / or purify cells. Therefore, certain aspects of this disclosure relate to chimeric peptides comprising, for example, one or more repeating extracellular domains comprising an amino acid sequence having at least 90% identity with SEQ ID NO:33, or at least two repeating extracellular domains comprising an amino acid sequence having at least 90% identity with SEQ ID NO:33. The chimeric peptides of this disclosure may also comprise one or more additional domains or regions, such as signal peptides, hinge regions, intracellular regions, linker regions, or any combination thereof. Cells (e.g., therapeutic cells) comprising one or more peptides of this disclosure (e.g., chimeric peptides), and methods for detecting, isolating, depleting, and / or purifying such cells are also disclosed.

[0061] In certain aspects, chimeric peptides are used for one or more specific purposes, such as those related to cell therapy. In certain aspects, chimeric peptides are used to directly or indirectly control the use of specific therapeutic cells and allow for monitoring cell therapy, detecting cells in cell therapy, isolating cells used for cell therapy, and / or terminating cell therapy at desired events and / or times. In certain aspects, chimeric peptides are used as transduction markers, safety switches, or both. In some cases, the chimeric peptides covered herein are used as transduction markers or selection markers in cells, but another safety switch controls cell inhibition. In other cases, chimeric peptides are used as safety switches in cells, optionally in conjunction with another safety switch in the same cell.

[0062] Safety-switch chimeric peptides can be used in transduced / transfected cells to induce cell death when needed. Cells utilizing chimeric peptides can contain one or more different chimeric peptides acting as safety switches. In some respects, safety-switch chimeric peptides function as "suicide genes," which, upon administration of a prodrug or other reagent, convert a gene product into a compound that kills its host cell. In other respects, safety-switch chimeric peptides function as suicide genes encoding a gene product that, when needed, is targeted by an agent that targets the suicide gene product (such as an antibody).

[0063] In some cases, individuals receive cell therapy in which cells express chimeric peptides. When an individual receiving and / or who has received cell therapy exhibits one or more symptoms of one or more adverse events (such as cytokine release syndrome, neurotoxicity, anaphylactic / hypersensitivity reactions, and / or target / extratumoral toxicity (as an example)), or is considered to be at risk (including impending risk) for one or more symptoms, one or more agents binding to the extracellular domains of the chimeric peptide may be used on the individual. The use of agents binding to the chimeric peptide may be part of the therapy protocol or may be used only when its use is recognized as necessary. In some cases, cell therapy is terminated by using one or more agents targeting one or more extracellular domains of the chimeric peptide because treatment is no longer required.

[0064] The application of chimeric peptides as a safety switch can be initiated upon the occurrence of at least one adverse event in an individual, and this adverse event can be identified by any means, including routine monitoring that may be continuous or discontinuous from the start of cell therapy. One or more adverse events can be detected during examination and / or testing. In cases where an individual suffers from cytokine release syndrome (also known as a cytokine storm), the individual may experience, for example, elevated levels of one or more inflammatory cytokines (examples only: interferon-γ, granulocyte-macrophage colony-stimulating factor, IL-10, IL-6, and TNF-α); fever; fatigue; hypotension; hypoxia, tachycardia; nausea; capillary leakage; cardiac / renal / hepatic dysfunction; or combinations thereof. In cases where an individual suffers from neurotoxicity, the individual may experience confusion, delirium, aphasia, and / or seizures. In some cases, markers associated with the onset and / or severity of cytokine release syndrome, such as C-reactive protein, IL-6, TNF-α, and / or ferritin, are tested in the individual.

[0065] In certain aspects, cell therapy may include one or more vectors encoding one or more heterologous proteins, and such heterologous proteins may be compositions that make the cells therapeutic. In some aspects, the vector encoding one or more heterologous proteins encodes one or more safety switches. For example, the safety switch may or may not be on the same vector as the CAR. In cases where the safety switch and the CAR are on the same vector, the safety switch and the CAR may be separated, for example, by an IRES or 2A element.

[0066] I. Polypeptides

[0067] This disclosure relates in various aspects to polypeptides, including chimeric polypeptides and methods of using them. As used herein, a “protein” or “polypeptide” means a molecule containing at least five amino acid residues. As used herein, the term “wild-type” refers to an endogenous version of a molecule that is naturally present in an organism. In some aspects, wild-type versions of proteins or polypeptides are used; however, in many aspects of this disclosure, modified proteins or polypeptides are used. The foregoing terms are used interchangeably. A “modified protein” or “modified polypeptide” or “variant” refers to a protein or polypeptide whose chemical structure, and in particular its amino acid sequence, is altered relative to a wild-type protein or polypeptide. In some aspects, a modified / variant protein or polypeptide has at least one modified activity or function (recognizing that a protein or polypeptide can have multiple activities or functions). Specifically, it is considered that a modified / variant protein or polypeptide may be altered in one activity or function while retaining wild-type activity or function in other aspects.

[0068] When referring specifically to proteins herein, they generally mean native (wild-type) or recombinant (modified) proteins, or optionally proteins in which any signal sequence has been removed. Proteins can be isolated directly from their naturally occurring organisms, produced by recombinant DNA / exogenous expression methods, or by solid-phase peptide synthesis (SPPS) or other in vitro methods. In certain aspects, there are isolated nucleic acid segments and recombinant vectors incorporating nucleic acid sequences encoding polypeptides (e.g., antibodies or fragments thereof). The term “recombinant” can be used in conjunction with the name of a polypeptide or a specific polypeptide, and this generally refers to a polypeptide produced from a nucleic acid molecule that has been manipulated in vitro or as a replication product of such a molecule.

[0069] In some respects, the size of the protein or polypeptide (wild-type or modified) may include, but is not limited to, at least, at most, or exactly 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42. 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91 92, 93, 94, 95, 96, 97, 98, 99, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 275, 300, 325, 350, 375, 400, 425, 450, 475, 500, 525, 550, 575, 600, 625 650, 675, 700, 725, 750, 775, 800, 825, 850, 875, 900, 925, 950, 975, 1000, 1100, 1200, 1300, 1400, 1500, 1750, 2000, 2250, 2500 amino acid residues or more, or any range thereof, or derivatives of the corresponding amino acid sequences described or referenced herein. It is considered that peptides can be mutated by truncation, making them shorter than their corresponding wild-type forms, and that they can be altered by fusion or conjugation with heterologous protein or peptide sequences having specific functions (e.g., for targeting or localization, for enhancing immunogenicity, for purification purposes, etc.). As used herein, the term "domain" refers to any unique functional or structural unit of a protein or peptide and generally refers to an amino acid sequence having a structure or function recognizable to those skilled in the art.

[0070] The polypeptides, proteins, or polynucleotides encoding such polypeptides or proteins of this disclosure may comprise at least, at most, or exactly 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50 (or any derivative range thereof) or more variant amino acids or nucleic acid substitutions, or may be associated with SEQ ID. NO: 1-39 at least, at most, or exactly 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 6 5, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 300, 400, 500, 550, 1000 or more consecutive amino acids or nucleotides, or any of the derivative ranges thereof having at least 60%, 61%, 62% of the range. The similarity, identity, or homology of 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% (or any range derived therefrom) is considered to be similar, identical, or homologous.

[0071] In some respects, the protein, polypeptide, or nucleic acid may each comprise SEQ ID. The amino acids or nucleotides NO:1-39 are 1 to 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79. 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 14 5, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 2 06, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266267、268、269、270、271、272、273、274、275、276、277、278、279、280、281、282、283、284、285、286、287、288、289、290、291、292、293、294、295、296、297、298、299、300、301、302、303、304、305、306、307、308、309、310、311、312、313、314、315、316、317、318、319、320、321、322、323、324、325、326、327、328、329、330、331、332、333、334、335、336、337、338、339、340、341、342、343、344、345、346、347、348、349、350、351、352、353、354、355、356、357、358、359、360、361、362、363、364、365、366、367、368、369、370、371、372、373、374、375、376、377、378、379、380、381、382、383、384、385、386、387、388、389、390、391、392、393、394、395、396、397、398、399、400、401、402、403、404、405、406、407、408、409、410、411、412、413、414、415、416、417、418、419、420、421、422、423、424、425、426、427、428、429、430、431、432、433、434、435、436、437、438、439、440、441、442、443、444、445、446、447、448、449、450、451、452、453、454、455、456、457、458、459、460、461、462、463、464、465、466、467、468、469、470、471、472、473、474、475、476、477、478、479、480、481、482、483、484、485、486、487、488、489、490、491、492、493、494、495、496、497、498、499、500、501、502、503、504、505、506、507、508、509、510、511、512、513、514、515、516、517、518、519、520、521、522、523、524、525、526、527、528、529、530、531、532、533、534、535、536、537、538、539、540、541、542、543、544、545、546、547、548、549、550、551、552、553、554、555、556、557、558、559、560、561、562、563、564、565、566、567、568、569、570、571、572、573、574、575、576、577、578、579、580、581、582、583、584、585、586、587、588、589、590、591、592、593、594、595、596、597、598、599、600、601、602、603、604、605、606、607、608、609、610、611、612、613、614、615、616、617、618、619、620、621、622、623、624、625、626、627、628、629、630、631、632、633、634、635、636、637、638、639、640、641、642、643、644、645、646、647、648、649、650、651、652、653、654、655、656、657、658、659、660、661、662、663、664、665、666、667、668、669、670、671、672、673、674、675、676、677、678、679、680、681、682、683、684、685、686、687、688、689、690、691、692、693、694、695、696、697、698、699、700、701、702、703、704、705、706、707、708、709、710、711、712、713、714、715、716、717、718、719、720、721、722、723、724、725、726、727、728、729、730、731、732、733、734、735、736、737、738、739、740、741、742、743、744、745、746、747、748、749、750、751、752、753、754、755、756、757、758、759、760、761、762、763、764、765、766、767, 768, 769, 770, 771, 772, 773, 774, 775, 776, 777, 778, 779, 780, 781, 782, 783, 784, 785, 786, 787, 788, 789, 790, 791, 792, 793, 794, 795, 796, 797, 798, 799, 800, 801, 802, 803, 804, 805, 806, 807, 808, 809, 810, 811, 812, 813, 814, 815, 816, 817, 818, 819, 820, 821, 822, 823, 824, 825, 8 26, 827, 828, 829, 830, 831, 832, 833, 834, 835, 836, 837, 838, 839, 840, 841, 842, 843, 844, 845, 846, 847, 848, 849, 850, 851, 852, 853, 854, 855, 856, 857, 858, 859, 860, 861, 862, 863, 864, 865, 866, 867, 868, 869, 870, 871, 872, 873, 874, 875, 876, 877, 878, 879, 880, 881, 882, 883, 884, 885 886, 887, 888, 889, 890, 891, 892, 893, 894, 895, 896, 897, 898, 899, 900, 901, 902, 903, 904, 905, 906, 907, 908, 909, 910, 911, 912, 913, 914, 915, 916, 917, 918, 919, 920, 921, 922, 923, 924, 925, 926, 927, 928, 929, 930, 931, 932, 933, 934, 935, 936, 937, 938, 939, 940, 941, 942, 943, 944 945, 946, 947, 948, 949, 950, 951, 952, 953, 954, 955, 956, 957, 958, 959, 960, 961, 962, 963, 964, 965, 966, 967, 968, 969, 970, 971, 972, 973, 974, 975, 976, 977, 978, 979, 980, 981, 982, 983, 984, 985, 986, 987, 988, 989, 990, 991, 992, 993, 994, 995, 996, 997, 998, 999, or 1000 (or any range derived therefrom).

[0072] In some respects, the protein, polypeptide, or nucleic acid may each comprise SEQ ID. NO:1-39 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 8 2, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 14 7, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 2 08, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268269、270、271、272、273、274、275、276、277、278、279、280、281、282、283、284、285、286、287、288、289、290、291、292、293、294、295、296、297、298、299、300、301、302、303、304、305、306、307、308、309、310、311、312、313、314、315、316、317、318、319、320、321、322、323、324、325、326、327、328、329、330、331、332、333、334、335、336、337、338、339、340、341、342、343、344、345、346、347、348、349、350、351、352、353、354、355、356、357、358、359、360、361、362、363、364、365、366、367、368、369、370、371、372、373、374、375、376、377、378、379、380、381、382、383、384、385、386、387、388、389、390、391、392、393、394、395、396、397、398、399、400、401、402、403、404、405、406、407、408、409、410、411、412、413、414、415、416、417、418、419、420、421、422、423、424、425、426、427、428、429、430、431、432、433、434、435、436、437、438、439、440、441、442、443、444、445、446、447、448、449、450、451、452、453、454、455、456、457、458、459、460、461、462、463、464、465、466、467、468、469、470、471、472、473、474、475、476、477、478、479、480、481、482、483、484、485、486、487、488、489、490、491、492、493、494、495、496、497、498、499、500、501、502、503、504、505、506、507、508、509、510、511、512、513、514、515、516、517、518、519、520、521、522、523、524、525、526、527、528、529、530、531、532、533、534、535、536、537、538、539、540、541、542、543、544、545、546、547、548、549、550、551、552、553、554、555、556、557、558、559、560、561、562、563、564、565、566、567、568、569、570、571、572、573、574、575、576、577、578、579、580、581、582、583、584、585、586、587、588、589、590、591、592、593、594、595、596、597、598、599、600、601、602、603、604、605、606、607、608、609、610、611、612、613、614、615、616、617、618、619、620、621、622、623、624、625、626、627、628、629、630、631、632、633、634、635、636、637、638、639、640、641、642、643、644、645、646、647、648、649、650、651、652、653、654、655、656、657、658、659、660、661、662、663、664、665、666、667、668、669、670、671、672、673、674、675、676、677、678、679、680、681、682、683、684、685、686、687、688、689、690、691、692、693、694、695、696、697、698、699、700、701、702、703、704、705、706、707、708、709、710、711、712、713、714、715、716、717、718、719、720、721、722、723、724、725、726、727、728、729、730、731、732、733、734、735、736、737、738、739、740、741、742、743、744、745、746、747、748、749、750、751、752、753、754、755、756、757、758、759、760、761、762、763、764、765、766、767、768、769, 770, 771, 772, 773, 774, 775, 776, 777, 778, 779, 780, 781, 782, 783, 784, 785, 786, 787, 788, 789, 790, 791, 792, 793, 794, 795, 796, 797, 798, 799, 800, 801, 802, 803, 804, 805, 806, 807, 808, 809, 810, 811, 812, 813, 814, 815, 816, 817, 818, 819, 820, 821, 822, 823, 824, 825, 826, 827, 82 8, 829, 830, 831, 832, 833, 834, 835, 836, 837, 838, 839, 840, 841, 842, 843, 844, 845, 846, 847, 848, 849, 850, 851, 852, 853, 854, 855, 856, 857, 858, 859, 860, 861, 862, 863, 864, 865, 866, 867, 868, 869, 870, 871, 872, 873, 874, 875, 876, 877, 878, 879, 880, 881, 882, 883, 884, 885, 886, 887, 888, 889, 890, 891, 892, 893, 894, 895, 896, 897, 898, 899, 900, 901, 902, 903, 904, 905, 906, 907, 908, 909, 910, 911, 912, 913, 914, 915, 916, 917, 918, 919, 920, 921, 922, 923, 924, 925, 926, 927, 928, 929, 930, 931, 932, 933, 934, 935, 936, 937, 938, 939, 940, 941, 942, 943, 944, 945, 946, 94 7, 948, 949, 950, 951, 952, 953, 954, 955, 956, 957, 958, 959, 960, 961, 962, 963, 964, 965, 966, 967, 968, 969, 970, 971, 972, 973, 974, 975, 976, 977, 978, 979, 980, 981, 982, 983, 984, 985, 986, 987, 988, 989, 990, 991, 992, 993, 994, 995, 996, 997, 998, 999, or 1000 (or any derivable range thereof) consecutive amino acids or nucleotides.

[0073] In some aspects, the polypeptide, protein, or nucleic acid may each contain SEQ ID. NO: 1-39 (at least, at most, or exactly) 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 14 5, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 2 06, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266267、268、269、270、271、272、273、274、275、276、277、278、279、280、281、282、283、284、285、286、287、288、289、290、291、292、293、294、295、296、297、298、299、300、301、302、303、304、305、306、307、308、309、310、311、312、313、314、315、316、317、318、319、320、321、322、323、324、325、326、327、328、329、330、331、332、333、334、335、336、337、338、339、340、341、342、343、344、345、346、347、348、349、350、351、352、353、354、355、356、357、358、359、360、361、362、363、364、365、366、367、368、369、370、371、372、373、374、375、376、377、378、379、380、381、382、383、384、385、386、387、388、389、390、391、392、393、394、395、396、397、398、399、400、401、402、403、404、405、406、407、408、409、410、411、412、413、414、415、416、417、418、419、420、421、422、423、424、425、426、427、428、429、430、431、432、433、434、435、436、437、438、439、440、441、442、443、444、445、446、447、448、449、450、451、452、453、454、455、456、457、458、459、460、461、462、463、464、465、466、467、468、469、470、471、472、473、474、475、476、477、478、479、480、481、482、483、484、485、486、487、488、489、490、491、492、493、494、495、496、497、498、499、500、501、502、503、504、505、506、507、508、509、510、511、512、513、514、515、516、517、518、519、520、521、522、523、524、525、526、527、528、529、530、531、532、533、534、535、536、537、538、539、540、541、542、543、544、545、546、547、548、549、550、551、552、553、554、555、556、557、558、559、560、561、562、563、564、565、566、567、568、569、570、571、572、573、574、575、576、577、578、579、580、581、582、583、584、585、586、587、588、589、590、591、592、593、594、595、596、597、598、599、600、601、602、603、604、605、606、607、608、609、610、611、612、613、614、615、616、617、618、619、620、621、622、623、624、625、626、627、628、629、630、631、632、633、634、635、636、637、638、639、640、641、642、643、644、645、646、647、648、649、650、651、652、653、654、655、656、657、658、659、660、661、662、663、664、665、666、667、668、669、670、671、672、673、674、675、676、677、678、679、680、681、682、683、684、685、686、687、688、689、690、691、692、693、694、695、696、697、698、699、700、701、702、703、704、705、706、707、708、709、710、711、712、713、714、715、716、717、718、719、720、721、722、723、724、725、726、727、728、729、730、731、732、733、734、735、736、737、738、739、740、741、742、743、744、745、746、747、748、749、750、751、752、753、754、755、756、757、758、759、760、761、762、763、764、765、766、767, 768, 769, 770, 771, 772, 773, 774, 775, 776, 777, 778, 779, 780, 781, 782, 783, 784, 785, 786, 787, 788, 789, 790, 791, 792, 793, 794, 795, 796, 797, 798, 799, 800, 801, 802, 803, 804, 805, 806, 807, 808, 809, 810, 811, 812, 813, 814, 815, 816, 817, 818, 819, 820, 821, 822, 823, 824, 825, 826, 827, 828, 829, 830, 831, 832, 833, 834, 835, 836, 837, 838, 839, 840, 841, 842, 843, 844, 845, 846, 847, 848, 849, 850, 851, 852, 853, 854, 855, 856, 857, 858, 859, 860, 861, 862, 863, 864, 865, 866, 867, 868, 869, 870, 871, 872, 873, 874, 875, 876, 877, 878, 879, 880, 881, 882, 883, 884, 885, 886, 887, 888 889, 890, 891, 892, 893, 894, 895, 896, 897, 898, 899, 900, 901, 902, 903, 904, 905, 906, 907, 908, 909, 910, 911, 912, 913, 914, 915, 916, 917, 918, 919, 920, 921, 922, 923, 924, 925, 926, 927, 928, 929, 930, 931, 932, 933, 934, 935, 936, 937, 938, 939, 940, 941, 942, 943, 944, 945, 946, 947, 948, 949 950, 951, 952, 953, 954, 955, 956, 957, 958, 959, 960, 961, 962, 963, 964, 965, 966, 967, 968, 969, 970, 971, 972, 973, 974, 975, 976, 977, 978, 979, 980, 981, 982, 983, 984, 985, 986, 987, 988, 989, 990, 991, 992, 993, 994, 995, 996, 997, 998, 999, or 1000 (or any derivative range thereof) consecutive amino acids or nucleotides, wherein each consecutive amino acid or nucleotide has at least one of SEQ ID NO:1-39.Similarity, identity, or homology of up to or exactly 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% (or any range derived therefrom)

[0074] In some respects, there exists a nucleic acid molecule or polypeptide that originates from SEQ ID. NO: Any one of the numbers 1-39, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79. 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 2 06, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266267、268、269、270、271、272、273、274、275、276、277、278、279、280、281、282、283、284、285、286、287、288、289、290、291、292、293、294、295、296、297、298、299、300、301、302、303、304、305、306、307、308、309、310、311、312、313、314、315、316、317、318、319、320、321、322、323、324、325、326、327、328、329、330、331、332、333、334、335、336、337、338、339、340、341、342、343、344、345、346、347、348、349、350、351、352、353、354、355、356、357、358、359、360、361、362、363、364、365、366、367、368、369、370、371、372、373、374、375、376、377、378、379、380、381、382、383、384、385、386、387、388、389、390、391、392、393、394、395、396、397、398、399、400、401、402、403、404、405、406、407、408、409、410、411、412、413、414、415、416、417、418、419、420、421、422、423、424、425、426、427、428、429、430、431、432、433、434、435、436、437、438、439、440、441、442、443、444、445、446、447、448、449、450、451、452、453、454、455、456、457、458、459、460、461、462、463、464、465、466、467、468、469、470、471、472、473、474、475、476、477、478、479、480、481、482、483、484、485、486、487、488、489、490、491、492、493、494、495、496、497、498、499、500、501、502、503、504、505、506、507、508、509、510、511、512、513、514、515、516、517、518、519、520、521、522、523、524、525、526、527、528、529、530、531、532、533、534、535、536、537、538、539、540、541、542、543、544、545、546、547、548、549、550、551、552、553、554、555、556、557、558、559、560、561、562、563、564、565、566、567、568、569、570、571、572、573、574、575、576、577、578、579、580、581、582、583、584、585、586、587、588、589、590、591、592、593、594、595、596、597、598、599、600、601、602、603、604、605、606、607、608、609、610、611、612、613、614、615、616、617、618、619、620、621、622、623、624、625、626、627、628、629、630、631、632、633、634、635、636、637、638、639、640、641、642、643、644、645、646、647、648、649、650、651、652、653、654、655、656、657、658、659、660、661、662、663、664、665、666、667、668、669、670、671、672、673、674、675、676、677、678、679、680、681、682、683、684、685、686、687、688、689、690、691、692、693、694、695、696、697、698、699、700、701、702、703、704、705、706、707、708、709、710、711、712、713、714、715、716、717、718、719、720、721、722、723、724、725、726、727、728、729、730、731、732、733、734、735、736、737、738、739、740、741、742、743、744、745、746、747、748、749、750、751、752、753、754、755、756、757、758、759、760、761、762、763、764、765、766、767, 768, 769, 770, 771, 772, 773, 774, 775, 776, 777, 778, 779, 780, 781, 782, 783, 784, 785, 786, 787, 788, 789, 790, 791, 792, 793, 794, 795, 796, 797, 798, 799, 800, 801, 802, 803, 804, 805, 806, 807, 808, 809, 810, 811, 812, 813, 814, 815, 816, 817, 818, 819, 820, 821, 822, 823, 824, 825, 826, 827, 828, 829, 830, 831, 832, 833, 834, 835, 836, 837, 838, 839, 840, 841, 842, 843, 844, 845, 846, 847, 848, 849, 850, 851, 852, 853, 854, 855, 856, 857, 858, 859, 860, 861, 862, 863, 864, 865, 866, 867, 868, 869, 870, 871, 872, 873, 874, 875, 876, 877, 878, 879, 880, 881, 882, 883, 884, 885, 886, 887, 888, 889, 890, 891, 892, 893, 894, 895, 896, 897, 898, 899, 900, 901, 902, 903, 904, 905, 906, 907, 908, 909, 910, 911, 912, 913, 914, 915, 916, 917, 918, 919, 920, 921, 922, 923, 924, 925, 926, 927, 928, 929, 930, 931, 932, 933, 934, 935, 936, 937, 938, 939, 940, 941, 942, 943 944, 945, 946, 947, 948, 949, 950, 951, 952, 953, 954, 955, 956, 957, 958, 959, 960, 961, 962, 963, 964, 965, 966, 967, 968, 969, 970, 971, 972, 973, 974, 975, 976, 977, 978, 979, 980, 981, 982, 983, 984, 985, 986, 987, 988, 989, 990, 991, 992, 993, 994, 995, 996, 997, 998, 999, or 1000, and containing SEQ. ID NO: at least, at most, or exactly any one of 1-39, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14,15、16、17、18、19、20、21、22、23、24、25、26、27、28、29、30、31、32、33、34、35、36、37、38、39、40、41、42、43、44、45、46、47、48、49、50、51、52、53、54、55、56、57、58、59、60、61、62、63、64、65、66、67、68、69、70、71、72、73、74、75、76、77、78、79、80、81、82、83、84、85、86、87、88、89、90、91、92、93、94、95、96、97、98、99、100、101、102、103、104、105、106、107、108、109、110、111、112、113、114、115、116、117、118、119、120、121、122、123、124、125、126、127、128、129、130、131、132、133、134、135、136、137、138、139、140、141、142、143、144、145、146、147、148、149、150、151、152、153、154、155、156、157、158、159、160、161、162、163、164、165、166、167、168、169、170、171、172、173、174、175、176、177、178、179、180、181、182、183、184、185、186、187、188、189、190、191、192、193、194、195、196、197、198、199、200、201、202、203、204、205、206、207、208、209、210、211、212、213、214、215、216、217、218、219、220、221、222、223、224、225、226、227、228、229、230、231、232、233、234、235、236、237、238、239、240、241、242、243、244、245、246、247、248、249、250、251、252、253、254、255、256、257、258、259、260、261、262、263、264、265、266、267、268、269、270、271、272、273、274、275、276、277、278、279、280、281、282、283、284、285、286、287、288、289、290、291、292、293、294、295、296、297、298、299、300、301、302、303、304、305、306、307、308、309、310、311、312、313、314、315、316、317、318、319、320、321、322、323、324、325、326、327、328、329、330、331、332、333、334、335、336、337、338、339、340、341、342、343、344、345、346、347、348、349、350、351、352、353、354、355、356、357、358、359、360、361、362、363、364、365、366、367、368、369、370、371、372、373、374、375、376、377、378、379、380、381、382、383、384、385、386、387、388、389、390、391、392、393、394、395、396、397、398、399、400、401、402、403、404、405、406、407、408、409、410、411、412、413、414、415、416、417、418、419、420、421、422、423、424、425、426、427、428、429、430、431、432、433、434、435、436、437、438、439、440、441、442、443、444、445、446、447、448、449、450、451、452、453、454、455、456、457、458、459、460、461、462、463、464、465、466、467、468、469、470、471、472、473、474、475、476、477、478、479、480、481、482、483、484、485、486、487、488、489、490、491、492、493、494、495、496、497、498、499、500、501、502、503、504、505、506、507、508、509、510、511、512、513、514、515、516、517、518、519、520、521、522、523、524、525、526、527、528、529、530、531、532、533、534、535、536、537、538、539、540、541、542、543、544、545、546、547、548、549、550、551、552、553、554、555、556、557、558、559、560、561、562、563、564、565、566、567、568、569、570、571、572、573、574、575、576、577、578、579、580、581、582、583、584、585、586、587、588、589、590、591、592、593、594、595、596、597、598、599、600、601、602、603、604、605、606、607、608、609、610、611、612、613、614、615、616、617、618、619、620、621、622、623、624、625、626、627、628、629、630、631、632、633、634、635、636、637、638、639、640、641、642、643、644、645、646、647、648、649、650、651、652、653、654、655、656、657、658、659、660、661、662、663、664、665、666、667、668、669、670、671、672、673、674、675、676、677、678、679、680、681、682、683、684、685、686、687、688、689、690、691、692、693、694、695、696、697、698、699、700、701、702、703、704、705、706、707、708、709、710、711、712、713、714、715、716、717、718、719、720、721、722、723、724、725、726、727、728、729、730、731、732、733、734、735、736、737、738、739、740、741、742、743、744、745、746、747、748、749、750、751、752、753、754、755、756、757、758、759、760、761、762、763、764、765、766、767、768、769、770、771、772、773、774、775、776、777、778、779、780、781、782、783、784、785、786, 787, 788, 789, 790, 791, 792, 793, 794, 795, 796, 797, 798, 799, 800, 801, 802, 803, 804, 805, 806, 807, 808, 809, 810, 811, 812, 813, 814, 815, 816, 817, 818, 819, 820, 821, 822, 823, 824, 825, 826, 827, 828, 829, 830, 831, 832, 833, 834, 835, 836, 837, 838, 839, 840, 8 41, 842, 843, 844, 845, 846, 847, 848, 849, 850, 851, 852, 853, 854, 855, 856, 857, 858, 859, 860, 861, 862, 863, 864, 865, 866, 867, 868, 869, 870, 871, 872, 873, 874, 875, 876, 877, 878, 879, 880, 881, 882, 883, 884, 885, 886, 887, 888, 889, 890, 891, 892, 893, 894, 895, 89 6, 897, 898, 899, 900, 901, 902, 903, 904, 905, 906, 907, 908, 909, 910, 911, 912, 913, 914, 915, 916, 917, 918, 919, 920, 921, 922, 923, 924, 925, 926, 927, 928, 929, 930, 931, 932, 933, 934, 935, 936, 937, 938, 939, 940, 941, 942, 943, 944, 945, 946, 947, 948, 949, 950, 951 952, 953, 954, 955, 956, 957, 958, 959, 960, 961, 962, 963, 964, 965, 966, 967, 968, 969, 970, 971, 972, 973, 974, 975, 976, 977, 978, 979, 980, 981, 982, 983, 984, 985, 986, 987, 988, 989, 990, 991, 992, 993, 994, 995, 996, 997, 998, 999, or 1000 (or any derivable range thereof) consecutive amino acids or nucleotides.

[0075] The polypeptides and peptides disclosed herein may include 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 (or any derivable range thereof) or more variant amino acid substitutions, or may be associated with SEQ ID. At least, at most, or exactly 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, or 17 consecutive amino acids or nucleotides (or any derivable range thereof) of any one of NO:1-39 have at least, at most, or exactly 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% (or any derivable range thereof) similarity, identity, or homology.

[0076] In some aspects, the peptide, polypeptide, or nucleic acid may comprise, may comprise at least, or may comprise at most, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 (or any derivative range thereof) consecutive amino acids or nucleotides of any one of SEQ ID NO: 1-39, said consecutive amino acids or nucleotides being consistent with SEQ ID NO: 1-39. NO:1-39 has at least, at most, or exactly 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% (or any range thereof) of similarity, identity, or homology.

[0077] Relative to SEQ ID NO:1-39, the peptide, polypeptide, or nucleic acid may contain, may contain at least, or may contain at most 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 (or any derivable range thereof) amino acids or nucleotides. For amino acid substitutions, the substitution may be made with alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, or valine. For nucleic acid substitutions, the substitution may be made with guanine, cytosine, adenine, thymine, uracil, or other nucleotides.

[0078] Nucleotide sequences of various genes, as well as protein, polypeptide, and peptide sequences, have been previously published and can be found in recognized computerized databases. Two commonly used databases are the GENBANK® and GENPEPT® databases of the National Center for Biotechnology Information (ncbi.nlm.nih.gov / on the World Wide Web) and the Universal Protein Resource (UniProt; uniprot.org on the World Wide Web). The coding regions of these genes can be amplified and / or expressed using the techniques disclosed herein or techniques known to those skilled in the art.

[0079] Considering the compositions of this disclosure, in some aspects, there is a total polypeptide, peptide, and / or protein present per ml at a concentration between about 0.001 mg and about 10 mg. The protein concentration in the composition may be about, at least about, or at most about 0.001, 0.010, 0.050, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5, 7.0, 7.5, 8.0, 8.5, 9.0, 9.5, 10.0 mg / ml or higher (or any of these derivative ranges).

[0080] A. Chimeric polypeptide

[0081] As disclosed herein, a “chimeric polypeptide” describes any polypeptide having regions, domains, or other portions derived from two or more different polypeptides. For example, an example of a chimeric polypeptide is a polypeptide having a first domain derived from a first protein and a second domain derived from a second protein. A region or domain is described as “from” or “derived from” the protein or polypeptide when it has the same sequence as at least a portion of the polypeptide. Thus, for example, a hinge region from PDL1 (also “derived from” PDL1) describes a hinge region having the same sequence as at least a portion of the hinge region of the PDL1 protein. A region or domain “derived from” a protein or polypeptide can also be described as a protein or polypeptide region or domain; for example, a transmembrane domain derived from PDL1 can also be described as a “PDL1 transmembrane domain”.

[0082] Chimeric polypeptides may comprise regions derived from at least 2, 3, 4, 5, 6, or more different polypeptides. Exemplary chimeric polypeptides include chimeric antigen receptors (CARs) and other chimeric cell surface polypeptides. In some aspects, the chimeric polypeptides of this disclosure are polypeptides comprising an extracellular domain and one or more additional regions or domains derived from a non-BCMA protein, said extracellular domain comprising one or more (e.g., at least two) repeats of an amino acid sequence having at least 90% identity with SEQ ID NO:33. Chimeric polypeptides of this disclosure may comprise, for example, signal peptides (e.g., tissue-type plasminogen activator (tPA) signal peptide, CD8α signal peptide, GM-CSFRα signal peptide, IL-2 signal peptide, IL-4 signal peptide, IL-21 signal peptide, CD33 signal peptide, CD7 signal peptide, PD1 signal peptide, PDL1 signal peptide, CD34 signal peptide, etc.), one or more extracellular domains (e.g., comprising regions derived from SEQ ID NO:33), and one or more extracellular domains derived from a non-BCMA protein. NO:33 has one or more repeating or at least two repeating extracellular domains of an amino acid sequence with at least 90% identity, hinge domains (e.g., hinge domains from PDL1, CD2, CD28, CD3e, CD45, CD4, CD40, CD5, CD7, CD8, CD9, CD16, CD19, CD22, CD30, CD33, CD34, CD37, CD38, CD64, CD70, PD-1, CTLA-4, BCMA, CD80, CD86, CD123, CD134, CD137 or CD154, IgG1, IgG2, IgG3, IgG4, GM-CSF receptor, etc., or combinations or derivatives thereof), transmembrane domains (e.g., transmembrane domains from PDL1), intracellular regions (e.g., intracellular regions from Trop2), linker regions (e.g., linker regions from CD34, such as CD34 epitopes), or any combination thereof. Any one or more of these regions or domains may be excluded from certain aspects of this disclosure.

[0083] In some aspects, a chimeric polypeptide is disclosed herein, comprising an extracellular domain, a hinge region, a transmembrane domain, and optionally an intracellular region, wherein the extracellular domain comprises one or more repeats of the amino acid sequence of SEQ ID NO:33. In some aspects, a chimeric polypeptide is disclosed herein, comprising an extracellular domain, a hinge region, a transmembrane domain, and optionally an intracellular region, wherein the extracellular domain comprises at least two repeats of the amino acid sequence of SEQ ID NO:33.

[0084] Each repeat of the extracellular domain may have an amino acid sequence that is at least 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% (or any of the derivative ranges thereof) identical to that in SEQ ID NO:33.

[0085] GQCSQNEYFDSLLHACIPCQLRCSSNTPPLTCQRYC.

[0086] In some respects, the extracellular domain comprises one or more repeats of an amino acid sequence that has at least or at most 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% (or any of the ranges from which such a sequence can be derived) identity with the extracellular domain of the BCMA protein. In some respects, the extracellular domains from BCMA have at least or at most 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% (or any of the ranges that can be derived therefrom) the same identity as SEQ ID NO:1 or SEQ ID NO:2.

[0087] The chimeric polypeptide of this disclosure may include, for example, a hinge region derived from PDL1. In some aspects, the hinge region has an amino acid sequence that is at least 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% (or any of these derivative ranges) identical to the PDL1 hinge. In some respects, the hinge region has at least 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% (or any range thereof) of identity with SEQ ID NO:3. In some respects, the hinge region comprises SEQ ID NO:3.

[0088] The chimeric polypeptide of this disclosure may comprise a transmembrane region derived from one or more transmembrane proteins. The chimeric polypeptide of this disclosure may comprise transmembrane regions derived from, for example, the following: 4-1BB / CD137, the α chain of the T cell receptor, the β chain of the T cell receptor, CD2, CD3δ, CD3ε, CD3γ, CD4, CD7, CD8α, CD8β, CD9, CD11a (ITGAL), CD11b (ITGAM), CD11c (ITGAX), CD11d (ITGAD), CD16, CD18 (ITGB2), CD19 (B4), CD22, CD27 (TNFRSF7), CD28, CD29 (ITGB1), CD30 (TNFRSF8), CD33, CD37, CD40 (TNF RSF5), CD48 (SLAMF2), CD49a (ITGA1), CD49d (ITGA4), CD49f (ITGA6), CD64, CD66a (CEACAM1), CD66b (CEACAM8), CD66c (CEACAM6), CD66d (CEACAM3), CD66e (CEACAM5), CD69 (CLEC2), CD79A (B cell antigen receptor complex-associated α chain), CD79B (B cell antigen receptor complex-associated β chain), CD80, CD84 (SLAMF5), CD86, CD96 (Tactile), CD100 (SEMA4) D), CD103 (ITGAE), CD123, CD134 (OX40), CD137 (4-1BB), CD150 (SLAMF1), CD154, CD158A (KIR2DL1), CD158B1 (KIR2DL2), CD158B2 (KIR2DL3), CD15 8C (KIR3DP1), CD158D (KIRDL4), CD158F1 (KIR2DL5A), CD158F2 (KIR2DL5B), CD158K (KIR3DL2), CD160 (BY55), CD162 (SELPLG), CD226 (DNAM1), CD2 29 (SLAMF3), CD244 (SLAMF4), CD247 (CD3-ζ), CD258 (LIGHT), CD268 (BAFFR), CD270 (TNFSF14), CD272 (BTLA), CD276 (B7-H3), CD279 (PD-1), CD314 (NKG2D), CD319 (SLAMF7), CD335 (NK-p46), CD336 (NK-p44), CD337 (NK-p30), CD352 (SLAMF6), CD353 (SLAMF8), CD355 (CRTAM), CD357 (TNFRSF18),Inducible T cell co-stimulatory factors (ICOS), LFA-1 (CD11a / CD18), NKG2C, DAP-10, ICAM-1, NKp80 (KLRF1), IL-2Rβ, IL-2Rγ, IL-7Rα, LFA-1, SLAMF9, LAT, GADS (GrpL), SLP-76 (LCP2), PAG1 / CBP, CD83 ligand, Fcγ receptor, MHC class 1 molecules, MHC class 2 molecules, or TNF receptor proteins. In some respects, the transmembrane domain is derived from the transmembrane domain of PDL1. In some respects, the transmembrane domain has at least, or at most, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% (or any range thereof) of identity with the PDL1 transmembrane domain. In some respects, the transmembrane domain has at least, or at most, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% (or any range thereof) of the same identity as SEQ ID NO:4. In some respects, the transmembrane domain comprises SEQ ID NO:4.

[0089] The chimeric polypeptides of this disclosure may comprise an intracellular region (also referred to as a “cytoplasmic region”) derived from one or more transmembrane proteins. As used herein, an “intracellular region” describes a region of the polypeptide that is present on the intracellular (or “cytoplasmic”) side of the cell surface when the polypeptide is expressed on the cell surface. In some aspects, the intracellular region does not contain a signal transduction domain (i.e., it cannot transmit or transduce any intracellular signal). In some aspects, the intracellular region is not derived from BCMA. In some aspects, the intracellular region is derived from BCMA. In some aspects, the intracellular region has endocytic or internalization activity. In some aspects, the intracellular region contains or contains at most 30, 29, 28, 27, 26, 25, 24, 23, 22, 21, 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, or 2 amino acid residues, or any range thereof. In some aspects, the intracellular region is derived from Trop2. In some respects, the intracellular region has at least 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% (or any range thereof) of identity with the Trop2 intracellular region. In some respects, the intracellular region has at least, or at most, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% (or any range thereof) of identity with SEQ ID NO:5. In some respects, the intracellular region comprises SEQ ID NO:5.

[0090] In some aspects, the chimeric polypeptide of this disclosure includes a linker region. In some aspects, the linker region is derived from CD34. In some aspects, the linker region includes a CD34 epitope, and in some aspects, the linker region can be used to enrich T cells with anti-CD34 granules. In some aspects, the linker region includes two or more CD34 epitopes. In some aspects, the linker region includes at least one amino acid sequence that has, at most has, or at least has 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% (or any of these derivative ranges) identity with the CD34 epitope. In some aspects, the linker region includes at least one amino acid sequence that has, at most has, or at least has 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% (or any range thereof) of identity with SEQ ID NO:6 or SEQ ID NO:7. In some aspects, the linker region includes at least one amino acid sequence comprising SEQ ID NO:6 or SEQ ID NO:7.

[0091] B. Sequence

[0092] The amino acid sequences of certain polypeptides (including chimeric polypeptides and their portions, regions and domains) are provided in Table 1.

[0093] Table 1

[0094]

[0095]

[0096]

[0097]

[0098]

[0099]

[0100]

[0101]

[0102]

[0103]

[0104]

[0105]

[0106]

[0107]

[0108]

[0109]

[0110]

[0111]

[0112] C. Variant polypeptides

[0113] The following discussion concerns altering the amino acid subunits of a protein to produce equivalent, or even improved, second-generation variant polypeptides or peptides. For example, certain amino acids can replace other amino acids in a protein or polypeptide sequence with or without a significant loss of binding ability to interact with structures such as, for example, antigen-binding regions of antibodies or binding sites on substrate molecules. Since the interacting abilities and properties of a protein define its functional activity, certain amino acid substitutions can be made in the protein sequence and its corresponding DNA-coding sequence, yet still produce proteins with similar or desired properties. Therefore, the inventors have considered making various alterations to the DNA sequence of the gene encoding the protein without a significant loss of its biological efficacy or activity.

[0114] The term "functionally equivalent codon" is used in this paper to refer to a codon that encodes the same amino acid, such as the six different codons for arginine. "Neutral substitution" or "neutral mutation" is also considered, referring to a change in one or more codons that encodes a biologically equivalent amino acid.

[0115] The amino acid sequence variants of this disclosure can be substitution, insertion, or deletion variants. Variations in the polypeptides of this disclosure, compared to the wild type, can affect 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50 or more non-continuous or continuous amino acids. Variants can contain amino acid sequences that are at least, at most, or exactly 50%, 60%, 70%, 80%, or 90% (inclusive) identical to any sequence provided or cited herein. Variants may include 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 or more substituted amino acids.

[0116] It should also be understood that amino acid and nucleic acid sequences can each contain additional residues, such as additional N-terminal or C-terminal amino acids, or or The sequence, but still substantially identical to one of the sequences disclosed herein, is provided that the sequence meets the aforementioned criteria, including maintaining the biological protein activity in relation to protein expression. The addition of terminal sequences is particularly suitable for nucleic acid sequences, which may include, for example, sequences located in coding regions. or Various non-coding sequences on the flanks.

[0117] Deletion variants typically lack one or more residues of the native or wild-type protein. A single residue can be deleted, or multiple consecutive amino acids can be deleted. Stop codons can be introduced (through substitution or insertion) into the coding nucleic acid sequence to produce truncated proteins.

[0118] Insertion mutants typically involve adding amino acid residues at a non-terminal point of a polypeptide. This can include the insertion of one or more amino acid residues. Terminal additions can also be produced, and said terminal additions can include fusion proteins, which are polymers or tandems of one or more peptides or polypeptides described or cited herein.

[0119] Substitution variants typically involve the exchange of one amino acid for another at one or more sites within a protein or polypeptide, and can be programmed to modulate one or more properties of the polypeptide with or without the loss of other functions or properties. Substitutions can be conserved, meaning that one amino acid is replaced by an amino acid with similar chemical properties. "Conserved amino acid substitution" can involve the exchange of a member of one amino acid class with another member of the same class. Conservative substitutions are well known in the art and include, for example, the following changes: alanine to serine; arginine to lysine; asparagine to glutamine or histidine; aspartic acid to glutamic acid; cysteine ​​to serine; glutamine to asparagine; glutamic acid to aspartic acid; glycine to proline; histidine to asparagine or glutamine; isoleucine to leucine or valine; leucine to valine or isoleucine; lysine to arginine; methionine to leucine or isoleucine; phenylalanine to tyrosine, leucine, or methionine; serine to threonine; threonine to serine; tryptophan to tyrosine; tyrosine to tryptophan or phenylalanine; and valine to isoleucine or leucine. Conservative amino acid substitutions can encompass amino acid residues that are not naturally occurring and are typically incorporated through chemical peptide synthesis rather than synthesis in biological systems. These include other reversed or inverted forms of peptide mimics or amino acid moieties.

[0120] Alternatively, substitutions can be "non-conservative," affecting the function or activity of the peptide. Non-conservative changes typically involve replacing an amino acid residue with a chemically dissimilar amino acid residue, such as replacing a polar or charged amino acid with a nonpolar or uncharged amino acid, and vice versa. Non-conservative substitutions can involve exchanging a member of one amino acid class for a member of another class.

[0121] D. Factors to consider in substitution

[0122] Those skilled in the art can use well-known techniques to determine suitable variants of the peptides shown herein. Those skilled in the art can identify suitable regions of a molecule that can be altered without destroying its activity by targeting regions considered unimportant to activity. Those skilled in the art can also identify conserved amino acid residues and molecule portions among similar proteins or peptides. In other respects, conserved amino acid substitutions can be made in regions that may be important for biological activity or structure without significantly altering biological activity or adversely affecting the protein or peptide structure.

[0123] When making such changes, the hydrophobicity index of the amino acids can be considered. The hydrophobicity of a protein is calculated by assigning a numerical value ("hydrophobicity index") to each amino acid and then averaging these values ​​along the peptide chain. Each amino acid is assigned a value based on its hydrophobicity and charge properties. They are: isoleucine (+4.5); valine (+4.2); leucine (+3.8); phenylalanine (+2.8); cysteine / cysteine ​​(+2.5); methionine (+1.9); alanine (+1.8); glycine (-0.4); threonine (-0.7); serine (-0.8); tryptophan (-0.9); tyrosine (-1.3); proline (1.6); histidine (-3.2); glutamate (-3.5); glutamine (-3.5); aspartic acid (-3.5); asparagine (-3.5); lysine (-3.9); and arginine (-4.5). The importance of the hydrophobic amino acid index in conferring biological functions of protein-protein interactions is well understood in the art (Kyte et al., J. Mol. Biol. 157:105-131 (1982)). It is generally accepted that the relative hydrophobic properties of amino acids contribute to the secondary structure of the resulting protein or polypeptide, which in turn defines the interaction of the protein or polypeptide with other molecules (e.g., enzymes, substrates, receptors, DNA, antibodies, antigens, etc.). It is also known that certain amino acids can be substituted with other amino acids having similar hydrophobicity indices or scores while still maintaining similar biological activity. In some aspects, this includes substitutions of amino acids whose hydrophobicity indices are within ±2. In some aspects of this disclosure, this includes substitutions within ±1, and in other aspects, substitutions within ±0.5.

[0124] It is also understood in the art that similar amino acid substitutions can be performed efficiently based on hydrophilicity. U.S. Patent 4,554,101 (incorporated herein by reference) states that the maximum local average hydrophilicity of a protein (as determined by the hydrophilicity of its adjacent amino acids) is related to the protein's biological properties. In some respects, the maximum local average hydrophilicity of a protein (as determined by the hydrophilicity of its adjacent amino acids) is related to its immunogenicity and antigen binding (i.e., as biological characteristics of the protein). The following hydrophilicity values ​​have been assigned to these amino acid residues: arginine (+3.0); lysine (+3.0); aspartic acid (+3.0±1); glutamic acid (+3.0±1); serine (+0.3); asparagine (+0.2); glutamine (+0.2); glycine (0); threonine (-0.4); proline (-0.5±1); alanine (-0.5); histidine (-0.5); cysteine ​​(-1.0); methionine (-1.3); valine (-1.5); leucine (-1.8); isoleucine (-1.8); tyrosine (-2.3); phenylalanine (-2.5); and tryptophan (-3.4). When alterations are made based on similar hydrophilicity values, in some respects this includes the substitution of amino acids with hydrophilicity values ​​within ±2, in others it includes the substitution of those amino acids with hydrophilicity values ​​within ±1, and in still others it includes the substitution of those amino acids with hydrophilicity values ​​within ±0.5. In some cases, epitopes can also be identified from the primary amino acid sequence based on hydrophilicity. These regions are also called “epitope core regions.” It should be understood that an amino acid can be substituted with another amino acid with a similar hydrophilicity value, and a biologically and immunologically equivalent protein can still be produced.

[0125] Additionally, those skilled in the art can review structure-function studies to identify residues in similar peptides or proteins that are important for activity or structure. Based on this comparison, the importance of amino acid residues in the protein corresponding to those in similar proteins that are important for activity or structure can be predicted. Those skilled in the art can then substitute chemically similar amino acids for these predicted important amino acid residues.

[0126] Those skilled in the art can also analyze the three-dimensional structure of similar proteins or peptides and the amino acid sequence associated with that structure. Given this information, those skilled in the art can predict the arrangement of amino acid residues of an antibody relative to its three-dimensional structure. Those skilled in the art may choose not to alter amino acid residues expected on the protein surface, as such residues may be involved in important interactions with other molecules. Furthermore, those skilled in the art can generate test variants containing a single amino acid substitution at each desired amino acid residue. These variants can then be screened using standard assays of binding and / or activity, generating information gathered from such routine experiments that allows those skilled in the art to determine amino acid positions where further substitutions should be avoided, whether the substitution is made alone or in combination with other mutations. Various tools available for determining secondary structure can be found on the World Wide Web, for example at expasy.org / proteomics / protein_structure.

[0127] In some aspects of this disclosure, amino acid substitutions are performed that: (1) reduce sensitivity to proteolysis, (2) reduce sensitivity to oxidation, (3) alter the binding affinity of the protein complex, (4) alter the binding affinity of the ligand or antigen, and / or (5) impart or modify other physicochemical or functional properties to such peptides. For example, single or multiple amino acid substitutions (in some respects, conserved amino acid substitutions) can be performed in naturally occurring sequences. Substitutions can be performed on portions of the antibody located outside one or more domains that form intermolecular contacts. In such respects, conserved amino acid substitutions that substantially do not alter the structural characterization of the protein or peptide (e.g., one or more substituted amino acids that do not disrupt the secondary structure characterizing the native antibody) can be used.

[0128] E. B cell maturation antigen (BCMA)

[0129] B-cell maturation antigen (BCMA), also known as tumor necrosis factor receptor superfamily member 17 or TNFRSF17, is preferentially expressed on plasma cells and is highly expressed in a variety of hematologic malignancies, including multiple myeloma. BCMA is composed of... TNFRSF17 Gene encoding. Exemplary mRNA is characterized by RefSeq accession number NM_001192. Exemplary protein is characterized by RefSeq accession number NP_001183. The complete polypeptide sequence of human BCMA is provided in SEQ ID NO:21. BCMA gene ( TNFRSF17 The complete DNA sequence of the sample is provided in SEQ ID NO:22.

[0130] F. Programmed cell death 1-ligand 1 (PDL1)

[0131] Programmed cell death 1 ligand 1 (PDL1), also known as CD274 or B7-H1, is an immunosuppressive receptor ligand expressed by hematopoietic cells, immune cells, and various types of tumor cells. Exemplary mRNAs are characterized by RefSeq accessions NM_001267706 and NM_014143. Exemplary proteins are characterized by RefSeq accessions NP_001254635 and NP_054862. The complete polypeptide sequence of human PDL1 is provided in SEQ ID NO:23 and SEQ ID NO:25. The complete DNA sequence of PDL1 is provided in SEQ ID NO:24 and SEQ ID NO:26.

[0132] G. Trop2

[0133] Trop2 (or "Trop-2"), also known as tumor-associated calcium signaling transducer 2, is a cancer-associated antigen. Trop2 is composed of... TACSTD2 Gene encoding. Exemplary mRNA is characterized by RefSeq accession number NM_002353. Exemplary protein is characterized by RefSeq accession number NP_002344. The complete polypeptide sequence of human Trop2 is provided in SEQ ID NO:27. Trop2 gene ( TACSTD2 The complete DNA sequence of the sample is provided in SEQ ID NO:28.

[0134] H. CD34

[0135] CD34 is a transmembrane phosphoglycoprotein that functions as a cell-cell adhesion factor. It also mediates the attachment of hematopoietic stem cells to the bone marrow extracellular matrix or directly to stromal cells. CD34 is composed of… CD34 Gene encoding. Exemplary mRNAs are characterized by RefSeq accessions NM_001773 and NM_001025109. Exemplary proteins are characterized by RefSeq accessions NP_001764 and NP_001020280. The complete polypeptide sequence of human CD34 is provided in SEQ ID NO:29 and SEQ ID NO:31. The complete DNA sequence of CD34 is provided in SEQ ID NO:30 and SEQ ID NO:32.

[0136] II. Nucleic Acids

[0137] In some respects, nucleic acid sequences can exist in a variety of forms, such as: integrated sequences of one or both strands encoding antibodies or fragments, derivatives, mutant proteins or variants thereof, isolated fragments of recombinant polynucleotides and recombinant vectors; polynucleotides sufficient to be used as hybridization probes, PCR primers or sequencing primers to identify, analyze, mutate or amplify polynucleotides encoding polypeptides; antisense nucleic acids for inhibiting polynucleotide expression; and complementary sequences to the aforementioned sequences described herein. Nucleic acids encoding epitopes targeted by certain antibodies provided herein are also provided. Nucleic acids encoding fusion proteins containing these peptides are also provided. Nucleic acids can be single-stranded or double-stranded and can contain RNA and / or DNA nucleotides and their artificial variants (e.g., peptide nucleic acids).

[0138] The term "polynucleotide" refers to a recombinant nucleic acid molecule or one isolated from the total genomic nucleic acid. Included within the term "polynucleotide" are oligonucleotides (nucleic acids of 100 residues or less in length), recombinant vectors, including, for example, plasmids, granules, bacteriophages, viruses, etc. In some respects, polynucleotides include regulatory sequences that are largely isolated from the gene or protein-coding sequences in which they are naturally present. Polynucleotides can be single-stranded (coding or antisense) or double-stranded, and can be RNA, DNA (genomic, cDNA, or synthetic), analogues thereof, or combinations thereof. Additional coding or non-coding sequences may, but do not necessarily, be present within the polynucleotide.

[0139] In this regard, the terms "gene," "polynucleotide," or "nucleic acid" are used to refer to nucleic acids (including any sequences required for proper transcription, post-translational modification, or localization) that encode proteins, polypeptides, or peptides. As those skilled in the art will understand, the term encompasses genomic sequences, expression cassettes, cDNA sequences, and smaller engineered nucleic acid segments that express or can be modified to express proteins, polypeptides, domains, peptides, fusion proteins, and mutants. Nucleic acids encoding all or part of a polypeptide may contain a continuous nucleic acid sequence encoding all or part of such a polypeptide. It is also contemplated that a particular polypeptide may be encoded by a nucleic acid containing a variant having a slightly different nucleic acid sequence but still encoding the same or substantially similar protein.

[0140] In some respects, there exist polynucleotide variants that are substantially identical to the sequences disclosed herein; those polynucleotide variants that, using the methods described herein (e.g., BLAST analysis using standard parameters), contain at least, at most, or exactly 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% or higher sequence identity (inclusive of all values ​​and ranges therebetween) compared to the polynucleotide sequences provided herein. In some respects, the isolated polynucleotide comprises a nucleotide sequence encoding a polypeptide that has at least 90%, preferably 95%, and higher identity with the amino acid sequence described herein over its entire length; or a nucleotide sequence complementary to the isolated polynucleotide.

[0141] Regardless of the length of the coding sequence itself, nucleic acid segments can be combined with other nucleic acid sequences (such as promoters, polyadenylation signals, additional restriction enzyme sites, multiple cloning sites, other coding segments, etc.) so that their total length can vary considerably. Nucleic acids can be of any length. Their length can be, for example, at least, at most, exactly 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 75, 100, 125, 175, 200, 250, 300, 350, 400, 450, 500, 750, 1000, 1500, 3000, 5000 or more nucleotides, or nucleotides in any of these ranges, and / or can contain one or more additional sequences, such as regulatory sequences, and / or can be part of a larger nucleic acid (e.g., a vector). Therefore, it is considered that nucleic acid fragments of almost any length can be used, wherein the total length is preferably limited by the ease of preparation and use in the intended recombinant nucleic acid protocol. In some cases, nucleic acid sequences can encode polypeptide sequences with additional heterologous coding sequences, for example, to allow for polypeptide purification, transport, secretion, post-translational modification, or to allow for therapeutic benefits (such as targeting or efficacy). As described above, tags or other heterologous polypeptides can be added to the modified polypeptide coding sequence, where "heterologous" refers to a polypeptide that is different from the modified polypeptide.

[0142] A. Hybridization

[0143] Nucleic acids that hybridize with other nucleic acids under specific hybridization conditions. Methods for hybridizing nucleic acids are well known in the art. See, for example, Current Protocols in Molecular Biology, John Wiley and Sons, NY (1989), 6.3.1–6.3.6. Moderately stringent hybridization conditions, as defined herein, use a pre-wash solution containing 5× sodium chloride / sodium citrate (SSC), 0.5% SDS, 1.0 mM EDTA (pH 8.0), approximately 50% formamide, 6× SSC, and a hybridization temperature of 55°C (or other similar hybridization solutions, such as a hybridization solution containing approximately 50% formamide at 42°C), and washing conditions at 60°C in 0.5× SSC, 0.1% SDS. Stringent hybridization conditions involve hybridization at 45°C in 6× SSC, followed by one or more washes at 68°C in 0.1× SSC, 0.2% SDS. Furthermore, those skilled in the art can manipulate hybridization and / or washing conditions to increase or decrease the stringency of hybridization, such that nucleic acids containing nucleotide sequences having at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity with each other generally remain hybridized with each other.

[0144] The parameters influencing the selection of hybridization conditions and guidelines for designing suitable conditions are provided below, for example: Sambrook, Fritsch and Maniatis (Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, Chapters 9 and 11 (1989); Current Protocols in Molecular Biology, Ausubel et al., eds., John Wiley and Sons, Inc., Sections 2.10 and 6.3–6.4 (1995), both of which are incorporated herein by reference in their entirety for all purposes), and can be readily determined by those skilled in the art based, for example, the length and / or base composition of DNA.

[0145] B. Mutation

[0146] Mutation can introduce changes into nucleic acids, resulting in alterations in the amino acid sequence of the peptides they encode (e.g., antibodies or antibody derivatives). Mutations can be introduced using any technique known in the art. In one aspect, one or more specific amino acid residues are altered using, for example, site-directed mutagenesis. In another aspect, one or more randomly selected residues are altered using, for example, random mutagenesis. Regardless of how the mutant peptide is prepared, it can be expressed and screened for desired properties.

[0147] Mutations can be introduced into nucleic acids without significantly altering the biological activity of the encoded polypeptide. For example, nucleotide substitutions can be performed, resulting in amino acid replacements at non-essential amino acid residues. Alternatively, one or more mutations can be introduced into the nucleic acid that selectively alter the biological activity of the encoded polypeptide. See, for example, Romain Studer et al., Biochem. J. 449:581-594 (2013). For example, mutations can quantitatively or qualitatively alter biological activity. Examples of quantitative changes include increasing, decreasing, or eliminating activity. Examples of qualitative changes include altering the antigen specificity of an antibody.

[0148] III. Carrier

[0149] In certain respects, the cells covered herein carry one or more vectors that can express any polypeptide covered herein. Different proteins can be delivered to recipient cells via any suitable vector, including viral or non-viral vectors. Examples of viral vectors include at least retroviral vectors, lentiviral vectors, adenoviral vectors, or adeno-associated virus vectors. Examples of non-viral vectors include at least plasmids, transposons, lipids, nanoparticles, liposomes, and combinations thereof.

[0150] In cases where cells are transduced using a vector encoding a chimeric polypeptide, and where it is also necessary to transduce one or more other genes (such as heterologous proteins) into the cells, these genes may or may not be contained within the same vector. In some cases, the chimeric polypeptide, one or more heterologous proteins, etc., are expressed from the same vector molecule (such as the same viral vector molecule). In such cases, polypeptide expression may or may not be regulated by the same one or more regulatory elements. When polypeptides are on the same vector, they may or may not be expressed as separate polypeptides. For example, where they are expressed as separate polypeptides, they may be separated on the vector by a 2A element or an IRES element (or both elements may be used once or more times on the same vector).

[0151] Those skilled in the art have sufficient ability to construct vectors for expressing antigen receptors of this disclosure using standard recombination techniques (see, for example, Sambrook et al., 2001 and Ausubel et al., 1996, both of which are incorporated herein by reference).

[0152] A. Control element

[0153] Expression cassettes contained in vectors that can be used in this disclosure specifically contain (in the 5'- to -3' orientation) a eukaryotic transcription promoter operatively linked to a protein-coding sequence, a splicing signal containing an interpolated sequence, and a transcription termination / polyadenylation sequence. Promoters and enhancers controlling protein-coding gene transcription in eukaryotic cells can consist of multiple genetic elements. Cellular mechanisms are able to collect and integrate the regulatory information transmitted by each element, enabling different genes to evolve different, often complex, transcriptional regulatory patterns. For example, promoters used in the context of this disclosure include constitutive, inducible, and tissue-specific promoters. In cases where the vector is used to generate cancer therapies, the promoter can be effective under hypoxic conditions.

[0154] B. Promoters / Enhancers

[0155] The expression constructs provided in this article contain promoters that drive the expression of any one or more polypeptides. Promoters typically contain sequences that locate the site of RNA synthesis initiation. The most well-known example of this is the TATA box, but in some promoters lacking a TATA box (such as, for example, the promoters of mammalian terminal deoxynucleotidyl transferase genes and SV40 late genes), discrete elements covering the initiation site itself help to fix the initiation location. Additional promoter elements regulate the frequency of transcription initiation. Typically, these promoter elements are located upstream of the initiation site, although it has been shown that many promoters also contain functional elements downstream of the initiation site. To bring the coding sequence under the “control” of the promoter, the 5’ end of the transcription start site of the transcription reading frame is placed “downstream” (i.e., the 3’ end) of the selected promoter. The “upstream” promoter stimulates DNA transcription and promotes the expression of the encoded RNA.

[0156] The spacing between promoter elements is typically flexible, allowing promoter function to be preserved when elements are inverted or moved relative to each other. For example, in the tk promoter, the spacing between promoter elements can be increased to 50 bp before activity begins to decline. Depending on the promoter, individual elements may appear to act synergistically or independently to activate transcription. Promoters may or may not be used in conjunction with "enhancers," which are cis-regulatory sequences involved in the transcriptional activation of nucleic acid sequences.

[0157] Promoters can be promoters naturally associated with a nucleic acid sequence, such as those obtained by isolating a 5' non-coding sequence located upstream of a coding region and / or exon. Such promoters can be called "endogenous" promoters. Similarly, enhancers can be enhancers naturally associated with a nucleic acid sequence, located downstream or upstream of that sequence. Alternatively, certain advantages can be obtained by placing the coding nucleic acid segment under the control of a recombinant or heterologous promoter, which refers to a promoter that is not normally associated with a nucleic acid sequence in its natural environment. Recombinant or heterologous enhancers also refer to enhancers that are not normally associated with a nucleic acid sequence in their natural environment. Such promoters or enhancers can include promoters or enhancers of other genes, and promoters or enhancers isolated from any other virus or prokaryotic or eukaryotic cell, as well as promoters or enhancers that are not "naturally present," i.e., containing different elements of different transcriptional regulatory regions, and / or mutations that alter expression. For example, the most commonly used promoters in recombinant DNA construction include β-lactamase (penicillinase), lactose, and tryptophan (trp) promoter systems. In addition to synthesizing nucleic acid sequences that generate promoters and enhancers, sequences can also be generated using recombinant cloning and / or nucleic acid amplification techniques (including PCR) in combination with the compositions disclosed herein. Furthermore, control sequences that direct sequence transcription and / or expression within non-nuclear organelles such as mitochondria, chloroplasts, etc., are also considered.

[0158] Naturally, it is important to employ promoters and / or enhancers that effectively guide the expression of DNA segments in the selected organelles, cell types, tissues, organs, or organisms for expression. Those skilled in the art of molecular biology are generally familiar with the uses of promoter, enhancer, and cell type combinations for protein expression (see, for example, Sambrook et al., 1989, incorporated herein by reference). The promoters employed can be constitutive, tissue-specific, inducible, and / or, under suitable conditions, can be used to guide high-level expression of the introduced DNA segment, such as facilitating the large-scale production of recombinant proteins and / or peptides. Promoters can be heterologous or endogenous.

[0159] Additionally, any promoter / enhancer combination (e.g., available from the eukaryotic promoter database EPDB via the World Wide Web at epd.isb-sib.ch / ) can also be used to drive expression. The use of T3, T7, or SP6 cytoplasmic expression systems is another possible aspect. Eukaryotic cells can support cytoplasmic transcription from certain bacterial promoters if appropriate bacterial polymerases are provided (either as part of a delivery complex or as additional gene expression constructs).

[0160] Non-limiting examples of promoters include early or late viral promoters, such as the SV40 early or late promoter, the cytomegalovirus (CMV) immediate early promoter, and the Rous sarcoma virus (RSV) early promoter; eukaryotic cell promoters, such as the β-actin promoter, the GADPH promoter, and the metallothionein promoter; and tandem response element promoters, such as the cyclic AMP response element promoter (cre), the serum response element promoter (sre), the phorbol ester promoter (TPA), and the response element promoter near the minimal TATA box (tre). Human growth hormone promoter sequences (e.g., the minimal human growth hormone promoter described in GENBANK®, accession number X05244, nucleotides 283-341) or mouse mammary tumor promoters (available from ATCC®, catalog number ATCC 45007) may also be used. In some respects, the promoter is CMV IE, dectin-1, dectin-2, human CD11c, F4 / 80, SM22, RSV, SV40, Ad MLP, β-actin, MHC class I or MHC class II promoters; however, any other promoter that can be used to drive the expression of therapeutic genes is suitable for the implementation of this disclosure.

[0161] In some respects, the methods of this disclosure also involve enhancer sequences, i.e., nucleic acid sequences that enhance promoter activity and have the potential to function in cis and regardless of orientation, even at relatively long distances (up to thousands of bases from the target promoter). However, the function of enhancers is not necessarily limited to such long distances, as they can also function close to a given promoter.

[0162] C. Initiation signals and linkage expression

[0163] Specific start signals can also be used in the expression constructs provided in this disclosure for efficient translation of the coding sequence. These signals include the ATG start codon or a neighboring sequence. Exogenous translation control signals, including the ATG start codon, may need to be provided. Those skilled in the art will be able to readily determine this and provide the necessary signals. It is well known that the start codon must be “in-frame” with the reading frame of the desired coding sequence to ensure translation of the entire insert sequence. Exogenous translation control signals and start codons can be natural or synthetic. Expression efficiency can be enhanced by including appropriate transcription enhancer elements.

[0164] In some respects, internal ribosome entry site (IRES) elements are used to generate multigene or polycistronic messengers. IRES elements can bypass... A ribosomal scanning model of cap-dependent translation with methylation is used, initiating translation at an internal site. IRES elements from two members of the parvovirus family (poliomyelitis and encephalomyocarditis) and from mammalian messengers have been described. IRES elements can link to heterologous open reading frames (OPFs). Multiple OPFs can be transcribed together, each separated by an IRES, resulting in polycistronic messengers. With IRES elements, each OPF is accessible to the ribosome for efficient translation. Multiple genes can be efficiently expressed by transcribing a single messenger using a single promoter / enhancer.

[0165] As detailed elsewhere herein, certain 2A sequence elements can be used in constructs provided in this disclosure to generate linked or co-expressed genes. For example, cleavage sequences can be used to co-express genes by connecting open reading frames to form a single cistron. Exemplary cleavage sequences are equine rhinitis A virus (E2A) or F2A (foot-and-mouth disease virus 2A) or “2A-like” sequences (e.g., Thosea asigna Virus 2A (T2A) or swine cyclovir-1 (P2A). Specifically, multiple 2A sequences are distinct within a single vector, although alternatively, the same vector may utilize two or more of the same 2A sequences. Examples of 2A sequences are provided in US 2011 / 0065779 (which is incorporated herein by reference in its entirety).

[0166] D. Replication starting point

[0167] To propagate the vector in host cells, it may contain one or more origin of replication sites (commonly referred to as "ori"), such as the nucleic acid sequence corresponding to the oriP of EBV as described above, or a genetically engineered oriP programmed to have similar or enhanced functions, which is the specific nucleic acid sequence on which replication is initiated. Alternatively, origin of replication or autonomous replication sequence (ARS) of other extrachromosomal replicating viruses as described above may be used.

[0168] E. Selecting markers and filterable markers

[0169] In some respects, CD30-positive cells of this disclosure can be identified in vitro or in vivo by including a biomarker in the expression vector. Such biomarkers confer identifiable changes to the cells, thereby allowing for easy identification of cells containing the expression vector. Generally, a selection biomarker is a biomarker that confers the property of allowing selection. A positive selection biomarker is a biomarker whose presence allows selection, while a negative selection biomarker is a biomarker whose presence prevents selection. An example of a positive selection biomarker is a drug resistance biomarker.

[0170] Typically, drug selection markers are helpful for cloning and identifying transformants; for example, genes conferring resistance to neomycin, puromycin, hygromycin, DHFR, GPT, bleomycin (zeocin), and histamine are useful selection markers. In addition to markers that confer resistance allowing condition-based differentiation of transformant phenotypes, other types of markers have been considered, including screenable markers such as GFP based on colorimetric analysis. Alternatively, screenable enzymes, such as herpes simplex virus thymidine kinase (HSV-T), can be used as negative selection markers. tk (e.g., chloramphenicol acetyltransferase (CAT)). Those skilled in the art also know how to use immunological markers, possibly in conjunction with FACS analysis. It is considered that the marker used is not important, as long as it can be expressed simultaneously with the nucleic acid encoding the gene product. Other examples of selectable and screenable markers are well known to those skilled in the art.

[0171] IV. Immune cells

[0172] Some aspects of this disclosure relate to immune cells comprising the polypeptides or nucleic acids of this disclosure, or immune cells engineered to express one or more genes. The expression of one or more genes directly or indirectly results in prolonged cell lifespan compared to cells lacking the expression of said one or more genes. In a particular aspect, cells are manipulated to express said one or more genes, including one or more heterologous genes. In other cases, cells are manipulated to upregulate the expression of one or more endogenous genes within the cell, such as by manipulating one or more regulatory elements of one or more endogenous genes within the cell.

[0173] In some cases, the cells are not immortalized cell lines, but cells obtained from an individual (e.g., primary cells). For example, in some cases, the cells are immune cells obtained from an individual. For example, the cells are T lymphocytes obtained from an individual. As another example, the cells are cytotoxic cells obtained from an individual. As yet another example, the cells are stem cells (e.g., peripheral blood stem cells) or progenitor cells obtained from an individual.

[0174] Immune cells can be any type of immune cell, including T cells (e.g., regulatory T cells, CD4+). + T cells, CD8 +Immune cells can be T cells, αβT cells, γ-δT cells, or mixtures thereof; NK cells, constant NKT cells, NKT cells, innate lymphoid cells, or mixtures thereof. Immune cells can be virus-specific, expressing CAR, and / or expressing TCR. In some respects, the cells are monocytes or granulocytes, such as myeloid cells, macrophages, neutrophils, dendritic cells (DCs), mast cells, eosinophils, and / or basophils. Methods for producing and engineering immune cells, as well as methods for using and administering cells for adoptive cell therapy, in which case the cells can be autologous or allogeneic, are also provided herein. Therefore, immune cells can be used as immunotherapies, such as to target cancer cells. These immune cells can be used for treatment as a single cell type or a combination of multiple immune cell types. In specific respects, immune cells are CD3+, CD4+, CD8+, CD16+, or mixtures thereof.

[0175] In some respects, the cell is an immune cell or a T cell. "T cell" encompasses all types of immune cells that express CD3, including helper T cells, invariant natural killer T (iNKT) cells, cytotoxic T cells, regulatory T cells (Treg), γδ T cells, natural killer (NK) cells, and neutrophils. T cells can refer to either CD4+ or CD8+ T cells.

[0176] Suitable mammalian cell lines include primary cells and immortalized cell lines. Suitable mammalian cell lines include human cell lines, non-human primate cell lines, and rodent (e.g., mouse, rat) cell lines. Suitable mammalian cell lines include, but are not limited to, HeLa cells (e.g., American Type Culture Collection (ATCC) number CCL-2), CHO cells (e.g., ATCC numbers CRL9618, CCL61, CRL9096), human embryonic kidney (HEK) 293 cells (e.g., ATCC number CRL-1573), Vero cells, NIH 3T3 cells (e.g., ATCC number CRL-1658), Huh-7 cells, BHK cells (e.g., ATCC number CCL10), PC12 cells (ATCC number CRL1721), COS cells, COS-7 cells (ATCC number CRL1651), RATI cells, mouse L cells (ATCC number CCLI.3), HLHepG2 cells, Hut-78, Jurkat, HL-60, and NK cell lines (e.g., NKL, NK92, and YTS).

[0177] Immune cells can be isolated from subjects, particularly human subjects. Immune cells can be obtained from subjects of interest, such as those suspected of having a specific disease or condition, those suspected of having a predisposition to a specific disease or condition, or those receiving treatment for a specific disease or condition. Immune cells can be collected from any location in the subject where they are present, including but not limited to blood, umbilical cord blood, spleen, thymus, lymph nodes, and bone marrow. Isolated immune cells can be used directly or can be preserved for a period of time, such as by cryopreservation.

[0178] Immune cells can be enriched / purified from any tissue in which they are present, including but not limited to blood (including blood collected from a blood bank or cord blood bank), spleen, bone marrow, tissue removed and / or exposed during surgical procedures, and tissue obtained through biopsy procedures. The tissue / organ from which immune cells are enriched, isolated, and / or purified can be isolated from both living and non-living subjects, wherein the non-living subject is an organ donor. In certain aspects, immune cells are isolated from blood (such as peripheral blood or cord blood). In some aspects, immune cells isolated from cord blood have enhanced immunomodulatory capabilities, such as those measured by suppression of CD4-positive or CD8-positive T cells. In specific aspects, immune cells are isolated from mixed blood, particularly mixed cord blood, for enhanced immunomodulatory capabilities. The mixed blood can be from two or more sources, such as three, four, five, six, seven, eight, nine, ten, or more sources (e.g., donor subjects).

[0179] Immune cell populations can be obtained from subjects requiring treatment or suffering from diseases associated with reduced immune cell activity. Therefore, these cells are autologous to the subject requiring treatment. Alternatively, immune cell populations can be obtained from donors, such as partially or completely tissue-compatible donors or completely tissue-incompatible donors. Immune cell populations can be collected from peripheral blood, umbilical cord blood, bone marrow, spleen, or any other organ / tissue in which immune cells are present in the subject or donor. Immune cells can be isolated from mixtures of subjects and / or donors, such as from mixed umbilical cord blood.

[0180] When obtaining a population of immune cells from a donor different from the subject, the donor can be allogeneic, provided that the obtained cells are compatible with the subject, meaning they can be introduced into the subject. Allogeneic donor cells may or may not be compatible with human leukocyte antigens (HLA).

[0181] Additional methods and compositions relating to infinite immune cells are described in PCT patent application publication number WO / 2021 / 034982 (incorporated herein by reference in its entirety).

[0182] A. T cells

[0183] In some respects, immune cells are T cells. Over the past two decades, several fundamental approaches have been described for the derivation, activation, and expansion of functional anti-tumor effector cells. These include: autologous cells, such as tumor-infiltrating lymphocytes (TILs); T cells activated in vitro using autologous dendritic cells or PBMCs, lymphocytes, artificial antigen-presenting cells (APCs), or beads coated with T cell ligands and activating antibodies, or cells isolated by capturing target cell membranes; allogeneic cells naturally expressing anti-host tumor T cell receptors (TCRs); and chimeric TCR molecules (referred to as “T-body”) from non-tumor-specific autologous or allogeneic cells that have been genetically reprogrammed or “redirected” to express tumor-responsive TCRs or exhibit antibody-like tumor recognition capabilities. These approaches have yielded numerous protocols for T cell preparation and immunization, which can be used in the methods described herein.

[0184] In some respects, T cells originate from blood, bone marrow, lymph, umbilical cord, or lymphatic organs. In some respects, the cells are human cells. The cells are typically primary cells, such as cells isolated directly from the subject and / or cells isolated from and frozen from the subject. In some respects, the cells include one or more subsets of T cells or other cell types, such as intact T cell populations, CD4+, etc. + Cells, CD8 + Cells and their subpopulations, such as those defined by function, activation state, maturity, differentiation potential, capacity for expansion, recycling, localization and / or persistence, antigen specificity, antigen receptor type, presence in a specific organ or compartment, marker or cytokine secretion profile and / or degree of differentiation. Regarding the subject to be treated, cells may be allogeneic and / or autologous. In some aspects, such as with off-the-shelf technologies, cells are pluripotent and / or multipotent, such as stem cells, such as induced pluripotent stem cells (iPSCs). In some aspects, the method includes isolating cells from the subject, preparing, processing, culturing and / or engineering them as described herein, and reintroducing them into the same patient before or after cryopreservation.

[0185] In T cells (e.g., CD4) + and / or CD8 + Among the subtypes and subsets of T cells, there are naive T cells (T1). N ) cells, effector T cells (T cells) EFF ), memory T cells and their subtypes, such as stem cell memory T cells (TSCs). M ), central memory T cells (TC) M ), effector memory T cells (T EMEffector memory T cells or terminally differentiated T cells, tumor-infiltrating lymphocytes (TILs), immature T cells, mature T cells, helper T cells, cytotoxic T cells, mucosa-associated invariant T (MAIT) cells, naturally occurring and adaptive regulatory T (Treg) cells, helper T cells such as TH1 cells, TH2 cells, TH3 cells, TH17 cells, TH9 cells, TH22 cells, follicular helper T cells, α / β T cells, and γ / δ T cells.

[0186] In some respects, one or more T cell populations enrich or deplete cells that are positive for a specific marker (such as a surface marker) or negative for a specific marker. In some cases, such markers are those that are absent or expressed at relatively low levels in some T cell populations (e.g., non-memory cells) but present or expressed at relatively high levels in some other T cell populations (e.g., memory cells).

[0187] In some respects, T cells are isolated from PBMC samples by negative selection of markers expressed on non-T cells (such as B cells, monocytes, or other leukocytes). In other respects, CD4... + or CD8 + Select the step for separating CD4 + Helper T cells and CD8 + Cytotoxic T cells. These CD4+ cells can be identified through positive or negative selection based on markers expressed or expressed at relatively high levels on one or more subsets of naive, memory, and / or effector T cells. + and CD8 + The group was further classified into subgroups.

[0188] In some aspects, such as by further enriching or depleting CD8 through positive or negative selection based on surface antigens associated with each subgroup. + Initial, central memory, effector memory, and / or central memory stem cells in T cells. In some respects, central memory T(T) stem cells... CM Enrichment of cells or stem cell memory cells to increase efficacy, such as improving long-term survival, expansion and / or engraftment after application, is particularly robust in some respects in such subpopulations.

[0189] In some respects, the T cells are autologous T cells. In this method, a tumor sample is obtained from the patient, and a single-cell suspension is obtained. The single-cell suspension can be obtained in any suitable manner, for example, mechanically (using, for example, GENTLEMACS). TMTumors are obtained using a dissociation apparatus (Miltenyi Biotec, Auburn, Calif.) or enzymatic methods (e.g., collagenase or DNase). A single-cell suspension of the enzymatically digested tumor is cultured in interleukin-2 (IL-2) or other growth factors.

[0190] Cultured T cells can be pooled and rapidly expanded. Rapid expansion increases the number of antigen-specific T cells by at least about 50-fold (e.g., 50-fold, 60-fold, 70-fold, 80-fold, 90-fold, or 100-fold or more) over a period of about 10 to about 14 days. More preferably, rapid expansion provides an increase of at least about 200-fold (e.g., 200-fold, 300-fold, 400-fold, 500-fold, 600-fold, 700-fold, 800-fold, 900-fold or more) over a period of about 10 to about 14 days.

[0191] Amplification can be accomplished by any of the many methods known in the art. For example, T cells can be rapidly expanded using nonspecific T cell receptor stimulation in the presence of feeder lymphocytes and interleukin-2 (IL-2) or interleukin-15 (IL-15) (preferably IL-2). Nonspecific T cell receptor stimulation may include about 30 ng / ml of OKT3 (a mouse monoclonal anti-CD3 antibody available from Ortho-McNeil®, Raritan, NJ)). Alternatively, T cells can be rapidly expanded in vitro by stimulating peripheral blood mononuclear cells (PBMCs) with one or more antigens of cancer (including antigenic portions thereof, such as one or more epitopes, or cells) in the presence of T cell growth factors (such as 300 IU / ml IL-2 or IL-15 (preferably IL-2)), said antigens optionally expressed from a vector, such as a human leukocyte antigen A2 (HLA-A2)-binding peptide or a peptide binding to other MHC class I or II molecules. Rapid expansion of in vitro induced T cells can be achieved by pulsed stimulation of one or more of the same cancer antigens on antigen-presenting cells expressing HLA-A2 or other HLA molecules. In vitro induced T cells can also be expanded in the absence of antigen-presenting cells.

[0192] Autologous T cells can be modified to express T cell growth or differentiation factors that promote the growth, differentiation, and activation of autologous T cells. Suitable T cell growth factors include, for example, interleukin (IL)-2, IL-7, IL-15, IL-18, IL-21, and IL-12. Suitable modification methods are known in the art. See, for example, Sambrook et al. Molecular Cloning: A Laboratory Manual,3rd edition, Cold Spring Harbor Press, Cold Spring Harbor, NY 2001; and Ausubel et al. Current Protocols in Molecular Biology, Greene Publishing Associates and John Wiley & Sons, NY, 1994. In certain respects, modified autologous T cells express T cell growth factors at high levels. T cell growth factor coding sequences, such as those for IL-12, are readily available in the art, as are promoters, whose operative linking to T cell growth factor coding sequences facilitates high-level expression.

[0193] B. NK cells

[0194] In some respects, immune cells are natural killer (NK) cells. NK cells are a subset of lymphocytes that possess spontaneous cytotoxicity against a variety of tumor cells, virus-infected cells, and some normal cells in the bone marrow and thymus. NK cells differentiate and mature in the bone marrow, lymph nodes, spleen, tonsils, and thymus. NK cells can be detected by specific surface markers such as CD16, CD56, and / or CD8 in humans. NK cells do not express T-cell antigen receptors, the pan-T marker CD3, or surface immunoglobulin B-cell receptors.

[0195] In some respects, NK cells are derived from human peripheral blood mononuclear cells (PBMCs), unstimulated leukapheresis products (PBSCs), human embryonic stem cells (hESCs), induced pluripotent stem cells (iPSCs), bone marrow, tissues, or umbilical cord blood by methods known in the art.

[0196] C. NKT cells

[0197] Natural killer T (NKT) cells are a heterogeneous group of T cells, possessing characteristics of both T cells and natural killer cells. Many of these cells recognize the non-polymorphic CD1d molecule, an antigen-presenting molecule that binds to both self- and exogenous lipids and glycolipids. They comprise only about 0.1% of all peripheral blood T cells. NKT cells are a subset of T cells that co-express the αβ T cell receptor and also express several molecular markers commonly associated with NK cells, such as NK1.1. Invariant natural killer T (iNKT) cells express high levels of the transcriptional regulator promyelocytic leukemia zinc finger and depend on it for development. Currently, there are five major distinct iNKT cell subsets. Once activated, these subsets produce a different set of cytokines. The iNKT1, iNKT2, and iNKT17 isoforms correspond to Th cell subsets in terms of cytokine production. Additionally, there are isoforms specifically targeting follicular helper T cell-like functions and IL-10-dependent regulatory functions.

[0198] D. Congenital lymphoid cells

[0199] Innate lymphocytes (ILCs) are a group of innate immune cells derived from common lymphoid progenitor cells (CLPs) and belonging to the lymphoid lineage. These cells are defined as lacking antigen-specific B or T cell receptors due to the absence of the recombinant activation gene (RAG). ILCs do not express myeloid or dendritic cell markers. They play a role in protective immunity as well as in the regulation of homeostasis and inflammation; therefore, their dysregulation can lead to immunopathologies such as allergies, bronchial asthma, and autoimmune diseases. ILCs can be classified based on the cytokines they can produce and the transcription factors that regulate their development and function.

[0200] V. Cell preparation and culture

[0201] In certain respects, the cells described herein can be specifically formulated and / or cultured in specific culture media. The cells can be formulated in a manner suitable for delivery to the recipient without harmful effects.

[0202] In some respects, culture media can be prepared using media used for culturing animal cells (such as any one of AIM V, X-VIVO-15, NeuroBasal, EGM2, TeSR, BME, BGJb, CMRL 1066, Glasgow MEM, Improved MEM Zinc Option, IMDM, Medium 199, Eagle MEM, αMEM, DMEM, Ham, RPMI-1640, and Fischer medium, and any combination thereof) as their basal medium, but are not particularly limited thereto, provided that the medium can be used for culturing animal cells. In particular, the culture medium can be free of heterologous components or have a defined chemical composition.

[0203] Culture media can be serum-containing media, serum-free media, or media without xenogeneic components. From the perspective of preventing contamination from xenogeneic animal-derived components, serum can be derived from the same animal as one or more stem cell sources. Serum-free media refers to media that do not contain unprocessed or unpurified serum, and therefore can include media containing purified blood-derived components or animal tissue-derived components (such as growth factors).

[0204] The culture medium may or may not contain any serum substitutes. Serum substitutes may include materials appropriately containing albumin (such as lipid-rich albumin, bovine albumin, albumin substitutes such as recombinant or humanized albumin, plant starch, dextran, and proteolytic products), transferrin (or other iron transporters), fatty acids, insulin, collagen precursors, trace elements, 2-mercaptoethanol, 3'-thioglycerol, or equivalents thereof. Serum substitutes may be prepared by methods disclosed, for example, in International Publication No. 98 / 30679 (inherited herein in its entirety). Alternatively, for convenience, any commercially available material may be used. Commercially available materials include KNOCKOUT. TM Serum substitutes (KSR), chemically defined lipid concentrates (GIBCO) TM ) and GLUTAMAX TM (GIBCO TM ).

[0205] In some respects, the culture medium may contain one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, twenty or more of the following or any combination thereof: vitamins, such as biotin; DLα-tocopherol acetate; DLα-tocopherol; vitamin A (acetate); proteins, such as BSA (bovine serum albumin) or human albumin, fatty acid-free fraction V; catalase; recombinant human insulin; human transferrin; superoxide dismutase; other components, such as corticosterone; D-galactose; ethanolamine hydrochloride; glutathione (reduced); L-carnitine hydrochloride; linoleic acid; linolenic acid; progesterone; putrescine dihydrochloride; sodium selenite; and / or T3 (triiodothyronine). In specific respects, one or more of these may be explicitly excluded.

[0206] In some aspects, the culture medium further comprises vitamins. In some aspects, the culture medium contains 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, or 13 of the following substances (and any derivative range or combination thereof): biotin, DLα-tocopherol acetate, DLα-tocopherol, vitamin A, choline chloride, calcium pantothenate, pantothenic acid, folic acid nicotinamide, pyridoxine, riboflavin, thiamine, inositol, vitamin B12, or a combination thereof or salts thereof. In some aspects, the culture medium contains biotin, DLα-tocopherol acetate, DLα-tocopherol, vitamin A, choline chloride, calcium pantothenate, pantothenic acid, folic acid nicotinamide, pyridoxine, riboflavin, thiamine, inositol, and vitamin B12, or is essentially composed of them. In some aspects, vitamins include biotin, DLα-tocopherol acetate, DLα-tocopherol, vitamin A, or combinations thereof or salts thereof, or are essentially composed of them. In some aspects, the culture medium further comprises proteins. In some aspects, the protein includes albumin or bovine serum albumin, a portion of BSA, catalase, insulin, transferrin, superoxide dismutase, or combinations thereof. In some aspects, the culture medium further comprises one or more of the following substances: corticosterone, D-galactose, ethanolamine, glutathione, L-carnitine, linoleic acid, linolenic acid, progesterone, putrescine, sodium selenite, or triiodothyronine, or combinations thereof. In some aspects, the culture medium comprises one or more of the following substances: B-27® supplement, heterologous component-free B-27. TM Supplements, GS21 TMSupplements or combinations thereof. In some aspects, the culture medium contains or further contains amino acids, monosaccharides, and inorganic ions. In some aspects, the amino acids include arginine, cystine, isoleucine, leucine, lysine, methionine, glutamine, phenylalanine, threonine, tryptophan, histidine, tyrosine, or valine, or combinations thereof. In some aspects, the inorganic ions include sodium, potassium, calcium, magnesium, nitrogen, or phosphorus, or combinations thereof or salts thereof. In some aspects, the culture medium further contains one or more of the following: molybdenum, vanadium, iron, zinc, selenium, copper, or manganese, or combinations thereof. In some aspects, the culture medium contains one or more vitamins discussed herein and / or one or more proteins discussed herein and / or one or more of the following substances: corticosterone, D-galactose, ethanolamine, glutathione, L-carnitine, linoleic acid, linolenic acid, progesterone, putrescine, sodium selenite or triiodothyronine, B-27. TM Supplement, foreign ingredient-free B-27 TM Supplements, GS21 TM Supplements, amino acids (such as arginine, cystine, isoleucine, leucine, lysine, methionine, glutamine, phenylalanine, threonine, tryptophan, histidine, tyrosine, or valine), monosaccharides, inorganic ions (such as sodium, potassium, calcium, magnesium, nitrogen, and / or phosphorus) or salts thereof and / or molybdenum, vanadium, iron, zinc, selenium, copper, or manganese, or substantially composed thereof. In specific respects, one or more of these may be explicitly excluded.

[0207] The culture medium may also contain one or more externally added fatty acids or lipids, amino acids (such as non-essential amino acids), one or more vitamins, growth factors, cytokines, antioxidants, 2-mercaptoethanol, pyruvate, buffers, and / or inorganic salts. In specific instances, one or more of these may be explicitly excluded.

[0208] One or more culture medium components may be added at concentrations of at least, at most, or about 0.1, 0.5, 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 150, 180, 200, 250 ng / L, ng / ml, µg / ml, mg / ml, or any of the derivative ranges thereof.

[0209] In particular, the cells of this disclosure are specifically formulated. They may be formulated as cell suspensions or not. In specific cases, they are formulated as a single dosage form. They may be formulated for systemic or local administration. In some cases, the cells are formulated for storage prior to use, and the cell formulation may contain one or more cryopreservatives, such as DMSO (e.g., in 5% DMSO). The cell formulation may contain albumin, including human albumin, wherein a specific formulation contains 2.5% human albumin. The cells may be specifically formulated for intravenous administration; for example, they are formulated for intravenous administration in less than one hour. In a particular aspect, the cells are in a formulated cell suspension that is stable at room temperature for 1, 2, 3, or 4 hours or longer from thawing.

[0210] VI. Chimeric antigen receptors

[0211] In some respects, the cells of this disclosure further comprise one or more chimeric antigen receptors (CARs). Examples of tumor cell antigens that a CAR may target include at least 5T4, 8H9, αvβ6 integrin, BCMA, B7-H3, B7-H6, CAIX, CA9, CD19, CD20, CD22, CD30, CD33, CD38, CD44, CD44v6, CD44v7 / 8, CD70, CD123, CD138, CD171, CEA, CSPG4, EGFR, and the EGFR family (including ErbB2). (HER2), EGFRvIII), EGP2, EGP40, ERBB3, ERBB4, ErbB3 / 4, EPCAM, EphA2, EpCAM, folate receptor-α, FAP, FBP, fetal AchR, FR□, GD2, G250 / CAIX, GD3, phosphatidylinositol proteoglycan-3 (GPC3), Her2, IL-13Rα2, Lambda, Lewis-Y, Kappa, KDR, MAGE, MCSP, mesothelin, Muc1, Muc16, NCAM, NKG2D ligand, NY-ESO-1, PRAME, PSC1, PSCA, PSMA, ROR1, SP17, survivin, TAG72, TEMs, carcinoembryonic antigen, HMW-MAA, AFP, CA-125, ETA, tyrosinase, MAGE, laminin receptor, HPV E6, E7, BING-4, calcium-activated chloride channel 2, cyclin-B1, 9D7, EphA3, telomerase, SAP-1, BAGE family, CAGE family, GAGE ​​family, MAGE family, SAGE family, XAGE family, NY-ESO-1 / LAGE-1, PAME, SSX-2, Melan-A / MART-1, GP100 / pmel17, TRP-1 / -2, P-peptide, MC1R, prostate-specific antigen, β-catenin, BRCA1 / 2, CML66, fibronectin, MART-2, TGF-βRII, or VEGF receptor (e.g., VEGFR2). The CAR can be a first-generation, second-generation, third-generation, or more. The CAR can be bispecific to any two different antigens, or specific to more than two different antigens.

[0212] In some aspects, the cells of this disclosure comprise one or more chimeric polypeptides. The cells may comprise the chimeric polypeptides of this disclosure, as well as chimeric antigen receptors, T-cell receptors, and / or other engineered receptors or molecules. In some aspects, the cells of this disclosure comprise 1, 2, 3, 4, or 5 chimeric polypeptides, or more.

[0213] Certain aspects of this disclosure relate to chimeric antigen receptors (CARs), cells containing one or more CARs, and methods of using them.

[0214] A. Signal peptide

[0215] The polypeptides disclosed herein may include signal peptides. A “signal peptide” is a peptide sequence that guides the transport and localization of proteins within the cell to, for example, an organelle (such as the endoplasmic reticulum) and / or the cell surface. In some respects, signal peptides guide nascent proteins into the endoplasmic reticulum. This is essential if the receptor is to be glycosylated and anchored in the cell membrane. Typically, signal peptides natively linked to the most amino-terminal component are used (e.g., in scFvs with oriented light chain-connector-heavy chain, a native signal peptide of the light chain is used).

[0216] In some respects, signal peptides are cleaved after passing through the endoplasmic reticulum (ER), i.e. , It is a cleavable signal peptide. In some respects, the restriction site is located at the carboxyl terminus of the signal peptide to facilitate cleavage.

[0217] Any signal peptide that guides the transport and localization of proteins within the cell can be used. In some respects, the spacer or hinge sequence is derived from tPA, CD8α, GM-CSFRα, IL-2, IL-4, IL-21, CD33, CD7, PD1, PDL1, CD34, or combinations or derivatives thereof.

[0218] B. Antigen-binding domain

[0219] The polypeptides disclosed herein may comprise one or more antigen-binding domains. An "antigen-binding domain" describes a polypeptide region capable of binding an antigen under appropriate conditions. In some aspects, the antigen-binding domain is a single-chain variable fragment (scFv) based on one or more antibodies. In some aspects, the antigen-binding domain comprises a heavy-chain variable fragment (V... H ) region and light chain variable (V L ) area, of which V H District and V L The region is on the same polypeptide. In some respects, the antigen-binding domain contains V. H With V L Connectors between regions. Connectors enable antigen-binding domains to form the desired structure for antigen binding.

[0220] It can be achieved by mutating V H and / or V LAmino acid residues within CDR 1, CDR 2, and / or CDR 3 regions can be used to modify the variable regions of the antigen-binding domains of the polypeptides of this disclosure to improve one or more binding properties of the antibody (e.g., affinity). The term "CDR" refers to a complementarity-determining region, which is based on a portion of the variable chain in immunoglobulins (antibodies) and T cell receptors, respectively produced by B cells and T cells, where these molecules bind their specific antigens. Since most sequence variations associated with immunoglobulins and T cell receptors are found in the CDRs, these regions are sometimes referred to as hypervariable regions. Mutations can be introduced by site-directed mutagenesis or PCR-mediated mutagenesis, and the effects on antibody binding or other functional properties of interest can be evaluated in appropriate in vitro or in vivo assays. Preferably, conserved modifications are introduced, and typically no more than 1, 2, 3, 4, or 5 residues within the CDR region are altered. Mutations can be amino acid substitutions, additions, or deletions.

[0221] Antibodies can be frame-modified to reduce immunogenicity, for example, by “reverting mutations” of one or more frame residues into the corresponding germline sequence.

[0222] It was also considered that V could be used by binding the same antigen (multivalent) or different antigens (multispecific). H and V L Regions can polymerize antigen-binding domains, making the antigen-binding domains multispecific or multivalent.

[0223] The binding affinity of the antigen-binding region (such as the variable region (heavy chain and / or light chain variable region)) or CDR can be at least 10. -5 M, 10 -6 M, 10 -7 M, 10 -8 M, 10 -9 M, 10 -10 M, 10 -11 M, 10 -12 M or 10 -13 M. In some respects, antigen-binding regions (such as variable regions (heavy chain and / or light chain variable regions)) or K of CDRs D It can be at least 10 -5 M, 10 -6 M, 10 -7 M, 10 -8 M, 10 - 9 M, 10 -10 M, 10 -11 M, 10 -12 M or 10 -13 M (or any range from which it can be derived).

[0224] Combining affinity, K Aor K D It can be determined by methods known in the art, such as by surface plasmon resonance (SRP) based biosensors, by kinetic exclusion measurement (KinExA), by optical scanners for microarray detection based on polarization-modulated oblique incident reflectance difference (OI-RD), or by ELISA.

[0225] In some respects, peptides containing humanized binding regions have equal, higher, or at least 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 104, 106, 106, 108, 109, 110, 115, or 120% binding affinity and / or expression levels in host cells compared to peptides containing non-humanized binding regions (such as binding regions derived from mice).

[0226] In some respects, relative to the mouse frame, the frame regions of the human frame, such as FR1, FR2, FR3 and / or FR4, may each or together have at least, at most or exactly 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 11 1, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 16 0, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, or 200 (or any range thereof) amino acid substitutions, consecutive amino acid additions, or consecutive amino acid deletions.

[0227] In some respects, relative to the human frame, the frame regions of the mouse frame, such as FR1, FR2, FR3 and / or FR4, may each or together have at least, at most or exactly 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 11 1, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 16 0, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, or 200 (or any range thereof) amino acid substitutions, consecutive amino acid additions, or consecutive amino acid deletions.

[0228] The substitution can be performed at positions 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47 in the variable region of the heavy or light chain. 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100.

[0229] C. Peptide spacer region

[0230] Peptide spacer regions, such as extracellular spacer regions, can connect antigen-binding domains to transmembrane domains. In some aspects, the peptide spacer region is flexible enough to allow the antigen-binding domain to orient in different directions, thereby facilitating antigen binding. In one aspect, the spacer region contains a hinge region derived from IgG. In some aspects, the spacer region contains or further contains a portion of the CH2CH3 region and CD3 of an immunoglobulin. In some aspects, the CH2CH3 region may have L235E / N297Q or L235D / N297Q modification, or have at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or 100% amino acid sequence identity with the CH2CH3 region. In some aspects, the spacer region is derived from IgG4. The extracellular spacer region may contain a hinge region.

[0231] As used herein, the term “hinge” refers to a flexible polypeptide linker region (also referred to herein as a “hinge region”) that provides structural flexibility and spacers for flanking polypeptide regions and may be composed of natural or synthetic polypeptides. A “hinge” derived from an immunoglobulin (e.g., IgG1) is generally defined as extending from Glu216 to Pro230 of human IgG1 (Burton (1985) Molec. Immunol., 22:161-206). Hinge regions of other IgG isotypes can be aligned to the IgG1 sequence by placing the first and last cysteine ​​residues forming the inter-heavy-chain disulfide bond (SS) in the same position. Hinge regions may be naturally occurring or non-natural, including, but not limited to, modified hinge regions described in U.S. Patent No. 5,677,425 (incorporated herein by reference). Hinge regions may include complete hinge regions derived from antibodies of a different class or subclass than the CH1 domain. The term "hinge" can also include regions derived from CD8 and other receptors that provide similar functionality in providing flexibility and spacing to the flank regions.

[0232] The length of the extracellular spacer region can be at least, at most, or exactly 4, 5, 6, 7, 8, 9, 10, 12, 15, 16, 17, 18, 19, 20, 20, 25, 30, 35, 40, 45, 50, 75, 100, 110, 119, 120, 130, 140, 150, 160, 170, 180, 190, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 21 4, 215, 216, 217, 218, 219, 220, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 260, 270, 280, 290, 300, 325, 350, or 400 amino acids (or any range thereof). In some aspects, the extracellular spacer region consists of or contains a hinge region derived from an immunoglobulin (e.g., IgG). The amino acid sequence of the immunoglobulin hinge region is known in the art; see, for example, Tan et al. (1990) Proc. Natl. Acad. Sci. USA 87:162; and Huck et al. (1986) Nucl. Acids Res.

[0233] The length of the extracellular spacer region may influence CAR signaling activity and / or the amplification characteristics of CAR-T cell signaling in response to antigen stimulation. In some respects, shorter spacers are used, such as fewer than 50, 45, 40, 30, 35, 30, 25, 20, 15, 14, 13, 12, 11, or 10 amino acids. In other respects, longer spacers are used, such as at least 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 22... Spacer regions of 5, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 260, 270, 280, or 290 amino acids can have the advantage of enhanced in vivo or in vitro amplification.

[0234] When the extracellular spacer region comprises multiple parts, 0-50 amino acids may be present between the various parts. For example, at least, at most, or exactly 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, or 50 amino acids (or any range thereof) may be present between the hinge region and the CH2 region or the CH3 region (when both are present). In some respects, the extracellular spacer region consists essentially of the hinge region, the CH2 region, and / or the CH3 region, meaning that the hinge region, the CH2 region, and / or the CH3 region are the only identifiable regions present, and all other domains or regions are excluded, but other amino acids that do not belong to the identifiable regions may be present.

[0235] Any spacer or hinge sequence that provides structural flexibility and / or spacing for flanking polypeptide regions may be suitable for use. In some respects, the spacer or hinge sequence is derived from PDL1, CD2, CD28, CD3e, CD45, CD4, CD40, CD5, CD7, CD8, CD9, CD16, CD19, CD22, CD30, CD33, CD34, CD37, CD38, CD64, CD70, PD-1, CTLA-4, BCMA, CD80, CD86, CD123, CD134, CD137 or CD154, IgG1, IgG2, IgG3, IgG4, GM-CSF receptor, etc., or combinations or derivatives thereof.

[0236] D. Transmembrane domain

[0237] The peptides disclosed herein may contain transmembrane domains. In some respects, the transmembrane domain is a hydrophobic α-helix that spans the membrane. Different transmembrane domains can lead to different receptor stability.

[0238] In some respects, the transmembrane domain lies between the extracellular spacer and the cytoplasmic region. In some respects, the transmembrane domain lies between the extracellular spacer and one or more co-stimulatory regions. In some respects, the adapter lies between the transmembrane domain and one or more co-stimulatory regions.

[0239] Any transmembrane domain that allows a polypeptide to be inserted into the cell membrane of a eukaryotic (e.g., mammalian) cell may be suitable for use. In some respects, the transmembrane domain is derived from PDL1, CD2, CD3-ζ (CD3ζ), CD28, CD3e, CD45, CD4, CD40, CD5, CD7, CD8, CD9, CD16, CD19, CD22, CD30, CD33, CD34, CD37, CD38, CD64, CD70, PD-1, CTLA-4, BCMA, CD80, CD86, CD123, CD134, CD137 or CD154, IgG1, IgG2, IgG3, IgG4, GM-CSF receptor, etc., or combinations or derivatives thereof.

[0240] E. Cytoplasmic region

[0241] Following antigen recognition, the receptors of this disclosure can aggregate, and signals are transmitted to the cell via cytoplasmic regions or cytoplasmic domains. In some aspects, the co-stimulatory domains described herein are part of a cytoplasmic region. In some aspects, the cytoplasmic region contains intracellular signal transduction domains. Intracellular signal transduction domains may contain primary signal transduction domains and one or more co-stimulatory domains.

[0242] The cytoplasmic and / or co-stimulatory regions of the peptides applicable to this disclosure include any desired signal transduction domains that provide a unique and detectable signal in response to activation induced by the binding of an antigen to an antigen-binding domain (e.g., increased production of one or more cytokines by the cell; altered transcription of target genes; altered protein activity; altered cell behavior (e.g., cell death); cell proliferation; cell differentiation; cell survival; regulation of cell signal transduction responses, etc.). In some aspects, the cytoplasmic region includes at least one (e.g., one, two, three, four, five, six, etc.) ITAM motif as described herein. In some aspects, the cytoplasmic region includes a DAP10 / CD28 type signal transduction chain.

[0243] The cytoplasmic region of the polypeptides applicable to this disclosure includes an intracellular signaling polypeptide containing an immune receptor tyrosine activation motif (ITAM). The ITAM motif is YX1X2(L / I), where X1 and X2 are independently any amino acid. In some cases, the cytoplasmic region contains 1, 2, 3, 4, or 5 ITAM motifs. In some cases, the ITAM motif is repeated twice in an endodomain, where the first and second instances of the ITAM motif are separated by 6 to 8 amino acids, for example, (YX1X2(L / I))(X3)n(YX1X2(L / I)), where n is an integer from 6 to 8, and each of the 6-8 X3 motifs can be any amino acid.

[0244] Suitable cytoplasmic regions can be portions containing the ITM motif, derived from peptides containing the ITM motif. For example, suitable cytoplasmic regions can be ITM-motif-containing domains from any ITM-motif-containing protein. Therefore, suitable inner domains do not need to contain the complete sequence of the complete protein from which they originate. Examples of suitable ITM-motif-containing peptides include, but are not limited to: DAP12, DAP10, FCER1G (Fcε receptor Iγ chain); CD3D (CD3δ); CD3E (CD3ε); CD3G (CD3γ); CD3-ζ; and CD79A (antigen receptor complex-associated protein α chain).

[0245] Exemplary cytoplasmic regions are known in the art. The cytoplasmic regions shown below also provide examples of regions that can be incorporated into a CAR of this disclosure:

[0246] In some respects, a suitable cytoplasmic region may contain the ITAM motif portion of the full-length DAP12 amino acid sequence. In some respects, the cytoplasmic region is derived from FCERI1G (also known as FCERG; Fcε receptor I γ chain; Fc receptor γ chain; fc-εRI-γ; fcRγ; fceRIγ; high-affinity immunoglobulin ε receptor subunit γ; high-affinity immunoglobulin E receptor γ chain; etc.). In some respects, a suitable cytoplasmic region may contain the ITAM motif portion of the full-length FCERI1G amino acid sequence.

[0247] In some respects, the cytoplasmic region originates from the T cell surface glycoprotein CD3δ chain (also known as CD3D; CD3-δ; T3D; CD3 antigen δ subunit; CD3 delta; CD3δ; CD3d antigen δ polypeptide (TiT3 complex); OKT3 δ chain; T cell receptor T3δ chain; T cell surface glycoprotein CD3δ chain; etc.). In some respects, a suitable cytoplasmic region may contain the portion of the full-length CD3δ amino acid sequence containing the ITAM motif. In some respects, the cytoplasmic region originates from the T cell surface glycoprotein CD3ε chain (also known as CD3e, CD3ε; T cell surface antigen T3 / Leu-4ε chain, T cell surface glycoprotein CD3ε chain, AI504783, CD3, CD3-ε, T3e, etc.). In some respects, a suitable cytoplasmic region may contain the portion of the full-length CD3ε amino acid sequence containing the ITAM motif. In some respects, the cytoplasmic region originates from the T cell surface glycoprotein CD3γ chain (also known as CD3G, CD3γ, T cell receptor T3γ chain, CD3-γ, T3G, γ polypeptide (TiT3 complex), etc.). In some respects, a suitable cytoplasmic region may contain the portion of the full-length CD3γ amino acid sequence containing the ITAM motif. In some respects, the cytoplasmic region originates from the T cell surface glycoprotein CD3ζ chain (also known as CD3Z, CD3γ, T cell receptor T3ζ chain, CD247, CD3-ζ, CD3H, CD3Q, T3Z, TCRZ, etc.). In some respects, a suitable cytoplasmic region may contain the portion of the full-length CD3ζ amino acid sequence containing the ITAM motif.

[0248] In some respects, the cytoplasmic region is derived from CD79A (also known as the B-cell antigen receptor complex-associated protein α chain; CD79a antigen (immunoglobulin-associated α); MB-1 membrane glycoprotein; ig-α; membrane-bound immunoglobulin-associated protein; surface IgM-associated protein, etc.). In other respects, a suitable cytoplasmic region may contain the portion of the full-length CD79A amino acid sequence containing the ITAM motif.

[0249] Any cytoplasmic domain having a desired signal transduction domain is suitable for use, which provides a unique and detectable signal in response to activation induced by the binding of an antigen to an antigen-binding domain (e.g., an increase in the production of one or more cytokines by the cell; alterations in target gene transcription; alterations in protein activity; alterations in cell behavior (e.g., cell death); cell proliferation; cell differentiation; cell survival; regulation of cell signal transduction responses, etc.). In some aspects, the cytoplasmic domain is derived from BCMA, CD4, PD1, CTLA4, CD3γ, CD16, etc., or combinations or derivatives thereof.

[0250] F. Co-stimulatory area

[0251] Non-restricted examples of suitable co-stimulatory regions, such as those contained in the cytoplasm, including but not limited to peptides from 4-1BB (CD137), CD28, ICOS, OX-40, BTLA, CD27, CD30, GITR, and HVEM.

[0252] The co-stimulatory region may have a length of at least, at most, or exactly 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, or 300 amino acids, or any range thereof. In some aspects, the co-stimulatory region is derived from the intracellular portion of the transmembrane protein 4-1BB (also known as TNFRSF9; CD137; CDwl37; ILA, etc.). In some aspects, the co-stimulatory region is derived from the intracellular portion of the transmembrane protein CD28 (also known as Tp44). In some aspects, the co-stimulatory region is derived from the intracellular portion of the transmembrane protein ICOS (also known as AILIM, CD278, and CVID1). In some aspects, the co-stimulatory region is derived from the intracellular portion of the transmembrane protein OX-40 (also known as TNFRSF4, RP5-902P8.3, ACT35, CD134, OX40, TXGP1L). In some respects, the co-stimulatory region originates from the intracellular portion of the transmembrane protein BTLA (also known as BTLA1 and CD272). In some respects, the co-stimulatory region originates from the intracellular portion of the transmembrane protein CD27 (also known as S152, T14, TNFRSF7, and Tp55). In some respects, the co-stimulatory region originates from the intracellular portion of the transmembrane protein CD30 (also known as TNFRSF8, D1S166E, and Ki-1). In some respects, the co-stimulatory region originates from the intracellular portion of the transmembrane protein GITR (also known as TNFRSF18, RP5-902P8.2, AITR, CD357, and GITR-D). In some respects, the co-stimulatory region originates from the intracellular portion of the transmembrane protein HVEM (also known as TNFRSF14, RP3-395M20.6, ATAR, CD270, HVEA, HVEM, LIGHTR, and TR2).

[0253] G. Detection of peptides

[0254] In some respects, the polypeptides described herein may further comprise detection peptides. Various suitable detection peptides are known in the art and are considered herein.

[0255] H. Peptide linker

[0256] In some respects, the polypeptides of this disclosure include peptide linkers (sometimes referred to as linkers). Peptide linkers can be used to separate any peptide domains / regions described herein. As an example, a linker can be located between a signal peptide and an antigen-binding domain, at the V... H With V LThe linker can be located between the antigen-binding domain and the spacer region, between the spacer region and the transmembrane domain, on the flank of the co-stimulatory region or on the N or C region of the co-stimulatory region, and / or between the transmembrane domain and the inner domain. The peptide linker can have any of a variety of amino acid sequences. Domains and regions can be linked by peptide linkers that are generally flexible, although other chemical bonds are not excluded. The linker can be a peptide of length between about 6 and about 40 amino acids, or between about 6 and about 25 amino acids. These linkers can be generated using synthetic oligonucleotide-coupled proteins that encode the linker.

[0257] Peptide linkers with a certain degree of flexibility can be used. Peptide linkers can have almost any amino acid sequence, but it is important to note that suitable peptide linkers have sequences that produce typically flexible peptides. The use of small amino acids (such as glycine and alanine) can be used to produce flexible peptides. The generation of such sequences is routine for those skilled in the art.

[0258] Suitable connectors can be easily selected and can have any suitable length, such as 1 amino acid (e.g., Gly) to 20 amino acids, 2 amino acids to 15 amino acids, 3 amino acids to 12 amino acids, including 4 amino acids to 10 amino acids, 5 amino acids to 9 amino acids, 6 amino acids to 8 amino acids or 7 amino acids to 8 amino acids, and can be 1, 2, 3, 4, 5, 6 or 7 amino acids.

[0259] Suitable connectors can be easily selected and can have any suitable different lengths, such as 1 amino acid (e.g., Gly) to 20 amino acids, 2 amino acids to 15 amino acids, 3 amino acids to 12 amino acids, including 4 amino acids to 10 amino acids, 5 amino acids to 9 amino acids, 6 amino acids to 8 amino acids or 7 amino acids to 8 amino acids, and can be 1, 2, 3, 4, 5, 6 or 7 amino acids.

[0260] Any adapter sequence that provides a generally flexible peptide to separate any peptide domains / regions described herein may be suitable for use. In some aspects, the adapter sequence comprises the following repeating sequence: GGGGS (SEQ ID NO:34) repeating sequence or AEAAAAKEAAAKEAAAKEAAAKALEAEAAAKEAAAKEAAAKEAAAKA (SEQ ID NO:35).

[0261] VII. Cytokines

[0262] In some respects, any cell covered herein may express one or more heterologous cytokines. Specifically, the cell is engineered to express one or more heterologous cytokines and / or engineered to upregulate the normal expression of one or more heterologous cytokines. The cell may or may not be transduced or transfected on the same vector as other genes, targeting one or more cytokines. In some cases, in addition to one or more cytokines, the cell also expresses one or more heterologous proteins, including any kind of chimeric protein. As an example, the cell may express a chimeric antigen receptor.

[0263] One or more cytokines can be co-expressed from a vector as peptides separate from other proteins, including chimeric peptides and / or CARs. For example, interleukin-15 (IL-15) is tissue-restricted, and any level of IL-15 can only be observed in serum or systemically under pathological conditions. IL-15 possesses several properties desired for adoptive therapy. IL-15 is a homeostatic cytokine that induces the development and proliferation of natural killer cells, promotes the eradication of established tumors by alleviating functional suppression of tumor-resident cells, and inhibits activation-induced cell death (AICD). Other cytokines besides IL-15 have been envisioned. These include, but are not limited to, cytokines, chemokines, and other molecules that contribute to the activation and proliferation of cells for human applications. NK cells expressing IL-15 are capable of sustained supportive cytokine signaling, which is useful for their survival after infusion.

[0264] Specifically, cells express one or more exogenously provided cytokines. As an example, the cytokines are IL-15, IL-12, IL-2, IL-18, IL-21, IL-23, GMCSF, or combinations thereof. Alternatively, one or more cytokines may be exogenously provided to the cells. Alternatively, endogenous cytokines in the cells are upregulated by manipulation of the expression of endogenous cytokines (e.g., genetic recombination at one or more promoter sites of the cytokines). When cytokines are provided to cells on an expression construct, the cytokines may be encoded by the same vector as other heterologous proteins.

[0265] In some respects, the heterologous protein used in the cell is a fusion of a cytokine with at least a portion of its receptor (including some or all of the extracellular domains of the receptor). In a specific case, part or all of IL-15 is fused with part or all of the IL-15Ra receptor (including some or all of the extracellular domains of the IL-15Ra receptor, such as the sushi domain).

[0266] VIII. Chimeric peptides as transduction markers and / or safety switches

[0267] Aspects of this disclosure include chimeric peptides that can be used as transduction markers and / or safety switches. For example, safety strategies can be used in conjunction with cell therapy as a means of overcoming toxicity (if toxicity occurs). Examples existing in the art include herpes simplex virus thymidine kinase (HSV-tk) / ganciclovir, inducible caspase 9, and a truncated EGFR gene (tEGFR). The EGFR gene primarily uses an antibody-dependent cytotoxicity (ADCC) mechanism to eliminate therapeutic cells, which requires the presence of NK cells and other effector cells, potentially limiting the efficacy of such safety switches in vivo. Ideally, a safety switch would utilize ADCC or an antibody-drug conjugate (ADC) mechanism to eliminate therapeutic cells in vivo. ADC methods do not require effector cells to eliminate therapeutic cells in vivo and are therefore expected to be more effective in vivo. Additionally, for example, the tEGFR safety switch may have limited or no efficacy in patients who have recently received lymphocyte-reducing chemotherapy. This disclosure provides a solution to the needs in the field of cell therapy safety.

[0268] This disclosure includes methods and compositions related to cell therapy that have a reduced risk of adverse effects compared to cell therapies not produced in the same manner. In certain aspects, the therapeutic cells of this disclosure express at least one protein biomarker, which can also serve as a safety switch, for example, in cases where the cell therapy becomes toxic to the individual recipient. In some cases, the protein is used as a biomarker rather than a safety switch; in others, it serves as both; and in still others, it serves as both. Therapeutic cells may or may not be monitored with the biomarker before any toxicity develops. The biomarker / safety switch can also be used to monitor cell production and / or cell use.

[0269] In certain respects, chimeric peptides serve both as markers of specific cells and, if desired, as safety switches for killing cells. In some respects, chimeric peptides are present in cells that do not normally express the peptide, and / or exist in cells as any kind of heterologous protein (in some cases, including as fusion proteins). In specific respects, chimeric peptide fusion proteins containing at least the extracellular domain of a specific protein serve as markers of cells expressing the peptide and, if desired, as targets for killing cells expressing the peptide. In specific cases, chimeric peptides exist as fusion proteins where the cytoplasmic domain is not native to any part of the rest of the protein (although the transmembrane domain of the fusion protein may or may not be a transmembrane domain naturally present with the extracellular domain), and in some respects, the cytoplasmic domain is a cytoplasmic domain of a cell receptor, such as an internalized cytoplasmic domain. In specific cases, the cytoplasmic domain of the chimeric peptide fusion protein is derived from B cell maturation antigen (BCMA).

[0270] The methods disclosed herein include at least a method for identifying cells expressing chimeric polypeptides (such as polypeptides containing at least a portion of a specific extracellular domain to such extent that an agent (such as an antibody) binding to that extracellular domain can bind thereto). Cell identification using a specific protein can be for any reason, such as the production quality of cells expressing it, monitoring cell location, and / or determining cell quantity.

[0271] Specifically, the chimeric polypeptide contains one or more repeats of some or all of the extracellular domains of BCMA. Specifically, cell therapy controls cells by targeting BCMA expressed on the cells. Control of BCMA-positive cells allows them to be suppressed (including killed), for example, if the recipient of the cells exhibits any indication that the cell therapy has become harmful in any way (such as showing toxicity to the individual). In some respects, BCMA-positive cells are of any species and express any kind of heterologous BCMA protein, including chimeric fusion proteins. In other respects, the cell's natural mechanisms lead to the expression of BCMA under non-natural conditions. For example, BCMA can be expressed after transfection or transduction of one or more heterologous genes (including specific combinations of heterologous genes). In a specific context, when an individual recipient exhibits toxicity to BCMA-positive cell therapy, the individual is provided with an effective amount of one or more agents targeting BCMA, such as antibodies or antibody-drug conjugates, including monoclonal antibodies or immune cells (T cells (including αβ or γδ), NK cells, NKT cells, monocytes, macrophages, B cells, mesenchymal stem cells (MSCs), hematopoietic stem cells (HSCs), hematopoietic cells, induced pluripotent stem cells (iPSCs), or derivatives thereof, mixtures thereof, or derivatives thereof).

[0272] This disclosure includes expression constructs comprising a sequence encoding a specific chimeric polypeptide, wherein the chimeric polypeptide comprises at least a portion of a specific extracellular domain fused to an intracellular domain having endocytic or internalizing activity. In certain cases, the cytoplasmic domain of the chimeric polypeptide fusion protein is derived from Trop2. In specific cases, the chimeric polypeptide may or may not include a specific transmembrane domain, such as a transmembrane domain derived from PDL1. In specific aspects, the fusion protein comprises SEQ ID NO:10, and the sequence encoding the fusion protein may comprise SEQ ID NO:20. Any expression constructs covered herein may be in a vector, including viral or non-viral vectors.

[0273] Specific aspects of this disclosure include isolated cells containing any expression constructs covered herein, such as immune cells. Cells may be αβ T cells, γδ T cells, NK cells, NKT cells, monocytes, macrophages, B cells, mesenchymal stem cells (MSCs), hematopoietic stem cells (HSCs), hematopoietic cells, iPSCs, or mixtures thereof. In some cases, the cells express one or more heterologous proteins other than the chimeric peptide. Any heterologous protein may be a therapeutic protein, a cytokine, a fusion of a cytokine and a cytokine receptor, a safety switch, or a mixture thereof. In specific cases, the therapeutic protein is an engineered antigen receptor, antibody, etc. The engineered antigen receptor may target cancer antigens. The engineered antigen receptor may be a chimeric antigen receptor, a T-cell receptor, or a B-cell receptor. In specific aspects of the cells, the chimeric peptide and one or more heterologous proteins are expressed from the same vector, although in other cases, the chimeric peptide and one or more heterologous proteins are expressed from different vectors. Aspects of this disclosure include isolated populations of any of the cell types covered herein contained in a suitable culture medium. The populations may be deposited in a depository and / or cryopreserved.

[0274] Specific aspects of this disclosure include a method for identifying BCMA-positive cells transduced or transfected with a heterologous BCMA gene or a BCMA fusion protein containing some or all of the BCMA extracellular domains, comprising the steps of: transducing or transfecting cells with a heterologous BCMA gene or a BCMA fusion protein containing one or more of the BCMA extracellular domains or one or more portions thereof; exposing the cells to an effective amount of a BCMA-binding reagent; and directly or indirectly detecting the binding of said reagent to BCMA on the cell surface. The exposure and detection steps may be performed during and / or after cell manufacturing. The method may also include a cell manufacturing step. In a specific instance, the method is further defined as: transfecting or transducing immune cells with a BCMA fusion protein; exposing the immune cells to an effective amount of a BCMA-binding antibody or antibody-drug conjugate; and directly or indirectly detecting the binding of the antibody or antibody-drug conjugate to BCMA on the cell surface.

[0275] In specific instances, the method is performed in vitro, although in some cases, at least a portion of the method is performed in vivo. Cells may express one or more heterologous proteins other than the BCMA fusion protein, such as therapeutic proteins, cytokines, fusions of cytokines and cytokine receptors, safety switches, or mixtures thereof. Therapeutic proteins may be engineered antigen receptors. In a specific aspect, the method further includes the step of transfecting or transforming immune cells with a heterologous protein other than heterologous BCMA or the BCMA fusion protein. In some aspects, the BCMA fusion protein and the heterologous protein other than the BCMA fusion protein are expressed from the same vector. The BCMA fusion protein and the heterologous protein other than the BCMA fusion protein may be expressed from different vectors.

[0276] In one aspect, there is a method for manufacturing immune cells for adoptive cell therapy, comprising the steps of: (a) transducing or transfecting immune cells with a heterologous BCMA gene or a BCMA fusion protein containing one or more repeats of the BCMA extracellular domain, wherein the immune cells express the BCMA gene or the BCMA fusion protein containing one or more BCMA extracellular domains or one or more portions thereof (e.g., containing one or more repeats or at least two repeats of the extracellular domain having at least 90% identity with the amino acid sequence of SEQ ID NO:33); and (b) transducing or transfecting the immune cells with one or more therapeutic proteins. In a specific aspect, step (a) occurs before, simultaneously with, or after step (b). The transformation or transfection in step (a) may be the same as the transformation or transfection in step (b). Specifically, the heterologous BCMA gene or a BCMA fusion protein containing one or more BCMA extracellular domains or one or more portions thereof (e.g., containing one or more repeats or at least two repeats of an extracellular domain having at least 90% identity with the amino acid sequence of SEQ ID NO:33) resides on the same vector as the therapeutic protein, although the heterologous BCMA gene or the BCMA fusion protein containing one or more BCMA extracellular domains or one or more portions thereof (e.g., containing one or more repeats or at least two repeats of an extracellular domain having at least 90% identity with the amino acid sequence of SEQ ID NO:33) may reside on a different vector than the therapeutic protein. Specifically, after step (a), the presence of BCMA expressed on the surface of immune cells from the method is analyzed, such as by flow cytometry, polymerase chain reaction, or a combination thereof.

[0277] In some cases, the method further includes the step of administering immune cells generated by the method to an individual in need. In any case, immune cells within the individual can be monitored, for example, using a BCMA-binding reagent (e.g., an antibody or antibody-drug conjugate). Specifically, an individual exhibits one or more harmful effects from immune cells, and an effective amount of a BCMA-binding reagent is administered to the individual. An individual may exhibit toxicity from immune cells, and an effective amount of a BCMA-binding reagent may be administered to the individual. An individual may exhibit graft-versus-host disease (GVHD) from immune cells, and an effective amount of a BCMA-binding reagent may be administered to the individual. An individual may no longer require immune cells, and an effective amount of a BCMA-binding reagent may be administered to the individual.

[0278] This disclosure includes methods for mitigating or preventing one or more adverse effects from cell therapies in an individual, comprising the step of targeting the extracellular domain of a chimeric polypeptide expressed on the cell surface of the cell therapy. The method may be further defined as administering to an individual an effective amount of one or more agents, such as antibodies (e.g., monoclonal antibodies) or antibody-drug conjugates, that bind to the extracellular domain of the chimeric polypeptide expressed on the cell. Examples of adverse effects include GVHD, cytokine release syndrome, or immune effector cell-related neurotoxicity syndromes. Where the polypeptide comprises one or more repeats of some or all of the BCMA extracellular domain, the expressed one or more BCMA extracellular domains or one or more portions thereof (e.g., extracellular domains comprising one or more repeats or at least two repeats of an amino acid sequence having at least 90% identity with SEQ ID NO:33) may or may not include the complete BCMA protein. In a specific case, BCMA is a fragment of the complete BCMA protein that comprises at least a portion of the extracellular domain. BCMA can be naturally expressed on immune cells. In some cases, BCMA is naturally heterologously expressed on immune cells. BCMA can be a BCMA fusion protein, such as a BCMA fusion protein comprising at least a portion of one or more extracellular domains of BCMA fused to an intracellular domain (e.g., one or more repeating or at least two repeating extracellular domains having at least 90% identity with an amino acid sequence of SEQ ID NO:33), wherein the intracellular domain has endocytic or internalization activity. An example of an intracellular domain is Trop2. BCMA fusion proteins may contain a PDL1 hinge and / or a transmembrane domain. BCMA fusion proteins may contain one or more linkers, such as one or more CD34 epitope sequences. In a specific case, the fusion protein comprises SEQ ID NO:10. The sequence encoding the fusion protein may comprise SEQ ID NO:20.

[0279] In specific cases, prior to any targeting step, an individual's cells may be monitored in vivo, for example, using one or more agents targeting their chimeric peptides. In a particular aspect, the agent targeting the chimeric peptide is an antibody, used in sufficiently low amounts without inhibiting the therapeutic cells. Cell therapy may be allogeneic or autologous to the individual. Cell therapy may include immune cells expressing one or more heterologous proteins, including therapeutic proteins, cytokines, fusions of cytokines and cytokine receptors, safety switches, or mixtures thereof. Therapeutic proteins may contain one or more engineered antigen receptors, including chimeric antigen receptors, T-cell receptors, or both expressed by the cells. Cells may express chimeric peptides and chimeric antigen receptors.

[0280] This disclosure includes a method for inhibiting cell activity, comprising the step of exposing cells transduced or transfected with one or more repeats of a BCMA fusion protein containing some or all of the BCMA extracellular domain (e.g., containing one or more repeats or at least two repeats of an extracellular domain having at least 90% identity with the amino acid sequence of SEQ ID NO:33) to an effective amount of a BCMA-binding reagent. In a specific aspect, inhibition of activity is further defined as induction of apoptosis. The method may further include detecting the binding of a reagent to BCMA expressed on the cells.

[0281] IX. BCMA-positive cells and related compositions

[0282] This disclosure relates to compositions comprising BCMA-positive cells that reduce the risk of toxicity to individual recipients of cell therapy and / or allow for monitoring of cell production and / or cell location. BCMA-positive cells produced using methods of this disclosure have a reduced risk of toxicity compared to cells produced using methods not described in this disclosure. The expression of the extracellular domain of the BCMA protein on the cell surface allows the protein to be targeted by one or more agents that recognize the domain on the surface and directly or indirectly cause cell inhibition, including cell death.

[0283] In a specific aspect, BCMA-positive cells are used as any kind of marker and safety switch, including for cells that may become toxic to an individual recipient. Aspects of this disclosure include methods and compositions in which BCMA is effective as one or both of a transduction marker and a safety switch. Cell therapies include BCMA-positive cells, which, in a specific aspect, are immune cells that may or may not contain modifications to express one or more heterologous genes.

[0284] BCMA-positive cells include those cells in which BCMA is naturally expressed on the cell surface. Alternatively, cells can be artificially modified to express partial or complete BCMA; in some cases, cells do not express BCMA without such modification. BCMA may or may not be wild-type. In certain aspects, a portion but not all, or multiple copies of a portion but not all, of the BCMA protein are expressed in the cell, and when less than complete BCMA protein is used, it contains at least a portion (if not all) of the BCMA extracellular domain. In particular aspects, the BCMA transmembrane domain is utilized, while in other cases it is not. In particular cases, at least a portion of BCMA is used in fusion proteins, including fusion proteins in which the BCMA fusion protein is expressed on the cell surface. In such cases, the BCMA fusion protein contains at least a portion (if not all) of the BCMA extracellular domain. In particular cases, the fusion protein contains sufficient BCMA extracellular domain such that an antibody recognizing the BCMA extracellular domain can bind to it at the appropriate epitope.

[0285] Following artificial modifications, such as transfection or transduction of one or more non-BCMA heterologous genes, the cells may also possess the unique ability to express BCMA as a cell surface marker. For certain cells, including at least T cells, NK cells, NKT cells, monocytes, macrophages, B cells, mesenchymal stem cells (MSCs), hematopoietic stem cells (HSCs), hematopoietic cells, induced pluripotent stem cells (iPSCs), or derivatives thereof, mixtures thereof, or derivatives thereof, transfection or transduction of one or more heterologous genes results in the expression of BCMA when it is not normally expressed. In such cases, this allows BCMA to be used as a transduction marker for cells successfully transfected or transduced with one or more heterologous genes.

[0286] BCMA (or its derivatives) as a membrane-bound protein can be used in a variety of therapeutic immune cell products. In some cases, immune cells include at least T cells, NK cells, NKT cells, monocytes, macrophages, B cells, mesenchymal stem cells (MSCs), hematopoietic stem cells (HSCs), hematopoietic cells, induced pluripotent stem cells (iPSCs), or derivatives thereof, mixtures thereof, and their derivatives.

[0287] In specific cases, the membrane-binding protein comprises one or more repeats of the extracellular domain of BCMA (e.g., an extracellular domain comprising one or more repeats of an amino acid sequence having at least 90% identity with SEQ ID NO:33, or at least two repeats of the extracellular domain). In some cases, the membrane-binding protein is a full-length wild-type BCMA protein. The membrane-binding BCMA protein may include a cytoplasmic tail (which has at least an internalization motif, meaning that the tail can interact with clathrin-mediated intracellular transport complexes to internalize BCMA-bound anti-BCMA antibodies), said cytoplasmic tail comprising one or more internalized cytoplasmic tails of one or more other membrane-binding receptors. Common sequences associated with clathrin-dependent endocytosis sorting signals are known in the art (Traub, Molecular Cell Biology, Vol. 10, pp. 583-596, 2009). In some cases, the cytoplasmic tail is the cytoplasmic portion of a surface-binding protein. In a specific aspect, the cytoplasmic tail is the cytoplasmic tail of Trop-2.

[0288] In one aspect, BCMA is co-expressed in cells with one or more heterologous proteins. The heterologous proteins may or may not be therapeutic proteins, including proteins that have therapeutic efficacy themselves and / or proteins that confer therapeutic efficacy to BCMA-positive cells expressing the protein. Cells may be manufactured simultaneously or at different times to express BCMA and the heterologous proteins. In some aspects, cells that may or may not be BCMA-positive are modified to express one or more heterologous proteins, and then the cells are stored in a repository, including cryopreservation. When needed, the cells can be thawed and further modified to express BCMA, express a BCMA fusion protein, or be transformed / transfected to express one or more heterologous genes, which then upregulate BCMA expression in the cells. In other cases, cells expressing BCMA, cells expressing a BCMA fusion protein, or cells transformed / transfected to express one or more heterologous genes (which then upregulate BCMA expression in the cells) are modified to express one or more heterologous proteins after being thawed from cryopreservation conditions in a repository.

[0289] In a specific context, for any BCMA-positive cell, one or more heterologous genes can be one or more engineered antigen receptors, including chimeric antigen receptors or cells expressing TCRs. In such cases, any engineered antigen receptor can target one or more antigens, including one or more cancer antigens. Engineered antigen receptors can be directed to target single or multiple antigens of interest, including cancer antigens.

[0290] In specific cases, BCMA-positive cells are autologous or allogeneic cells (for an individual) that may or may not express one or more heterologous proteins.

[0291] In some respects, BCMA-positive cells express additional safety switches in addition to BCMA or BCMA fusion proteins, including herpes simplex virus thymidine kinase (HSV-tk) / ganciclovir, iCaspase9, tEGFR, synNotch, combinatorial target antigen recognition, and inhibitory chimeric antigen receptors.

[0292] In some respects, BCMA fusion proteins are used, where fusion is the fusion of the BCMA extracellular domain or a portion thereof with another protein fragment (including a fragment that is at least a portion of the cytoplasmic region of a membrane-bound protein). As an example, two copies of the BCMA extracellular domain or a portion thereof (in bold) are fused with the PDL1 hinge (in italics), the transmembrane domain (in underline), and the Trop2 intracellular region (in bold and italics). The BCMA extracellular domain may be linked, for example, via two CD34 epitopes (in underline and italics). The amino acid sequence of a representative BCMA-Trop2 fusion protein is as follows:

[0293]

[0294] The DNA sequence of a representative BCMA-Trop2 fusion protein is as follows:

[0295]

[0296] In some respects, wild-type BCMA is used because it is naturally present in cells, because it is a heterologous BCMA that has been transduced into cells, or because it is expressed in cells due to transduction or transfection by one or more other genes. Wild-type full-length BCMA is as follows:

[0297] amino acid sequence:

[0298]

[0299] DNA sequence:

[0300]

[0301] Other specific fusion protein combinations were considered. As an example, two copies of the BCMA extracellular domain or a portion thereof (in bold) were fused with the PDL1 hinge (in italics) and transmembrane domain (in underline) and the Trop2 intracellular region (in bold and italics). The BCMA extracellular domain portion could be linked by, for example, two CD34 epitopes (in underline and italics).

[0302]

[0303] As another example, no BCMA molecule with an intracellular internalization domain can function as a safety switch in conjunction with a T-cell adaptor or antibody (e.g., a bispecific antibody such as teratumab, enoatumab, alanuctamab, rivosaminidumab, ABBV-383, HPN217 (TriTAC), or ISB 2001). These molecules are bispecific monoclonal antibodies, also described as BCMA-directed CD3 T-cell adaptors. These agents induce killing without internalization and can recruit host T cells or induce cannibalism to kill BCMA-expressing CAR T cells. In some respects, the safety switch molecule does not include an intracellular domain, and the ability of the BCMA-binding protein-antibody fusion protein to bind to and activate T cells to kill BCMA-expressing CAR T cells is not diminished or inhibited compared to other BCMA-binding protein-T-cell adaptor fusion proteins (e.g., the BCMA-binding protein-belantamab fusion protein). Examples of such BCMA safety switch molecules may include two copies of the BCMA extracellular domain or a portion thereof (in bold), which are fused together with two CD34 epitope linkers (in underline and italics) and a spacer region and transmembrane domain from PD-L1 (in underline).

[0304]

[0305] X. Methods related to BCMA-positive cells

[0306] This disclosure relates to BCMA-positive cells and their uses, including cells that are positive for natural or recombinant BCMA (including membrane-bound BCMA proteins that may or may not be intercalated with one or more other protein fragments) and their uses. In particular, BCMA is used as follows: (1) as a transduction and selection marker for enriching therapeutic cell products during manufacturing; (2) as a transduction marker for monitoring infused cell products to assess amplification, phenotype, function, transport, and persistence in vivo; or (3) as a safety switch to eliminate infused therapeutic cells as needed using monoclonal antibodies, antibody-drug conjugates, or other methods.

[0307] In specific cases, this disclosure covers methods in which BCMA is used as a transduction marker. For example, cells that may or may not express BCMA are transfected or transduced to express proteins having an extracellular domain comprising one or more repeats or at least two repeats of an amino acid sequence having at least 90% identity with SEQ ID NO:33, and the presence of the BCMA extracellular domain in successfully transfected or transduced candidate cells is determined, for example, using one or more reagents that bind at least a portion of the extracellular domain. In some cases, one or more reagents are labeled to allow detection (including detection by light, fluorescence, color, radioactivity, etc.) of this interaction. In other cases, cells that may or may not express BCMA are transfected or transduced to express one or more non-BCMA proteins, but following the respective transfection or transduction, the cells express BCMA as a direct or indirect result of the transfection or transduction.

[0308] In some respects, BCMA proteins are used as selection markers. In other words, methods for selectively selecting BCMA-positive cells from a cell population that at least has a suspected BCMA-positive subset, such as using a matrix containing a BCMA-binding reagent on its surface. The population can be exposed under sufficient conditions to allow those BCMA-positive cells in the population to bind the reagent, thereby excluding those non-BCMA-positive cells. The cells can then be released from the binding reagent, such as after appropriate washing. Specifically, the BCMA used as a selection marker is not endogenous BCMA, but rather expressed by the cells due to artificial reasons, such as after transfection or transduction with heterologous BCMA or a BCMA fusion protein.

[0309] The methods of this disclosure also utilize BCMA or BCMA-related derived proteins (e.g., fusion proteins) to monitor cell products. Monitoring can be in vitro or in vivo, and may include measuring cell expansion, cell-related specific functions, etc. In some cases, monitoring is in vivo and is performed after the administration (including administration via infusion) of BCMA-positive cells to the recipient individual. In specific cases, BCMA-positive infused cell products allow for the evaluation of multiple aspects of the infused cell therapy in vivo, including expansion, phenotype, function, transport, and persistence. In some aspects, monitoring of BCMA-positive cells provides information on the risk that the cell therapy may become toxic to the individual. For example, CAR T cells may exhibit excessive proliferation after infusion and can lead to toxicity.

[0310] In certain aspects, BCMA or BCMA-related derivative proteins (e.g., fusion proteins) on cells act as safety switches to inhibit the activity of BCMA-positive cells in a cell therapy when it is no longer necessary for the cells or the individual to exhibit signs that one or more cell therapies are toxic to the individual or become toxic to the individual for any specific period of time. The methods and compositions of the present invention can be used to reduce or prevent one or more adverse events, such as cytokine release syndrome, neurotoxicity, immune effector cell-related neurotoxicity syndrome, anaphylactic / hypersensitivity reactions, host rejection, including at least GVHD, on-target / tumor toxicity and / or on-target / off-tumor toxicity (depletion of normal cells), or being considered at risk (including impending risk) with one or more symptoms. The use of suicide genes or safety switches may be part of the therapeutic protocol or may be used only when it is recognized that their use is necessary. In some cases, safety switches delay the onset of toxicity and / or reduce the severity of toxicity, while in others, they prevent or completely inhibit toxicity.

[0311] Following infusion of therapeutically transferred T cells to an individual, membrane-bound BCMA proteins can be used to monitor the fate of the adopted T cells, including via flow cytometry, PCR, or other laboratory methods such as next-generation sequencing, or through clinical trials (such as imaging studies). In cases where the therapy results in adverse events such as cytokine release syndrome, GVHD, tumorigenesis, etc., antibodies or antibody-drug conjugates or other methods can be used to eliminate the infused cells in vivo.

[0312] This disclosure provides membrane-bound BCMA proteins or fusion proteins that can be used alone or in combination as transduction and selection markers and / or elimination safety switches. In some cases, cells express BCMA or BCMA fusion proteins that act as safety switches but not as transduction or selection markers, while in other cases, they act as transduction or selection markers but not as safety switches.

[0313] The methods disclosed herein also cover methods for inhibiting cell activity by targeting surface proteins on cells, said surface proteins comprising some or all of the extracellular domains of BCMA. The inhibited activity can be of any type, but in a specific respect, inhibition of activity is defined as induction of apoptosis. When cells are exposed to an effective amount of one or more BCMA-binding agents, cell proliferation can be inhibited or delayed, or the cells can be killed. One or more BCMA-binding agents can control cell survival in any of the methods disclosed herein.

[0314] XI. General pharmaceutical compositions

[0315] In some respects, a pharmaceutical composition is administered to a subject. Different respects may involve administering an effective amount of the composition to a subject. In some respects, cell therapy (e.g., CAR T cells, CAR NK cells, TCR T cells, etc.) is administered to a subject to prevent or treat a condition (e.g., cancer). Furthermore, such compositions may be administered in combination with other therapeutic agents (e.g., chemotherapy agents, immunotherapy agents, biotherapy agents, etc.). Such compositions are typically dissolved or dispersed in a pharmaceutically acceptable carrier or aqueous medium.

[0316] The phrase "pharmaceutically acceptable" or "pharmacologically acceptable" refers to molecular entities and compositions that, when administered to animals or humans, will not produce adverse reactions, allergic reactions, or other adverse effects. As used herein, "pharmaceutically acceptable carriers" include any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic agents, and absorption delay agents. The use of such media and reagents for pharmaceutically active substances is well known in the art. Their use in immunogenic and therapeutic compositions is considered unless to the extent that any conventional media or reagent is incompatible with the active ingredient. Supplemental active ingredients, such as other anti-infective agents and vaccines, may also be incorporated into the composition.

[0317] The active compounds can be formulated for parenteral administration, for example, for injection via intravenous, intramuscular, subcutaneous, or intraperitoneal routes. Typically, such compositions can be prepared as liquid solutions or suspensions; they can also be prepared in solid forms suitable for use in preparing solutions or suspensions after addition of liquid prior to injection; and the formulations can be emulsified.

[0318] Suitable drug forms for injection include sterile aqueous solutions or dispersions; formulations (including, for example, aqueous propylene glycol); and sterile powders for the ad hoc preparation of sterile injectable solutions or dispersions. In all cases, the dosage form must be sterile and must be a fluid to the extent that it can be easily injected. It should also be stable under the conditions of manufacture and storage and must be protected against contamination by microorganisms such as bacteria and fungi.

[0319] Compositions with protein properties can be formulated into neutral or salt forms. Pharmaceutically acceptable salts include acid addition salts (formed from the free amino groups of proteins), which are formed from inorganic acids (such as, for example, hydrochloric acid or phosphoric acid) or organic acids (such as acetic acid, oxalic acid, tartaric acid, mandelic acid, etc.). Salts formed with free carboxyl groups can also be derived from inorganic bases (such as, for example, sodium hydroxide, potassium hydroxide, ammonium hydroxide, calcium hydroxide, or iron hydroxide) and organic bases (such as isopropylamine, trimethylamine, histidine, procaine, etc.).

[0320] Pharmaceutical compositions may contain solvents or dispersion media comprising, for example, water, ethanol, polyols (e.g., glycerol, propylene glycol, and liquid polyethylene glycol), suitable mixtures thereof, and vegetable oils. Appropriate flowability can be maintained, for example, by using coatings (such as lecithin), maintaining the desired particle size in the case of dispersions, and using surfactants. Prevention of microbial activity can be achieved by various antibacterial and antifungal agents (e.g., parabens, chlorobutanol, phenol, sorbic acid, thimerosal, etc.). In many cases, isotonic agents, such as sugars or sodium chloride, are preferred. Prolonged absorption of injectable compositions can be achieved by using agents that delay absorption (e.g., aluminum monostearate and gelatin) in the composition.

[0321] Sterile injectable solutions are prepared by incorporating the active compound, in the desired amount, along with various other components listed above, into a suitable solvent, followed by filtration sterilization or an equivalent process. Typically, dispersions are prepared by incorporating various sterilized active ingredients into a sterile medium comprising a basic dispersion medium and other desired components selected from those listed above. In the case of sterile powders used to prepare sterile injectable solutions, preferred methods of preparation include vacuum drying and freeze-drying techniques, which yield powders of the active ingredient and any additional desired components from solutions that have been previously sterile filtered.

[0322] The composition is typically administered via any conventional route. This includes, but is not limited to, oral or intravenous administration. Alternatively, administration may be performed via in situ, intradermal, subcutaneous, intramuscular, intraperitoneal, or intranasal administration. Such compositions are typically administered as pharmaceutically acceptable compositions comprising physiologically acceptable carriers, buffers, or other excipients.

[0323] After preparation, the solution is administered in a manner compatible with the dosage form and in an amount effective for treatment or prevention. The formulation is readily administered in various dosage forms, such as the type of injectable solution described above.

[0324] XII. Combination Therapy

[0325] In some aspects, the compositions and methods of this invention relate to cancer therapies other than those comprising therapeutic cells. The adjunctive therapy may be radiation therapy, surgery (e.g., mastectomy and lumpectomy), chemotherapy, gene therapy, DNA therapy, viral therapy, RNA therapy, immunotherapy, bone marrow transplantation, nanotherapy, monoclonal antibody therapy, hormone therapy, or a combination of the foregoing therapies. The adjunctive therapy may be in the form of adjuvant therapy or neoadjuvant therapy.

[0326] In some aspects, adjunctive therapy is the administration of one or more small molecule enzyme inhibitors or one or more anti-transfer agents. In some aspects, adjunctive therapy is the administration of side effect limiters (e.g., agents designed to reduce the occurrence and / or severity of treatment side effects, such as antinausea agents). In some aspects, adjunctive therapy is radiotherapy. In some aspects, adjunctive therapy is surgery. In some aspects, adjunctive therapy is a combination of radiotherapy and surgery. In some aspects, adjunctive therapy is gamma irradiation. In some aspects, adjunctive therapy is a therapy targeting the PBK / AKT / mTOR pathway, an HSP90 inhibitor, a tubulin inhibitor, an apoptosis inhibitor, and / or one or more chemopreventive agents. Adjunctive therapy may be one or more chemotherapeutic agents known in the art.

[0327] Immunotherapy (in addition to the cell therapies disclosed herein) can be administered before, during, or after additional cancer therapies (such as immune checkpoint therapy), or in various combinations thereof. Administration can be performed at intervals ranging from simultaneous to minutes to days to weeks. In cases where immunotherapy is administered separately from one or more compositions of this disclosure, it is generally ensured that a substantial period of time does not elapse between each delivery, allowing both compounds to still exert a beneficial combined effect on the patient. In such cases, it is considered that the immunotherapy and the disclosed compositions may be administered to the patient within approximately 12 to 24 or 72 hours of each other, more specifically within approximately 6 to 12 hours of each other. In some cases, a significantly longer treatment duration may be required, with intervals between administrations ranging from several days (2, 3, 4, 5, 6, or 7 days) to several weeks (1, 2, 3, 4, 5, 6, 7, or 8 weeks).

[0328] Given the potential toxicity of the reagents (if any), administration of any compound or cell therapy of this invention to a patient will follow the general protocol for administering such compounds. Therefore, in some respects, there are steps for monitoring toxicity attributable to combination therapies.

[0329] A. Chemotherapy

[0330] Various chemotherapeutic agents can be used according to aspects of the present invention. The term "chemotherapy" refers to the treatment of cancer with drugs. "Chemotherapy agent" is used to refer to compounds or compositions administered in cancer treatment. These agents or drugs are classified according to their patterns of activity within cells, such as whether and at what stage they affect the cell cycle. Alternatively, agents may be characterized based on their ability to directly crosslink DNA, embed in DNA, or induce chromosomal and mitotic aberrations by influencing nucleic acid synthesis.

[0331] Examples of chemotherapeutic agents include alkylating agents such as thiotepa and cyclophosphamide; alkyl sulfonates such as busulfan, improsulfan, and piposulfan; aziridines such as benzodopa, carboquone, meturedopa, and uredopa; ethylene imines and methylamelamines, including altretamine, triethylenemelamine, triethylenephosphoramide, triethylenethiophosphoramide, and trimethylolomelamine; acetogenin. (Especially bullatacin and bullatacinone); camptothecin (including its synthetic analogue topotecan); bryostatin; callystatin; CC-1065 (including its synthetic analogues adozelesin, carzelesin, and bizelesin); cryptophycin (especially cryptophycin 1 and cryptophycin 8); dolastatin; duocarmycin (Including synthetic analogs KW-2189 and CB1-TM1); eleutherobin; pancratistatin; sarcodictyin; spongistatin; nitrogen mustards, such as chlorambucil, chlornaphazine, cholophosphamide, estramustine, ifosfamide, mechlorethamine, mechlorethamine oxide hydrochloride, melphalan, novombhichin, phenesterine, prednimustine, trofosfamide, and uracil mustard;Nitrosoureas, such as carmustine, chlorozotocin, fotemustine, lomustine, nimustine, and ranimnustine; antibiotics, such as acetylenes (e.g., calicheamicin, especially calicheamicin γI and calicheamicin ωI1); dynemicins, including dynemicin A; bisphosphonates, such as clodronate; esperamicin; and neocarzinostatin chromophores and related chromogens, acetylenes, aclacinomycin, actinomycin, authramycin, and azoserine. Azaserine, bleomycin, cactinomycin, carabicin, carminomycin, carzinophilin, chromomycin, dactinomycin D, daunorubicin, detorubicin, 6-diazo-5-oxo-L-leucine, doxorubicin (including morpholino-doxorubicin, cyanomorpholino-doxorubicin, 2-pyrrololino-doxorubicin, and deoxydoxorubicin), epirubicin, esorubicin, idarubicin, marcellomycin, mitomycin (e.g., mitomycin C), mycophenolic acid The following are listed: nogalarnycin, olivomycin, peplomycin, potfiromycin, puromycin, quelamycin, rodorubicin, streptonigrin, streptozocin, tubercidin, ubenimex, zinostatin, and zorubicin; antimetabolites, such as methotrexate and 5-fluorouracil (5-FU).Folic acid analogs, such as denopterin, pteropterin, and trimetrexate; purine analogs, such as fludarabine, 6-mercaptopurine, thiamiprine, and thioguanine; pyrimidine analogs, such as ancitabine, azacitidine, 6-azauridine, carmofur, cytarabine, dideoxyuridine, doxifluridine, enocitabine, and fluxuridine; and androgens, such as calusterone and dromostanolone. Propionate, epitiostanol, mepitiostane, and testolactone; anti-adrenal drugs such as mitotane and trilostane; folic acid supplements such as frolinic acid; aceglatone; aldophosphamide glycoside; aminolevulinic acid; eniluracil; amsacrine; bestrabucil; bisantrene; edatraxate; defofamine; demecolcine; diaziquone; elformithine; elliptinium acetate); epothilone; etoglucid; gallium nitrate; hydroxyurea; lentinan; lonidainine; maytansinoids, such as maytansine and ansamitocin; mitoguazone; mitoxantrone; mopidanmol; nitraerine; pentostatin;Phenamet; Pirarubicin; Losoxantrone; Podophyllinic acid; 2-ethylhydrazide; Procarbazine; PSK polysaccharide complex; Razoxane; Rhizoxin; Sizofiran; Spirogermanium; Tenuazonic acid; Triaziquone; 2,2',2''-Trichlorotriethylamine; Trichothecene toxins (especially T-2 toxin, Verracurin A, Roridin A) A) and anguidine); urethan; vindesine; dacarbazine; mannomustine; mitobronitol; mitolactalol; piperoman; gacytosine; arabinoside (“Ara-C”); cyclophosphamide; taxoids, such as paclitaxel and docetaxel, gemcitabine; 6-thioguanine; mecaptopurine; platinum coordination complexes, such as cisplatin. Cisplatin, oxaliplatin, and carboplatin; vinblastine; platinum; etoposide (VP-16); ifosfamide; mitoxantrone; vincristine; vinorelbine; novantrone; teniposide; edatrexate; daunomycin; aminopterin; xeloda; ibandronate; irinotecan (e.g., CPT-11); topoisomerase inhibitor RFS 2000; difluoromethylornithine (DMFO); retinoids such as retinoic acid; capecitabine;Carboplatin, procarbazine, plicomycin, gemcitabine, navelbine, farnesyltransferase inhibitors, transplatinum, and pharmaceutically acceptable salts, acids, or derivatives of any of the above.

[0332] B. Radiation therapy

[0333] Other factors that cause DNA damage and have been widely used include commonly known gamma rays, X-rays, and / or targeted delivery of radioisotopes to tumor cells. Other forms of DNA damage have also been considered, such as microwaves, proton beam irradiation (US Patents 5,760,395 and 4,870,287), and UV irradiation. All of these factors are likely to cause extensive damage to DNA, DNA precursors, DNA replication and repair, and chromosome assembly and maintenance. X-ray doses range from long-term (3 to 4 weeks) daily doses of 50 to 200 roentgens to single doses of 2,000 to 6,000 roentgens. Radioisotope dose ranges vary considerably depending on the isotope's half-life, the intensity and type of emitted radiation, and the uptake by tumor cells.

[0334] C. Immunotherapy

[0335] Those skilled in the art will understand that additional immunotherapies (in addition to the disclosed cell therapies) can be used in combination with or in conjunction with the methods of this invention. In the context of cancer treatment, immunotherapy typically relies on the use of immune effector cells and molecules to target and destroy cancer cells. Rituximab (RITUXAN®) is such an example. Immune effectors can be, for example, antibodies that specifically target certain markers on the surface of tumor cells. The antibody itself can be used as an effector of the therapy, or it can recruit other cells to actually influence cell killing. Antibodies can also be conjugated with drugs or toxins (chemotherapeutic agents, radionuclides, ricin A chain, cholera toxin, pertussis toxin, etc.) as targeting agents. Alternatively, the effector can be lymphocytes carrying surface molecules that interact directly or indirectly with tumor cell targets. Various effector cells include cytotoxic T cells and NK cells, excluding cells with knocked-down or deactivated TGF-βR2.

[0336] Antibody-drug conjugates have emerged as a breakthrough approach for cancer therapeutics development. Antibody-drug conjugates (ADCs) comprise monoclonal antibodies (MAbs) covalently linked to a cytotoxic drug. This approach combines the high specificity of the MAb against its antigenic target with a highly potent cytotoxic drug, resulting in an “armed” MAb that delivers the payload (drug) to tumor cells with enriched antigen levels. Targeted drug delivery also minimizes its exposure to normal tissues, thereby reducing toxicity and improving the therapeutic index. The FDA approval of ADCETRIS® (brentuximab vedotin) in 2011 and KADCYLA® (trastuzumab emtansine or T-DM1) in 2013 validates this approach. Currently, over 30 ADC candidates are in various phases of clinical trials for cancer treatment (Leal et al., 2014). As antibody engineering and adaptor-payload optimization become increasingly sophisticated, the discovery and development of new ADCs increasingly rely on the identification and validation of novel targets suitable for this approach, as well as the generation of targeting MAbs. Two criteria for ADC targets are upregulated / high-level expression in tumor cells and robust internalization.

[0337] In one aspect of immunotherapy, tumor cells must carry markers that are easily targeted, i.e., not present on most other cells. Many tumor markers exist, and any one of these markers is suitable for targeting in the context of this invention. Common tumor markers include CD20, carcinoembryonic antigen, tyrosinase (p97), gp68, TAG-72, HMFG, sialylated Lewis antigen, MucA, MucB, PLAP, laminin receptor, erb B, and p155. An alternative aspect of immunotherapy is combining anticancer effects with immunostimulatory effects. Immunostimulatory molecules also exist, including: cytokines such as IL-2, IL-4, IL-12, GM-CSF, and γ-IFN; chemokines such as MIP-1, MCP-1, and IL-8; and growth factors such as FLT3 ligand.

[0338] Examples of immunotherapies currently under investigation or in use include immune adjuvants, such as Mycobacterium bovis (B. bovis). Mycobacterium bovis ), Plasmodium falciparum ( Plasmodium falciparum), dinitrochlorobenzene and aromatic compounds (US Patents 5,801,005 and 5,739,169; Hui and Hashimoto, 1998; Christodoulides et al., 1998); cytokine therapy, such as any kind of interferon, IL-1, GM-CSF and TNF (Bukowski et al., 1998; Davidson et al., 1998; Hellstrand et al., 1998); gene therapy, such as TNF, IL-1, IL-2 and p53 (Qin et al., 1998; Austin-Ward and Villaseca, 1998; US Patents 5,830,880 and 5,846,945); and monoclonal antibodies, such as anti-CD20, anti-ganglioside GM2 and anti-p185 (Hollander, 2012; Hanibuchi et al., 1998; US Patent 5,824,311). Consider using one or more anticancer therapies in conjunction with the antibody therapies described in this article.

[0339] In some respects, immunotherapy can be an immune checkpoint inhibitor. Immune checkpoints either upregulate signaling (e.g., co-stimulatory molecules) or downregulate signaling. Inhibitory immune checkpoints that can be targeted by immune checkpoint blockade include adenosine A2A receptor (A2AR), B7-H3 (also known as CD276), B and T lymphocyte attenuation factor (BTLA), cytotoxic T lymphocyte-associated protein 4 (CTLA-4, also known as CD152), indoleamine 2,3-dioxygenase (IDO), killer cell immunoglobulin (KIR), lymphocyte activation gene-3 (LAG3), programmed death 1 (PD-1), T cell immunoglobulin domain and mucin domain 3 (TIM-3), and T cell activation V domain Ig inhibitor (VISTA). In particular, immune checkpoint inhibitors target the PD-1 axis and / or CTLA-4.

[0340] D. Surgery

[0341] Approximately 60% of people diagnosed with cancer will undergo some type of surgery, including preventative, diagnostic or staging, curative, and palliative procedures. Curative surgeries include resection (where all or part of the cancerous tissue is physically removed, excised, and / or destroyed) and can be used in combination with other therapies, such as treatments of this invention, chemotherapy, radiation therapy, hormone therapy, gene therapy, immunotherapy, and / or alternative therapies. Tumor resection refers to the physical removal of at least a portion of a tumor. Besides tumor resection, surgical treatments include laser surgery, cryosurgery, electrosurgery, and microsurgical manipulation (Moser procedures).

[0342] After the removal of part or all of the cancerous cells, tissue, or tumor, a cavity may form in the body. Treatment can be accomplished by perfusing, directly injecting, or topically applying additional anticancer therapies to this area. For example, this treatment can be repeated every 1, 2, 3, 4, 5, 6, or 7 days, or every 1, 2, 3, 4, and 5 weeks, or every 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 months. These treatments may also be administered at different dosages.

[0343] E. Other reagents

[0344] It is considered that other agents can be used in combination with certain aspects of this invention to improve the therapeutic efficacy. These additional agents include agents that affect the upregulation of cell surface receptors and gap junctions, cell growth inhibitors and differentiation agents, cell adhesion inhibitors, agents that increase the sensitivity of hyperproliferating cells to apoptosis-inducing agents, or other biological agents. Increasing intercellular signaling by increasing the number of gap junctions enhances the anti-hyperproliferative effect against neighboring hyperproliferating cell populations. In other aspects, cell growth inhibitors or differentiation agents can be used in combination with certain aspects of this invention to improve the anti-hyperproliferative efficacy of the treatment. It is considered that cell adhesion inhibitors can improve the efficacy of the aspects of this invention. Examples of cell adhesion inhibitors are focal adhesion kinase (FAK) inhibitors and lovastatin. Further consideration is that other agents that increase the sensitivity of hyperproliferating cells to apoptosis (such as antibody c225) can be used in combination with certain aspects of this invention to improve therapeutic efficacy.

[0345] XIII. Treatment Methods

[0346] In various respects, the expression constructs, nucleic acid sequences, vectors, host cells, and / or pharmaceutical compositions comprising them considered herein are intended for the prevention, treatment, or improvement of cancerous diseases, such as neoplastic diseases. In particular, the pharmaceutical compositions of this disclosure may be specifically used, for example, for the prevention, improvement, and / or treatment of cancer. For example, an individual may utilize the treatment methods of this disclosure as initial treatment or after (or in conjunction with) another treatment, such as after HSCT. Based on the type and / or stage of cancer, immunotherapy approaches can be tailored to the needs of an individual with cancer, and in at least some cases, immunotherapy can be modified during an individual's treatment process.

[0347] In some aspects, this disclosure provides immunotherapeutic methods comprising administering an effective amount of cells produced by the methods of this disclosure. In one aspect, a medical disease or condition is treated by transferring a population of cells produced by the methods herein and eliciting an immune response. In some aspects of this disclosure, cancer is treated by transferring a population of cells produced by the methods of this disclosure. Methods for treating cancer in an individual or delaying its progression are provided herein, comprising administering an effective amount of cell therapy to the individual. The methods of the present invention can be used to treat solid tumors or hematologic malignancies.

[0348] The tumors to which the treatment methods of this invention are applicable include any malignant cell type, such as those found in solid tumors or hematologic malignancies. Exemplary solid tumors may include, but are not limited to, tumors of organs selected from the group consisting of: acute myeloid leukemia, lymphoma, lung cancer, kidney cancer, bladder cancer, melanoma, glioblastoma, breast cancer, head and neck cancer, mesothelioma, multiple myeloma, and pancreatic cancer.

[0349] In some aspects of this disclosure, the immune cells covered herein are delivered to individuals in need, such as individuals with cancer. In some cases, one or more doses of immune cells are provided to the individual. In the case of providing two or more doses of immune cells to an individual, the duration between administrations should be sufficient to allow time for proliferation in the individual, and in specific aspects, the duration between doses is 1, 2, 3, 4, 5, 6, 7 days or more.

[0350] In specific terms, the therapeutically effective dose is delivered to the individual (from 1 to 10 cells). 10 The effective dose of the treatment (within the range of 1 to 10 cells) improves at least one cancer-related symptom in an individual. The effective dose can be 1 to 10. 10 10 to 10 10 10 2 -10 10 10 3 Up to 10 10 10 3 Up to 10 9 10 3 Up to 10 8 10 3 Up to 10 7 10 3 Up to 10 6 10 3 Up to 10 5 10 3 Up to 10 4 10 4 Up to 10 10 10 4 Up to 10 9 104 Up to 10 8 10 4 Up to 10 7 10 4 Up to 10 6 10 4 Up to 10 5 10 5 Up to 10 10 10 5 Up to 10 9 10 5 Up to 10 8 10 5 Up to 10 7 10 5 Up to 10 6 10 6 Up to 10 10 10 6 Up to 10 9 10 6 Up to 10 8 10 6 Up to 10 7 10 7 Up to 10 10 10 7 Up to 10 9 10 7 Up to 10 8 10 8 Up to 10 10 10 8 Up to 10 9 One or 10 9 Up to 10 10 Individual cells. Specifically, providing an individual with cancer with a specific therapeutic amount of cells effective for one or more treatments. In some aspects, when the individual is at risk of adverse effects from these cells as a therapy, the concentration can be adjusted and / or one or more chimeric peptide agents targeting antigens on the cells can be administered. Specifically, providing an individual with cancer with a specific immune cell amount effective for one or more treatments, and then when the individual is at risk of adverse effects from the cells as a therapy, the concentration can be adjusted and / or one or more chimeric peptide agents targeting antigens on the cells can be administered.

[0351] In some respects, after administration, the vector can be stably integrated into the subject's genome. Specifically, for example, viral vectors that specifically target certain cells or tissues and persist within those cells can be used. Suitable drug carriers and excipients are well known in the art. Compositions prepared according to this disclosure can be used for the prevention, treatment, or delay of the diseases identified above.

[0352] Furthermore, this disclosure relates to methods for the prevention, treatment, or improvement of neoplastic diseases, comprising the steps of administering to a subject in need an effective amount of BCMA-positive cells, nucleic acid sequences, or vectors as described herein, said nucleic acid sequences or vectors being generated herein and / or by methods as described herein.

[0353] The possible indication for the application of one or more compositions to exemplary cells is a cancerous disease, including any kind of neoplastic disease. The exemplary indication for the application of one or more compositions to BCMA-positive cells is a cancerous disease, including any malignant tumor expressing a specific antigen, said antigen including the antigen targeted by the CAR. The application of one or more compositions of this disclosure can be used for cancers at all stages and types, including, for example, minimal residual disease, early-stage cancer, advanced-stage cancer and / or metastatic cancer and / or refractory cancer.

[0354] The therapeutically effective amount of produced cells can be administered via a variety of routes, including parenteral administration, such as intravenous, intraperitoneal, intramuscular, intrasternal, intratumoral, intrathecal, intracardiac, via reservoir, intra-articular injection or infusion.

[0355] The therapeutically effective amount of cells produced for adoptive cell therapy is the amount that achieves the desired effect in the treated subject. For example, this could be the amount of immune cells necessary to inhibit cancer progression or lead to cancer regression.

[0356] The resulting cell population can be administered within a treatment regimen consistent with the disease, such as in single or multiple doses over 1 to 2 days to improve the disease status, or in regular doses over an extended period to inhibit disease progression and prevent relapse. The precise dosage used in the formulation will also depend on the route of administration and the severity of the disease or condition, and should be determined based on the practitioner's judgment and each patient's individual circumstances. The therapeutically effective dose of the cells will depend on the subject being treated, the severity and type of the disease, and the method of administration. In some respects, the dose range suitable for treating human subjects is at least 1 × 10⁻⁶. 3 At least 1×10 4 3.8 × 10 4 At least 3.8 × 10 5 At least 3.8 × 10 6 At least 3.8 × 10 7 At least 3.8 × 10 8 At least 3.8 × 10 9 One or at least 3.8 × 10 10 T cells / m 2 In one respect, the dosage range for treating human subjects is approximately 3.8 × 10⁻⁶. 9 Approximately 3.8 × 10 10T cells / m 2 In another aspect, the effective therapeutic dose of T cells can be increased from approximately 5 × 10⁻⁶. 6 The number of cells per kg of body weight varied to approximately 7.5 × 10⁻⁶. 8 Cells / kg body weight, such as from approximately 2 × 10 7 The number of cells / kg body weight varies to approximately 5 × 10⁻⁶. 8 Cells / kg body weight, or from approximately 5 × 10 7 The number of cells / kg body weight changes to approximately 2×10⁻⁶. 8 Cells / kg body weight. The exact number of T cells can be readily determined by those skilled in the art based on the subject's age, weight, sex, and physiological condition. The effective dose can be extrapolated from dose-response curves derived from in vitro or animal model testing systems.

[0357] This disclosure further covers co-administration regimens with other compounds that act through immune cells (e.g., bispecific antibody constructs, targeted toxins, or other compounds). Clinical regimens for co-administration of one or more compounds of the present invention may cover co-administration with, before, or after administration of other components. Specific combination therapies include chemotherapy, radiation therapy, surgery, hormone therapy, or other types of immunotherapy.

[0358] XIV. Reagent kits for this disclosure

[0359] The invention relates to kits that contain cells, constructs, nucleic acid sequences, vectors, and / or hosts as defined herein. Kits containing this disclosure may also contain pharmaceutical compositions described above, alone or in combination with other drugs to be administered to an individual requiring medical treatment or intervention.

[0360] Any composition described herein may be included in a kit. In non-limiting examples, the kit may comprise BCMA molecules, cells containing BCMA molecules, a vector encoding a specific BCMA protein or BCMA fusion protein, a vector encoding one or more heterologous proteins, and / or reagents for generating said heterologous proteins, and any of these may be included in a suitable container device of the kit of this disclosure. The kit may comprise immune cells, vectors, expression construct polynucleotides for inserting vectors (whether viral or not), etc. Primers for amplifying any polynucleotide may be included. In some cases, the kit comprises cryopreserved cells, including BCMA-positive cells. Any reagents for cell transfection or transduction may be included.

[0361] The kit compositions can be packaged in an aqueous medium or in lyophilized form. The container device of the kit typically includes at least one vial, test tube, flask, bottle, syringe, or other container device in which one or more components can be placed, and preferably, the components are suitably aliquoted. When the kit contains more than one component, the kit may also include a second, third, or other additional container in which additional components can be placed individually. However, various combinations of components can be included in vials. The kits of this disclosure typically also include means for containing molecules, cells containing said molecules, and / or reagents that produce said molecules in a closed environment for commercial sale. Such containers may include injection-molded or blow-molded plastic containers in which the desired vials are held.

[0362] When the components of the kit are provided in the form of one or more liquid solutions, the liquid solutions are aqueous solutions, with sterile aqueous solutions particularly contemplated. The compositions can also be formulated as injectable compositions. In this case, the container device itself can be a syringe, pipette, and / or other similar device by which the formulation can be applied to the infected area of ​​the body, injected into an animal, and / or even applied to and / or mixed with other components of the kit.

[0363] However, the reagent kit components can be provided in one or more dry powder forms. When reagents and / or components are provided in dry powder form, the powder can be reconstituted by adding a suitable solvent. It is also envisioned that the solvent can be provided in another container device.

[0364] Regardless of the number and / or type of containers, the kits of this disclosure may also include and / or be packaged with instruments for assisting the injection / application and / or placement of the final composition in an animal. Such instruments may be syringes, pipettes, forceps, and / or any such medically approved delivery medium. In some aspects, the kits include reagents or devices or containers for ex vivo use.

[0365] XV. Example

[0366] The following embodiments are included to illustrate certain aspects of the invention. Those skilled in the art should understand that the techniques disclosed in the following embodiments represent techniques that the inventors have discovered that work well in the practice of the invention, and therefore can be considered to constitute certain patterns for its practice. However, those skilled in the art should understand that, based on this disclosure, many changes can be made to the specific aspects disclosed without departing from the spirit and scope of the invention, and similar or related results can still be obtained.

[0367] Example 1 - Expression of the extracellular domain of ctdBCMA on T cells

[0368] Human cells were transduced with a lentivirus containing one of three different membrane-binding receptors: control, construct encoding a single BCMA extracellular domain (“ctBCMA”). Figure 2 ) or constructs encoding two BCMA extracellular domains (“ctdBCMA”; SEQ ID NO:10 and SEQ ID NO:20) Figure 1-2 Cells were stained with anti-BCMA antibody. Figure 3 As shown, ctdBCMA expression was significantly higher than that of the ctBCMA construct. ctdBCMA expression driven by either a weak promoter (short EF1a promoter) or a strong promoter (long EF1a promoter) was stable for 6 days in 293T cells expressing γ-secretase and MDA-MB-231 cells expressing ADAM10 / 17, indicating that this chimeric molecule is resistant to cleavage by these proteases. Figure 4 ).

[0369] Example 2 – Using BCMA as a safety switch in therapeutic T cells expressing BCMA

[0370] To evaluate the efficacy of a construct encoding two BCMA extracellular domains (“ctdBCMA”; SEQ ID NO:10 and SEQ ID NO:20) as a safety switch, human T cells were co-transduced with one of three lentiviral constructs: the first containing GFP and firefly luciferase, the second containing a CD19 CAR and a construct encoding a single BCMA extracellular domain (“ctBCMA”), and the third containing a CD19 CAR and the ctdBCMA safety switch. GFP+ and BCMA+ CAR T cells were sorted, expanded, and used for functional assays.

[0371] CAR T cells were co-cultured with Daudi Burkitt lymphoma cells in a 1:1:1 ratio with or without different concentrations of teratumab and with or without autologous untransduced effector T cells. Teratumab is a representative T-cell connector. Other T-cell connectors considered for use with the BCMA safety switch include, for example, enoatumab, alunutamab, rivosaminidumab, ABBV-383, HPN217 (TriTAC), and ISB 2001.

[0372] Changes in CAR-T cell numbers were measured using the INCUCYTE® live-cell imaging system. In the absence of effector T cells, teratumab effectively inhibited the proliferation of CAR T cells expressing ctBCMA and ctdBCMA. Figure 5In the presence of effector T cells, teratumab at very low concentrations (≥100 ng / mL, relative to serum C levels observed in humans) max Rapid elimination of CAR T cells expressing ctBCMA and CAR T cells expressing ctdBCMA at a concentration of 23.8 mcg / mL was observed. However, CAR-T cells expressing ctdBCMA, rather than those expressing ctBCMA, were sensitive to teratolumab at a concentration of 10 ng / mL. Figure 6 , Figure 7 ).

[0373] The ctdBCMA safety switch was also evaluated in vivo in NSG mice. Four groups of NSG mice (N=5 / group) with established Daudi tumors (intravenous (IV) injection on day -13) were treated with intravenous (IV) injection of luciferase-labeled CD19 CAR T cells on day -3. Autologous effector T cells, equal in number to CAR T cells, were injected intravenously (IV) into both groups on day 0; teratumab was administered intraperitoneally at 2.5 mg / kg on days 0 and 3. CAR T cell expansion or elimination was monitored by bioluminescence imaging. Although CAR T cells expanded in the presence of tumors in control mice, a rapid and sustained reduction in CAR T cells was observed in teratumab-treated mice, both in the presence and absence of effector T cells. Figure 8 , Figure 9 In similar in vitro and in vivo studies, in the absence of effector T cells, belantamab mafodotin rapidly eliminated CAR T cells expressing ctBCMA (data not shown).

[0374] Example 3 - Teratumab eliminates anti-CD19 CAR T cells carrying ctBCMA

[0375] Primary T cells transduced with anti-CD19 CAR, ctBCMA, BCL6, and BCL2L1 were depleted after 4 days of culture in the presence of 100 ng / mL teratolumab. Figure 10 This elimination was not observed using the IgG4 isotype control antibody, suggesting that the response is specific to teratumab. In the absence of effector T cells, reduced CAR T cell expansion was observed in the presence of teratumab compared to the IgG4 isotype control. Without being bound by theory, this could be due to cannibalistic effects induced by teratumab binding to tBCMA and CD3 on CAR T cells.

[0376] In the bone marrow of NSG mice, primary T cells transduced with anti-CD19 CAR, ctBCMA, BCL6, and BCL2L1 were eliminated after 7 days, in the presence or absence of effector T cells. Figure 11A-11C This elimination was not observed using the IgG4 isotype control, indicating that the response is specific to teratumab. Similar results were observed in peripheral blood (data not shown).

[0377] Example 4 - Teratumab eliminates anti-CD94 CAR T cells carrying ctdBCMA

[0378] Teritumumab (concentration higher than serum C observed in humans) max Incubation in the presence of 25-fold lower concentrations of ctdBCMA+ anti-CD94 CAR T cells led to rapid elimination of ctdBCMA+ anti-CD94 CAR T cells, but ctdBCMA- anti-CD94 CAR T cells were not eliminated. Figures 12A-12C The efficacy of the safety switch was also evaluated in vivo in NSG mice. Although anti-CD94 CAR T cells persisted in control mice in the presence of tumors, rapid and sustained elimination was observed in mice treated with teratumab. Figure 12D ).

[0379] In view of this disclosure, all methods disclosed and claimed herein can be performed and executed without excessive experimentation. Although the compositions and methods of this disclosure have been described according to preferred aspects, it will be apparent to those skilled in the art that variations can be made to the methods and steps or order of steps described herein without departing from the concept, spirit, and scope of the invention. More specifically, it will be apparent that certain chemically and physiologically relevant reagents can be substituted for those described herein to achieve the same or similar results. All such similar substitutions and modifications that are apparent to those skilled in the art are considered to be within the spirit, scope, and concept of the invention as defined by the appended claims.

Claims

1. A chimeric polypeptide comprising: (a) An extracellular domain comprising one or more repeats of an amino acid sequence having at least 90% identity with SEQ ID NO:33; (b) Hinge area; and (c) Transmembrane domain.

2. The chimeric polypeptide according to claim 1, wherein the extracellular domain comprises one or more repeats of an amino acid sequence having at least 95% identity with SEQ ID NO:

33.

3. The chimeric polypeptide according to claim 1 or claim 2, wherein the extracellular domain comprises one or more repeats of an amino acid sequence having at least 99% identity with SEQ ID NO:

33.

4. The chimeric polypeptide according to any one of claims 1-3, wherein the extracellular domain comprises one or more repeats of the amino acid sequence containing SEQ ID NO:

33.

5. The chimeric polypeptide according to any one of claims 1-4, wherein the extracellular domain comprises one or more repeats of the amino acid sequence consisting of SEQ ID NO:

33.

6. The chimeric polypeptide according to any one of claims 1-5, wherein the extracellular domain comprises one or more repeats of an amino acid sequence having at least 95% identity with SEQ ID NO:1 or SEQ ID NO:

2.

7. The chimeric polypeptide according to any one of claims 1-6, wherein the extracellular domain comprises one or more repeats of an amino acid sequence containing SEQ ID NO:1 or SEQ ID NO:

2.

8. The chimeric polypeptide according to any one of claims 1-7, wherein the extracellular domain comprises one or more repeats of an amino acid sequence consisting of SEQ ID NO:1 or SEQ ID NO:

2.

9. The chimeric polypeptide according to any one of claims 1-8, wherein the extracellular domain comprises at least two repeats of an amino acid sequence having at least 95% identity with SEQ ID NO:

33.

10. The chimeric polypeptide according to any one of claims 1-9, wherein the extracellular domain comprises at least two repeats of an amino acid sequence having at least 95% identity with SEQ ID NO:

33.

11. The chimeric polypeptide according to any one of claims 1-10, wherein the extracellular domain comprises at least two repeats of an amino acid sequence having at least 99% identity with SEQ ID NO:

33.

12. The chimeric polypeptide according to any one of claims 1-11, wherein the extracellular domain comprises at least two repeats of the amino acid sequence containing SEQ ID NO:

33.

13. The chimeric polypeptide according to any one of claims 1-12, wherein the extracellular domain comprises at least two repeats of the amino acid sequence consisting of SEQ ID NO:

33.

14. The chimeric polypeptide according to any one of claims 1-13, wherein the extracellular domain comprises at least two repeats of an amino acid sequence having at least 95% identity with SEQ ID NO:1 or SEQ ID NO:

2.

15. The chimeric polypeptide according to any one of claims 1-14, wherein the extracellular domain comprises at least two repeats of an amino acid sequence containing SEQ ID NO:1 or SEQ ID NO:

2.

16. The chimeric polypeptide according to any one of claims 1-15, wherein the extracellular domain comprises at least two repeats of an amino acid sequence consisting of SEQ ID NO:1 or SEQ ID NO:

2.

17. The chimeric polypeptide according to any one of claims 1-16, wherein the hinge region comprises a hinge region derived from programmed cell death ligand 1 (PDL1).

18. The chimeric polypeptide according to any one of claims 1-17, wherein the hinge region comprises SEQ ID NO:

3.

19. The chimeric polypeptide according to any one of claims 1-18, wherein the hinge region is composed of SEQ ID NO:

3.

20. The chimeric polypeptide according to any one of claims 1-19, wherein the transmembrane domain comprises a transmembrane domain derived from programmed cell death 1 ligand 1 (PDL1).

21. The chimeric polypeptide according to any one of claims 1-20, wherein the transmembrane domain comprises an amino acid sequence having at least 95% identity with SEQ ID NO:

4.

22. The chimeric polypeptide according to any one of claims 1-21, wherein the transmembrane domain comprises SEQ ID NO:

4.

23. The chimeric polypeptide according to any one of claims 1-22, wherein the transmembrane domain is composed of SEQ ID NO:

4.

24. The chimeric polypeptide according to any one of claims 1-23, further comprising an intracellular region.

25. The chimeric polypeptide of claim 24, wherein the intracellular region has endocytic or internalization activity.

26. The chimeric polypeptide of claim 24 or 25, wherein the intracellular region comprises a cytoplasmic domain from Trop2.

27. The chimeric polypeptide according to any one of claims 24-26, wherein the intracellular region comprises an amino acid sequence having at least 95% identity with SEQ ID NO:

5.

28. The chimeric polypeptide according to any one of claims 24-27, wherein the intracellular region comprises SEQ ID NO:

5.

29. The chimeric polypeptide according to any one of claims 24-28, wherein the intracellular region comprises SEQ ID NO:

5.

30. The chimeric polypeptide according to any one of claims 1-29, further comprising a linker region between one or more repeats of an amino acid sequence having at least 90% identity with SEQ ID NO:

33.

31. The chimeric polypeptide of claim 30, wherein the linker region comprises one or more CD34 epitopes.

32. The chimeric polypeptide of claim 31, wherein each of the one or more CD34 epitopes comprises an amino acid sequence having at least 95% identity with SEQ ID NO:6 or SEQ ID NO:

7.

33. The chimeric polypeptide according to claim 31 or 32, wherein each of the one or more CD34 epitopes comprises SEQ ID NO:6 or SEQ ID NO:

7.

34. The chimeric polypeptide according to any one of claims 31-33, wherein each of the one or more CD34 epitopes comprises SEQ ID NO:6 or SEQ ID NO:

7.

35. The chimeric polypeptide according to any one of claims 31-34, wherein the linker region comprises at least two CD34 epitopes.

36. The chimeric polypeptide of claim 35, further comprising a linker region following each of the at least two CD34 epitopes.

37. The chimeric polypeptide of claim 36, wherein the linker region comprises an amino acid sequence having at least 95% identity with SEQ ID NO:8 or SEQ ID NO:

9.

38. The chimeric polypeptide according to claim 36 or 37, wherein the connector region comprises SEQ ID NO:8 or SEQ ID NO:

9.

39. The chimeric polypeptide according to any one of claims 36-38, wherein the linker region is composed of SEQ ID NO:8 or SEQ ID NO:

9.

40. The chimeric polypeptide according to any one of claims 1-39, wherein the chimeric polypeptide comprises an amino acid sequence having at least 95% identity with SEQ ID NO:

10.

41. The chimeric polypeptide according to any one of claims 1-40, wherein the chimeric polypeptide comprises an amino acid sequence having at least 99% identity with SEQ ID NO:

10.

42. The chimeric polypeptide according to any one of claims 1-41, wherein the chimeric polypeptide comprises SEQ ID NO:

10.

43. A chimeric polypeptide comprising an amino acid sequence having at least 95% identity with SEQ ID NO:

10.

44. A chimeric polypeptide comprising SEQ ID NO:

10.

45. A chimeric polypeptide comprising SEQ ID NO:

10.

46. ​​A nucleic acid molecule comprising a nucleotide sequence encoding a chimeric polypeptide according to any one of claims 1-45.

47. The nucleic acid molecule of claim 46, wherein the nucleic acid molecule comprises a nucleic acid sequence having at least 95% identity with SEQ ID NO:

20.

48. The nucleic acid molecule according to claim 47, wherein the nucleic acid molecule comprises SEQ ID NO:

20.

49. A vector comprising the nucleic acid molecule of any one of claims 46-48.

50. A method for generating engineered cells, comprising introducing into the cells a chimeric polypeptide of any one of claims 1-45, a nucleic acid molecule of any one of claims 46-48, or a vector of claim 49.

51. An engineered cell comprising a chimeric polypeptide according to any one of claims 1-45, a nucleic acid molecule according to any one of claims 46-48, or a vector according to claim 49.

52. The engineered cell according to claim 51, wherein the engineered cell is a T cell.

53. The engineered cell according to claim 52, wherein the T cell is CD4. + T cells, CD8 + T cells, iNKT cells, NKT cells, γδ T cells, or regulatory T cells.

54. The engineered cell according to claim 51, wherein the engineered cell is a natural killer cell.

55. The engineered cell according to claim 51, wherein the engineered cell is an induced pluripotent stem cell (iPSC).

56. The engineered cell of claim 51, wherein the engineered cell is an iPSC-derived cell.

57. The engineered cell according to any one of claims 51-56, further comprising a chimeric antigen receptor (CAR).

58. The engineered cell of claim 57, wherein the chimeric polypeptide is operatively linked to the CAR.

59. The engineered cell according to any one of claims 51-58, further comprising a T cell receptor (TCR).

60. The engineered cell of claim 59, wherein the chimeric polypeptide is operatively linked to the TCR.

61. An engineered cell population comprising the engineered cells of any one of claims 51-60.

62. A method for detecting, separating, depleting, or purifying engineered cells according to any one of claims 51-60, the method comprising contacting the engineered cells with BCMA-binding protein.

63. The method of claim 62, wherein the BCMA-binding protein is an anti-BCMA antibody or its antigen-binding fragment.

64. The method of claim 62 or 63, further comprising using the BCMA-binding protein to isolate the cells from the cell population.

65. The method according to any one of claims 62-64, further comprising detecting the cells with an imaging agent, wherein the BCMA-binding protein is linked to the imaging agent.

66. The method of claim 62 or 63, wherein the BCMA-binding protein is linked to a T-cell adaptor molecule.

67. The method of claim 66, wherein the T-cell adaptor molecule is teratumab, enatumab, alanuctamab, rivosaminidumab, ABBV-383, HPN217 (TriTAC), or ISB 2001.

68. The method according to any one of claims 62-67, wherein contacting the engineered cells with the BCMA-binding protein is performed in vitro.

69. The method according to any one of claims 62-67, wherein contacting the engineered cells with the BCMA-binding protein is performed in vitro.

70. The method according to any one of claims 62-67, wherein contacting the engineered cells with the BCMA-binding protein is performed in vivo.

71. A method for detecting, separating, depleting, or purifying cells, said cells comprising: (a) An extracellular domain comprising one or more repeats of an amino acid sequence having at least 90% identity with SEQ ID NO:33; (b) Hinge area; and (c) Transmembrane domains, The method includes contacting the cells with BCMA-binding proteins.

72. The method of claim 71, wherein the extracellular domain comprises at least two repeats of an amino acid sequence having at least 90% identity with SEQ ID NO:

33.

73. An expression construct comprising a sequence encoding a BCMA fusion protein, wherein the fusion protein comprises an extracellular domain comprising one or more repeats of an amino acid sequence having at least 90% identity with SEQ ID NO:33, the extracellular domain being fused to an intracellular domain having endocytic or internalizing activity.

74. The expression construct according to claim 73, wherein the extracellular domain comprises at least two repeats of an amino acid sequence having at least 90% identity with SEQ ID NO:

33.

75. The expression construct according to claim 73 or 74, wherein the intracellular domain is derived from Trop2.

76. The expression construct according to any one of claims 73-75, wherein the BCMA fusion protein further comprises a PDL1 hinge region, a PDL1 transmembrane domain, or a combination thereof.

77. The expression construct according to any one of claims 73-76, wherein the BCMA fusion protein further comprises a linker region between one or more repeats of an amino acid sequence having at least 90% identity with SEQ ID NO:33, wherein the linker region comprises one or more CD34 epitopes.

78. The expression construct according to any one of claims 73-76, wherein the fusion protein comprises SEQ ID NO:

10.

79. The expression construct according to any one of claims 73-78, wherein the sequence encoding the fusion protein comprises SEQ ID NO:

20.

80. An isolated cell comprising the expression construct of any one of claims 73-79.

81. The cell of claim 80, wherein the cell is an immune cell.

82. The cell according to claim 80 or 81, wherein the cell is an αβ T cell, γδ T cell, NK cell, NKT cell, monocyte, macrophage, B cell, mesenchymal stem cell (MSC) cell, hematopoietic stem cell (HSC), hematopoietic cell, iPSC, or a mixture thereof.

83. The cell according to any one of claims 80-82, wherein the cell expresses one or more heterologous proteins other than the BCMA fusion protein.

84. The cell of claim 83, wherein the heterologous protein is a therapeutic protein, a cytokine, a fusion of a cytokine and a cytokine receptor, a safety switch, or a mixture thereof.

85. The cell of claim 84, wherein the therapeutic protein is an engineered antigen receptor or antibody.

86. The cell of claim 85, wherein the engineered antigen receptor targets cancer antigens.

87. The cell according to claim 85 or 86, wherein the engineered antigen receptor is a chimeric antigen receptor, a T-cell receptor, or a B-cell receptor.

88. A population of isolated cells according to any one of claims 80-87, said population being contained in a suitable culture medium.

89. The group according to claim 88, deposited in a depository.

90. The population according to claim 88 or 89, wherein the population is cryopreserved.

91. A method for identifying BCMA-positive cells transduced or transfected with a heterologous BCMA gene or a BCMA fusion protein, wherein the BCMA fusion protein comprises an extracellular domain, the extracellular domain comprising one or more repeats of an amino acid sequence having at least 90% identity with SEQ ID NO:33, the method comprising the following steps: Cells are transduced or transfected with a heterologous BCMA gene or a BCMA fusion protein, wherein the BCMA fusion protein comprises an extracellular domain comprising one or more repeats of an amino acid sequence having at least 90% identity with SEQ ID NO:33; The cells were exposed to an effective amount of a BCMA-binding reagent; and The binding of the reagent to BCMA on the cell surface can be detected directly or indirectly.

92. The method of claim 91, wherein the extracellular domain comprises at least two repeats of an amino acid sequence having at least 90% identity with SEQ ID NO:

33.

93. The method according to claim 91 or 92, wherein the exposure and detection steps are performed during and / or after the manufacture of the cells.

94. The method according to claim 91 or 93, further comprising the step of manufacturing the cells.

95. The method according to any one of claims 91-94, further defined as: Use the BCMA fusion protein to transfect or transduce immune cells; The immune cells are exposed to an effective amount of an antibody or antibody-drug conjugate that binds to BCMA; and The binding of the antibody or antibody-drug conjugate to BCMA on the cell surface can be detected directly or indirectly.

96. The method according to any one of claims 91-95, wherein the method is performed in vitro.

97. The method according to any one of claims 91-95, wherein at least a portion of the method is performed in vivo.

98. The method according to any one of claims 91-97, wherein the cells express one or more heterologous proteins other than the BCMA fusion protein.

99. The method of claim 98, wherein the heterologous protein is a therapeutic protein, a cytokine, a fusion of a cytokine and a cytokine receptor, a safety switch, or a mixture thereof.

100. The method of claim 99, wherein the therapeutic protein is an engineered antigen receptor.

101. The method according to any one of claims 91-100, further comprising the step of transfecting or transforming the immune cells with a heterologous protein other than the heterologous BCMA or the BCMA fusion protein.

102. The method of claim 101, wherein the BCMA fusion protein and the heterologous protein other than the BCMA fusion protein are expressed from the same vector.

103. The method of claim 101, wherein the BCMA fusion protein and the heterologous protein other than the BCMA fusion protein are expressed from different vectors.

104. A method for manufacturing immune cells for adoptive cell therapy, comprising the following steps: (a) Transducing or transfecting immune cells with heterologous BCMA protein or BCMA fusion protein, wherein the immune cells express BCMA or BCMA fusion protein, respectively; as well as (b) Transducing or transfecting the immune cells with one or more therapeutic proteins.

105. The method of claim 104, wherein step (a) is performed before, simultaneously with, or after step (b).

106. The method of claim 104, wherein the transformation or transfection in step (a) is the same as the transformation or transfection in step (b).

107. The method according to any one of claims 104-106, wherein BCMA or the BCMA fusion protein is on the same carrier as the therapeutic protein.

108. The method according to any one of claims 104-106, wherein the BCMA or the BCMA fusion protein is on a different carrier than the therapeutic protein.

109. The method according to any one of claims 104-108, wherein after step (a), the presence of BCMA expressed on the surface of the immune cells from the method is analyzed.

110. The method of claim 109, wherein the analysis comprises flow cytometry, polymerase chain reaction, or a combination thereof.

111. The method according to any one of claims 104-110, further comprising the step of administering the immune cells produced by the method to an individual in need.

112. The method of claim 111, wherein the immune cells in the individual are monitored.

113. The method of claim 111 or 112, wherein the immune cells in the individual are monitored using a reagent that binds to BCMA.

114. The method of claim 113, wherein the reagent is an antibody or an antibody-drug conjugate.

115. The method according to any one of claims 104-114, wherein the individual exhibits one or more harmful effects from the immune cells, and an effective amount of a BCMA-binding agent is administered to the individual.

116. The method of claim 115, wherein the individual exhibits toxicity from the immune cells, and an effective amount of a BCMA-binding agent is administered to the individual.

117. The method of claim 115, wherein the individual exhibits graft-versus-host disease (GVHD) from the immune cells, and an effective amount of a BCMA-binding agent is administered to the individual.

118. The method according to any one of claims 114-117, wherein the individual no longer needs the immune cells, and an effective amount of the BCMA-binding reagent is administered to the individual.

119. A method for reducing or preventing one or more harmful effects of a cell therapy on an individual, comprising the step of targeting BCMA expressed on the cell surface of the cell therapy.

120. The method of claim 119, further defined as administering an effective amount of one or more reagents that bind to BCMA expressed on cells to the individual.

121. The method of claim 120, wherein the reagent is an antibody or an antibody-drug conjugate.

122. The method of claim 121, wherein the antibody is a monoclonal antibody.

123. The method according to any one of claims 119-122, wherein the adverse effects include GVHD, cytokine release syndrome, or immune effector cell-related neurotoxicity syndrome.

124. The method according to any one of claims 119-123, wherein the BCMA is the intact BCMA protein.

125. The method according to any one of claims 119-123, wherein the BCMA is a fragment of the complete BCMA protein containing at least a portion of the extracellular domain.

126. The method according to any one of claims 119-124, wherein the BCMA is naturally expressed on the immune cells or is naturally heterologously expressed on the immune cells.

127. The method according to any one of claims 119-125, wherein the BCMA is a BCMA fusion protein.

128. The method of claim 127, wherein the fusion protein comprises an extracellular domain comprising one or more repeats of an amino acid sequence having at least 90% identity with SEQ ID NO:33, the extracellular domain being fused to an intracellular domain having endocytic or internalizing activity.

129. The method according to claim 127 or 128, wherein the fusion protein comprises an extracellular domain comprising at least two repeats of an amino acid sequence having at least 90% identity with SEQ ID NO:33, and the extracellular domain is fused to an intracellular domain having endocytic or internalizing activity.

130. The method of claim 128 or 129, wherein the intracellular domain originates from Trop2.

131. The method according to any one of claims 128-130, wherein the BCMA fusion protein further comprises a PDL1 hinge region, a PDL1 transmembrane domain, or a combination thereof.

132. The method according to any one of claims 128-131, wherein the BCMA fusion protein further comprises a linker region between one or more repeats of an amino acid sequence having at least 90% identity with SEQ ID NO:33, wherein the linker region comprises one or more CD34 epitopes.

133. The method according to any one of claims 119-132, wherein prior to the targeting step, the cells of the individual are monitored in vivo.

134. The method of claim 133, wherein one or more reagents targeting BCMA are used to monitor the cells.

135. The method of claim 134, wherein the BCMA-targeting agent is used in a sufficiently low amount to not inhibit the antibody in the therapeutic cells.

136. The method according to any one of claims 119-135, wherein the cell therapy is autologous or allogeneic relative to the individual.

Citation Information

Patent Citations

  • AAV vector compositions and methods for enhanced expression of immunoglobulins using the same

    US20110065779A1

  • Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity

    US4554101A

  • Multi-station proton beam therapy system

    US4870287A

  • Recombinant antibody

    US5677425A

  • Aromatic compounds for inhibiting immune response

    US5739169A